e10vk
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
(Mark One)
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended
December 31, 2010
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period
from to
|
Commission file number
001-33689
athenahealth, Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
State or other jurisdiction
of
incorporation or organization
|
|
04-3387530
(I.R.S. Employer
Identification No.)
|
|
|
|
311 Arsenal Street,
Watertown, Massachusetts
(Address of principal
executive offices)
|
|
02472
(Zip Code)
|
617-402-1000
Registrants telephone
number, including area code
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
Title of Each Class
|
|
Name of Each Exchange on Which Registered
|
|
Common Stock, $0.01 par value
|
|
The NASDAQ Stock Market LLC
|
Securities registered pursuant to Section 12(g) of the
Act:
None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes þ No o
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant
was required to submit and post such
files). Yes þ No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
(§ 229.405 of this chapter) is not contained herein,
and will not be contained, to the best of registrants
knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this
Form 10-K
or any amendment to this
Form 10-K. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the
Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting
company o
|
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the
Act). Yes o No þ
The aggregate market value of the common stock held by
non-affiliates of the registrant was approximately $871,223,716
based on the closing price on the NASDAQ Global Select Market on
June 30, 2010.
At February 16, 2011, the registrant had
34,640,692 shares of common stock, par value $0.01 per
share, outstanding.
DOCUMENTS
INCORPORATED BY REFERENCE
Part III of this
Form 10-K
incorporates information by reference from the registrants
definitive proxy statement to be filed with the Securities and
Exchange Commission within 120 days after the close of the
fiscal year ended December 31, 2010.
PART I
SPECIAL
NOTE REGARDING
FORWARD-LOOKING
STATEMENTS AND INDUSTRY DATA
This Annual Report on
Form 10-K
contains forward-looking statements. All statements other than
statements of historical fact contained in this Annual Report on
Form 10-K
are forward-looking statements, including the combination or
integration of newly acquired services; expanded sales and
marketing efforts; changes in expenses related to operations,
selling, marketing, research and development, general and
administrative matters, and depreciation and amortization;
liquidity issues; additional fundraising; and the expected
performance period and estimated term of our client
relationships, as well as more general statements regarding our
expectations for future financial or operational performance,
product and service offerings, regulatory environment, and
market trends. In some cases, you can identify forward-looking
statements by terminology such as may,
will, should, expects,
plans, anticipates,
believes, estimates,
predicts, potential, or
continue; the negative of these terms; or other
comparable terminology.
Forward-looking statements are only current predictions and are
subject to known and unknown risks, uncertainties, and other
factors that may cause our or our industrys actual
results, levels of activity, performance, or achievements to be
materially different from those anticipated by such statements.
These factors include, among other things, those listed under
Risk Factors and elsewhere in this Annual Report on
Form 10-K.
Although we believe that the expectations reflected in the
forward-looking statements contained in this Annual Report on
Form 10-K
are reasonable, we cannot guarantee future results, levels of
activity, performance, or achievements. Except as required by
law, we are under no duty to update or revise any of such
forward-looking statements, whether as a result of new
information, future events, or otherwise, after the date of this
Annual Report on
Form 10-K.
Unless otherwise indicated, information contained in this Annual
Report on
Form 10-K
concerning our industry and the markets in which we operate,
including our general expectations and market position, market
opportunity, and market share, is based on information from
independent industry analysts and third-party sources (including
industry publications, surveys, and forecasts), our internal
research, and management estimates. Management estimates are
derived from publicly available information released by
independent industry analysts and third-party sources, as well
as data from our internal research, and are based on assumptions
made by us based on such data and our knowledge of such industry
and markets, which we believe to be reasonable. None of the
sources cited in this Annual Report on
Form 10-K
has consented to the inclusion of any data from its reports, nor
have we sought their consent. Our internal research has not been
verified by any independent source, and we have not
independently verified any third-party information. While we
believe the market position, market opportunity, and market
share information included in this Annual Report on
Form 10-K
is generally reliable, such information is inherently imprecise.
In addition, projections, assumptions, and estimates of our
future performance and the future performance of the industries
in which we operate are necessarily subject to a high degree of
uncertainty and risk due to a variety of factors, including
those described in Risk Factors in Item 1A of
Part I of this Annual Report on
Form 10-K
and elsewhere in this Annual Report on
Form 10-K.
These and other factors could cause results to differ materially
from those expressed in the estimates made by the independent
parties and by us.
In this Annual Report on
Form 10-K,
the terms the Company, athenahealth,
we, us, and our refer to
athenahealth, Inc. and its subsidiaries, Anodyne Health
Partners, Inc., athenahealth MA, Inc., athenahealth Security
Corporation, and athenahealth Technology Private Limited, and
any subsidiary that may be acquired or formed in the future. We
were incorporated in Delaware on August 21, 1997, as Athena
Healthcare Incorporated. We changed our name to
athenahealth.com, Inc. on March 31, 2000, and to
athenahealth, Inc. on November 17, 2000. Our corporate
headquarters are located at 311 Arsenal Street, Watertown,
Massachusetts, 02472, and our telephone number is
(617) 402-1000.
1
Overview
athenahealth provides business services that help medical
practices achieve and sustain financial health by collecting
more money and improving their control over administrative
tasks. These services are designed to reduce the administrative
burden of complex billing rules, quality measurement and
reporting, clinical documentation and data exchange, patient
communication, and many of the related tasks that distract
medical providers and staff from the practice of medicine. Our
services are delivered and consumed through a single instance of
our cloud-based platform, athenaNet. We differentiate our
services by regularly deploying updates and improvements through
athenaNet to clients without any action on the part of the
client. athenaNet enables us to quickly implement our service
offerings at a low up-front cost and to seamlessly work in
tandem with our clients in real time.
The services provided through our single-instance cloud are
currently packaged as three integrated components:
athenaCollector for revenue cycle management, athenaClinicals
for clinical cycle management, and athenaCommunicator for
patient cycle management. The use of our single-instance
platform allows all clients to benefit from the collective
knowledge of all of our other clients through our patented
billing Rules Engine and our clinical Quality Management
Engine, collectively called the athenaRules. Our
clients use these rules engines to monitor and benchmark their
performance with peer practices across the network. Our business
intelligence application, Anodyne Analytics, also supports our
clients in their pursuit of financial health by equipping users
with data visualization tools and insight into their
practices performance.
Each service we provide is supported by a model comprised of
three distinct components: Software, Knowledge, and Work. The
cloud-based software is provided at no extra charge to users but
is the primary conduit through which we exchange information
between clients, payers, and our staff of experts. Knowledge is
infused into each of our services via our athenaRules as we work
with clients, payers, and other partners to codify rules
associated with reimbursement, clinical quality measures, and
other factors related to our clients performance. The
third component to each of our services is the Work that we
perform on behalf of our clients. Wherever possible, we replace
manual processes with automation, but where automation is not
possible, we provide that manual labor rather than returning it
to clients to be completed. This unique service model of
Software, Knowledge, and Work has allowed us to align our
success with our clients performance, creating a continual
cycle of improvement and efficiency. We charge clients a
percentage of collections in most cases, so our financial
results are a direct reflection of our ability to drive revenue
to medical practices.
In 2000, we released our first service offering,
athenaCollector, and we released athenaClinicals in 2006.
athenaCommunicator, introduced in 2010, represented the
integration and rebranding of our first acquisition, Crest Line
Technologies, LLC (d.b.a. MedicalMessaging.net). We continued
this expansion of our offerings in October 2009 with our newest
acquisition, Anodyne Health Partners, Inc.
(Anodyne), the privately held company that developed
the Anodyne Analytics service. In 2010, we generated revenue of
$245.5 million from the sale of our services, compared to
$188.5 million in 2009. As of December 31, 2010, there
were 27,114 medical providers, including 19,197 physicians,
using our athenaCollector service across 45 states and the
District of Columbia and 60 medical specialties.
Market
Opportunity
The healthcare industry is complex and fragmented, and is
largely served by legacy software systems that do not offer the
core competencies of collaboration, flexibility, and
interoperability. A disproportionate amount of communication
still takes place on paper instead of automated communications.
The combination of outdated, inflexible systems and paper
workflows creates significant costs for medical practices as a
result of administrative work, duplication, and errors. By
addressing these problems head on, medical practices can free
their staff to focus on the practice of medicine.
While
fee-for-service
reimbursement is fraught with complexity for physician
practices, managed care plans typically are even more complex,
creating reimbursement structures with greater complexity than
previous methods and placing greater responsibility on physician
practices to capture and provide appropriate data to obtain
payments. This reality is further complicated by newer, emerging
reimbursement models such as
Pay-For-Reporting,
Pay-For-Performance,
and Shared Savings. These programs require providers to identify
2
programs for which they are eligible, enroll in those programs,
identify eligible patients, and record relevant billing and
clinical data for each eligible encounter. In addition,
providers may be penalized for non-reporting or
non-participation in these programs. Many of these programs also
require a much greater focus on coordination of care and cost
efficiency across multiple providers.
Physician practice-based activities that are required to ensure
appropriate payment for services rendered have increased in
number and complexity for the following reasons:
|
|
|
|
|
Legislative reform efforts. Legislative
reform, including the Patient Protection and Affordable Care
Act, or PPACA, that was signed into law in March 2010, is
expected to drive many fundamental shifts in the healthcare
reimbursement landscape. Millions of additional patients could
be required to purchase health insurance coverage, and private
payers may have to limit percentages of non-clinical expenses as
a portion of their revenues. Payers ability to raise
insurance premiums will likely also be regulated, forcing them
to focus on other ways of improving their financial performance,
including new contracting options for physicians and new
programs to identify preventable costs. Many of these programs
would require the aggregation and exchange of clinical data in
order to ensure continuity of care for each patient.
|
|
|
|
Diversity of health benefit plan
design. Health insurers have introduced a wide
range of benefit structures, many of which are customized to
unique goals of particular employer groups. This has resulted in
an increase in rules regarding who is eligible for healthcare
services, what healthcare services are eligible for
reimbursement, and who is responsible for payment for healthcare
services delivered. It has also resulted in more plans with a
larger portion of patient responsibility, such as High
Deductible Health Plans (HDHP) or plans with little
coverage other than negotiated discounts, increasing the burden
on practices to manage and pursue receivables directly with the
patient.
|
|
|
|
Dynamic nature of health benefit plan
design. Health insurers continually update their
reimbursement rules based on ongoing monitoring of consumption
patterns, in response to new medical products and procedures,
and to address changing employer demands. As these changes are
made frequently throughout the year and are often specific to
each individual health plan, physician practices need to be
continually aware of this dynamic element of the reimbursement
cycle, as it could impact overall reimbursement and specific
workflows.
|
|
|
|
Proliferation of new payment models. New
health benefit plans and reimbursement structures have
considerably modified the ways in which physician practices are
paid. Care-based initiatives, including
Pay-for-Performance,
which provide reimbursement incentives centered around capture
and submission of specified clinical information, have
dramatically increased the administrative and clinical
documentation burden of the physician practice. Shared Savings
programs, including Accountable Care Organizations, or ACOs,
reward providers for managing care cost-efficiently, requiring
much more coordination of clinical effort across physician
practices and their trading partners. These newer models are
continuing to evolve and grow in both number and complexity.
|
|
|
|
New financial incentives spurring a new wave of EHR
purchasing activity. The federal government has
enacted a financial incentive program through the 2009 Health
Information Technology for Economic and Clinical Health Act (the
HITECH Act) for providers who demonstrate
Meaningful Use of a certified Electronic Health
Record (EHR) technology. While these payments do not
represent a sustained market opportunity, they have shifted
recent buying patterns, with many providers accelerating their
purchase of EHRs and making revenue cycle decisions tied to the
EHR selection.
|
In addition to administering typical business functions,
physician practices must invest significant time and resources
processing inbound and outbound communications related to
physician orders, including referrals to specialists, imaging
centers, laboratories, pharmacies, and inpatient admissions. In
order to process these communications, physician practices often
interact with multiple software systems; execute paper-based and
fax-based communications to and from payers; and contact
patients, payers, and other trading partners to effectively
communicate the appropriate clinical information to accompany
the order. All of this work must
3
also be conducted to ensure that the patient receives
appropriate care and that the procedure is eligible for
reimbursement.
Our
Strategy
Our mission is to be the most trusted business service to
medical groups. In almost all cases, we price our services as a
percentage of practice collections which incentivizes us to
increase their performance while simultaneously reducing cost
through more efficient operations. As physician practices face
rising costs, rising complexity, and changing reimbursement
rates, they will need solutions for a diverse set of problems.
These problems include more administrative work to manage new
reimbursement models; greater demand from trading partners and
Shared Savings program members for electronic exchange of data;
pressure to adopt expensive EHRs; continued changes to federally
mandated transaction standards; new insurance payer rules; more
complicated reimbursement structures; and increased work to
collect self-pay balances for uninsured, underinsured, and HDHP
patients.
We believe that traditional, locally installed software fails to
address all of these needs, solving only the subset of problems
that can be managed through electronic storage and transmission
of data without allowing for intelligent evolution of the
functionality. Locally installed software also favors larger
organizations that can afford an up-front investment in hardware
and software as well as the staff to manage and maintain these
systems. Software that is cloud-based can solve a greater set of
these problems particularly when implemented in a
single instance because it can be quickly updated
and delivered to all clients without expensive upgrades or new
hardware installation. However, there remain many challenges
that even cloud-based software alone cannot address without a
corresponding service component. Examples include processing and
sorting all incoming paper documents that a practice receives,
identifying and managing payer rules, identifying and enrolling
providers in
Pay-For-Performance
programs, selecting and alerting providers to
Pay-for-Performance
measures for specific patients, and taking phone calls from
patients with a live operator when a practice is closed. Our
unique service model addresses these problems for clients
through cloud-based software that delivers targeted knowledge to
the right user at the right time and through large service
operations that can achieve comparative advantage by executing
work that would otherwise fall upon the practice.
The electronic connectivity and system infrastructure that we
provide would normally be out of reach for small independent
practices, which represent the majority of the physician market.
However, our ability to automate processes and scale work across
our entire provider network allows our services to be
efficiently delivered to medical practices of every size. By
enabling small practices to receive the same level of technical
and service infrastructure available to large clients, we
provide significant benefit to physician practices as well as to
all of their trading partners and fellow Shared Savings program
members. As physician practices continue to be acquired or
divested by other entities, this strategic flexibility will
enhance our ability to compete, regardless of whether the
practice is independent or owned by a large enterprise.
Key elements of our strategy include:
|
|
|
|
|
Remaining intensely focused on our clients
success. Our business model aligns our goals with
our clients goals and provides us with an ongoing
incentive to improve client performance. We believe that this
approach enables us to maintain client loyalty (demonstrated
through high and sustained client satisfaction and retention),
enhance our reputation, and improve the quality of our solutions.
|
|
|
|
Integration of revenue cycle, clinical cycle, and patient
cycle. As payment models continue to integrate
cost efficiency and performance into reimbursement formulas,
activities that previously were not factors in reimbursement
will become more important in driving practice performance. Only
practices that control these activities in a way that is fully
integrated with their revenue cycle will have visibility into
the financial health of their business. Some examples might be
care handoffs between physicians and trading partners, care
coordination to prevent duplicate procedures, patient adherence
reminders, and closed-loop order management. We proactively
demonstrate to practices how, when fully adopted and optimized,
a combined athenaCollector, athenaClinicals, and
athenaCommunicator solution can help them manage and monitor
performance comprehensively.
|
4
|
|
|
|
|
Maintaining and growing athenaRules. Our
Rules Engine leverages our single-instance platform to
allow all clients to benefit from knowledge across the network.
We proactively seek out new revenue opportunities for practices
and use the Rules Engine to deliver the right information
to the right person at the right time. For athenaCollector
clients, these rules are introduced during charge entry and
claim submission to alert users to any errors or omissions. This
increases the percentage of transactions that are successfully
executed on the first attempt and reduces the time to resolution
after claims or other transactions are submitted. We continue to
build our centralized payer reimbursement rules by learning from
the collective experience of our national network of clients as
well as through proactive outreach to payers.
|
The rules embedded in athenaClinicals are becoming increasingly
tied to reimbursement as more
Pay-for-Reporting,
Pay-for-Performance,
and other bonus payments require specific action at the point of
care. The athenaClinicals workflow allows customizable alerts to
surface during the encounter to ensure that the proper quality
measures are being prompted. The administrative burden of these
payment programs could significantly impair physicians
ability to practice without the type of automation included in
our Quality Management Engine.
|
|
|
|
|
Increasing awareness and attracting new
clients. We will continue to expand sales and
marketing efforts to address our market opportunity by
aggressively seeking new clients. We believe that our
cloud-based business services provide significant value for
physician practices of any size. Our athenaCollector client base
currently represents less approximately three percent of the
U.S. addressable market, comprised of an estimated 650,000
physicians practicing in the ambulatory segment. In addition to
our traditional marketing efforts to small and group practices
market, we have introduced several new programs to reach
hospitals and health systems and help them manage their
affiliated and employed physician strategies.
|
|
|
|
Uncovering and delivering new sources of revenue to
clients. We have worked closely with payers and
other healthcare trading partners to demonstrate the process
efficiencies and reduction in administrative work that our
services provide to medical practices. We believe that, as these
trading partners gain understanding of these advantages and the
related system-wide benefits, they will reward these
efficiencies in a manner that accrues direct benefits to our
clients.
|
|
|
|
High levels of user adoption and network
transparency. One of the biggest challenges for
traditional EHR software vendors has been lack of physician
adoption. Many physicians fear that EHRs will slow them down and
have not habitually documented encounters using software
templates. Traditional documentation styles such as paper or
dictation are preferred in many cases. Due to our large service
operation, we can support many alternate documentation styles
that are not available with software-only solutions. For
example, physicians can continue to document on paper and
transmit that document to us to be processed and attached to the
patient chart. By supporting multiple work styles and
integrating these activities into the complete revenue,
clinical, and patient cycles, our clients realize significant
benefits by utilizing the EHR, which drives our high adoption
rate. We, in turn, convert this usage data into system-wide
measures of top-line practice performance, individual clinician
performance, and the associated drivers of each. We can then
share this intelligence on the measures that correlate with, or
drive, practice performance with our clients.
|
Our
Solutions
Our service offerings are based on our proprietary cloud-based
software, a continually updated database of rules, and
integrated back-office service operations. Our services are
designed to help our clients achieve faster reimbursement from
all parties, reduce error rates, increase collections, lower
operating costs, improve operational workflow controls, and more
efficiently manage clinical and billing information.
athenaCollector
and Anodyne Analytics
Our principal offering, athenaCollector, is our revenue cycle
management service that automates and manages billing-related
functions for physician practices and includes a practice
management platform.
5
athenaCollector assists our physician clients with the proper
handling of claims and billing processes to help manage
reimbursement quickly and efficiently. Complementing
athenaCollector is our business intelligence offering, Anodyne
Analytics, which provides physicians and practice managers with
detailed insight into practice performance.
Software
(athenaNet and Anodyne Analytics)
Through athenaNet, athenaCollector utilizes the Internet to
connect physician practices to our Rules Engine and service
operations team. athenaCollector is a complete practice
management system that includes scheduling, payment processing,
and a workflow dashboard. The system is used by our clients and
our services team to track claims requiring edits in real-time
before they are sent to the payer, claims requiring work that
have come back from the payer unpaid, and claims that are being
held up due to administrative steps required by the individual
client. This web-native functionality provides our clients with
the benefits of our database of payer rules as it is updated and
enables them to interact with our services team to efficiently
monitor workflows. Each transaction runs through our centralized
Rules Engine so that preventable mistakes can be corrected
quickly across all of our clients. We also include a full set of
reporting tools in athenaNet so that users can track their
ongoing performance and benchmark against other practices.
With the acquisition of our newest acquisition, Anodyne, in
October 2009, we expanded the business intelligence function of
our existing services through the addition of Anodyne Analytics.
This web-based, Software-as-a-Service platform organizes and
analyzes billing and claims-based data across physician
practices, allowing decision makers to quickly and easily
present that data visually through a wide array of business
performance metrics. These metrics can be provided either as
broad, practice-wide summaries or as discrete, highly specific
analyses based on complex user-defined requests. In the future,
we plan to further leverage the additional detail and analysis
offered by Anodyne Analytics and the Anodyne Intelligence
Platform to present visually other data sets such as clinical
and patient cycle metrics.
Knowledge
(athenaRules)
Physician practices route all of their
day-to-day
electronic and paper-based payer communications to us, which we
then process using our patented billing Rules Engine and
our service operations to avoid reimbursement delays and improve
practice performance. Our proprietary database of payer
knowledge has been constructed based on over ten years of
experience in handling the physician workflow in thousands of
physician practices with medical claims from tens of thousands
of health benefit packages. The core focus of the database is on
the payer rules, which are the key drivers of claim payment and
denials. Understanding denials allows us to construct rules to
avoid future denials across our entire client base, resulting in
increased automation of our workflow processes. On average, over
100 rules are added or revised in our Rules Engine each
month. athenaRules has been designed to interact seamlessly with
athenaNet in the medical office workflow and with our service
operations.
Work
(athenahealth Service Operations)
athenahealth service operations enables the service teams that
collaborate with client staff to achieve successful
transactions. Our service operations consists of both
knowledgeable staff and technological infrastructure used to
execute the key steps associated with proper handling of
physician claims and clinical data management. The service
operations team is comprised of 691 people who interact
with physicians, providers, and clinicians at all of the key
steps in the revenue cycle, including:
|
|
|
|
|
coordinating with payers to ensure that client providers are
properly set up for billing;
|
|
|
|
checking the eligibility of scheduled patients electronically;
|
|
|
|
submitting claims to payers directly or through intermediaries,
whether electronically or via printed claim forms;
|
|
|
|
obtaining confirmation of claim receipt from payers, either
electronically or through phone calls;
|
6
|
|
|
|
|
receiving and processing checks and remittance information from
payers and documenting the result of payers responses;
|
|
|
|
evaluating denied claims and determining the best approach to
appealing or resubmitting claims to obtain payment;
|
|
|
|
billing patients for balances that are due;
|
|
|
|
compiling and delivering management reporting about the
performance of clients at both the account level and the
provider level;
|
|
|
|
transmitting key clinical data to the revenue cycle workflow to
eliminate the need for code re-entry and to permit assembly of
all key data elements required to achieve maximum appropriate
reimbursement; and
|
|
|
|
providing proactive and responsive client support to manage
issues, address questions, identify training needs, and
communicate trends.
|
athenaClinicals
athenaClinicals is our EHR service that automates and manages
medical-record-management-related functions for physician
practices. It assists medical groups with the proper handling of
physician documentation, orders, and related inbound and
outbound communications to ensure that orders are carried out
quickly and accurately. athenaClinicals is designed to improve
clinical administrative workflow.
Software
(athenaNet)
Through athenaNet, athenaClinicals displays key clinical
measures by office location related to the drivers of high
quality and efficient care delivery on a workflow dashboard,
including lab results requiring review, patient referral
requests, prescription requests, and family history of previous
exams. athenaClinicals is a 2011/2012 compliant Complete EHR
technology and has been certified by the Certification
Commission for Healthcare Information Technology
(CCHIT), an ONC-ATCB, in accordance with the
applicable certification criteria. Similar to its functionality
within athenaCollector, athenaNet provides comprehensive
reporting on a range of clinical results, including distribution
of different procedure codes (leveling), incidence of different
diagnoses, timeliness of turnaround by lab companies and other
intermediaries, and other key performance indicators.
Knowledge
(athenaRules)
Reporting and quality programs have collectively become a
greater portion of physician revenue but are very difficult to
manage on paper or in a static software system that does not
prompt the user for the appropriate action to be taken. Clinical
data must be captured according to the requirements and
incentives of different payers and plans. Clinical
intermediaries such as laboratories and pharmacy networks
require specific formats and data elements as well. athenaRules
is designed to access medication formularies, identify potential
medication errors (such as
drug-to-drug
interactions or allergy reactions), and identify the specific
clinical activities that are required to adhere to
Pay-for-Performance
programs, including Medicare incentive payments under the HITECH
Act.
Work
(athenahealth Service Operations)
Medical practices that use an EHR still receive large amounts of
paper documentation from third parties. These can include
consult letters, lab results, general correspondence, and
multiple other document types. Practices can receive an average
of over 1,000 clinical documents per provider per month,
creating a significant administrative burden. We capture inbound
paper documents, convert them to electronic format, attach them
to the appropriate patient chart, classify them according to
type, and associate results with the original order where
applicable. Additionally, even if the physician creates an order
in the EHR, the intended recipient may not accept orders
electronically. We reduce the electronically generated order to
paper for
7
delivery on behalf of the practice. We also perform many of the
Pay-for-Performance
program identification and enrollment tasks on behalf of
practices so that they can participate without significant
up-front research and effort.
athenaCommunicator
Through athenaNet, athenaCommunicator which includes
ReminderCall (part of the acquisition of Crest Line
Technologies, LLC in September 2008) and other automated
patient messaging services, live operator services, and a
patient portal was commercially released in the
first half of 2010. These services help to reduce patient
no-show rates and improve overall schedule density, which
increases the number of revenue-generating appointments for our
clients. The ability to increase patient outreach also helps to
provide clinical education and adherence reminders to patients,
which increases the quality of care and improves outcomes
without increasing practice work to monitor and contact
patients. The service provides a personalized, high-quality
experience for patients while driving practice performance.
Software
(athenaNet)
athenaCommunicator allows practices to manage many patient
communication tasks electronically, including use of automated
reminder calls with customizable criteria and opt-out
functionality; creation of a self-service patient portal for
registration, appointment requests, bill payments, and general
communication; automatic generation of emails to patients; and
patient education tools. The automated phone calls are
multi-purpose and may include appointment reminders, outbound
campaigns, and
follow-up on
outstanding balances while prompting patients to make payments
by mail, telephone, or online through our systems.
Knowledge
(athenaRules)
athenaCommunicator allows practices to build a highly flexible
set of communication rules with their patients. They can set
patient or group-specific communication preferences that will
automatically tailor communications to the preferred timing and
mode of delivery, including phone call,
e-mail, or
patient portal. These communication rules allow each patient to
receive a personalized experience, including delivery of
messages with branding and using the Caller ID of the practice,
if desired.
Work
(athenahealth Service Operations)
Practices spend a great deal of time fielding phone calls from
patients on topics ranging from scheduling requests, bill
payment, directions, and clinical cases. As part of the
athenaCommunicator service, we provider live operators who field
these calls on behalf of practices, including redirected
automated calls for appointment scheduling, patient payments,
and message-taking on behalf of the practice. We also print and
mail paper statements to patients on behalf of the practice to
assist with patient payment collection. Collectively, these
activities extend the availability of the office to patients and
help to free staff time to focus on more critical tasks.
Research
and Development
Our research and development efforts are focused on enhancing
our service offerings in response to changes in the market and
evolving our technology platform to better serve physician
practices. All of our clients use the same version of our
software, although some athenaRules are designed to take effect
only locally for particular clients. We continually update our
software and rules, executing bimonthly releases of new software
functionality for our clients. Our software development life
cycle methodology ensures that each software release is properly
designed, built, tested, and rolled out. Our software
development technologists are primarily located in the United
States. We complement this teams work with software
development services from third-party technology development
providers in Huntsville, Alabama, and Pune, India, and with our
own employees at our development center operated through our
subsidiary located in Chennai, India. In addition to our core
software development activities, we dedicate full-time staff to
our ongoing development and maintenance of the rules database.
On average, over 100 rules are added or revised in our billing
Rules Engine
8
each month. We also employ program management and product
management personnel, who work continually on improvements to
our service operations processes and our service design,
respectively.
athenaIntelligence
The team behind the athenaRules is based in Watertown,
Massachusetts, and is supported by employees at all of our
locations. This team is responsible for creation of the billing
rules that alert clients to potential problems on claims and for
the creation of the clinical rules that alert clinical staff to
quality measures applicable to particular patients and
encounters. Some key metrics delivered by the athenaIntelligence
team in 2010 were:
|
|
|
|
|
over 20 different
Pay-for-Performance
programs were built into the Rules Engine;
|
|
|
|
over 7.3 million
Pay-For-Performance
rules were surfaced during encounters; and
|
|
|
|
94.4% of claims were resolved on the first submission.
|
Taken as a whole, these activities result, in most cases, in a
direct reduction in practices work. Rather than submitting
a claim with missing information, waiting for adjudication,
receiving a denial, and then resubmitting the claim to start the
cycle over again, our practices are alerted prior to the first
submission. Similarly, they are spared the tedious process of
identifying upcoming appointments for patients that qualify for
a specific
Pay-for-Performance
program and remembering to track the appropriate measure during
the encounter; instead, athenaClinicals introduces the measure
seamlessly into the workflow.
Operations
Our operations team assists clients at each critical step in the
revenue cycle, clinical cycle, and patient cycle workflow
process and provides services that include insurance benefits
packaging, insurance eligibility confirmation, claims
submission, claims tracking, remittance posting, denials
management, payment processing, formatting of lab requisitions,
submission of lab requisitions, and monitoring and
classification of all inbound faxes. Additionally, we use third
parties for data entry, data matching, data characterization,
and outbound and inbound telephone services. We have contracted
with International Business Machines Corporation and Vision
Business Process Solutions Inc., a subsidiary of Dell, Inc.
(formerly Perot Systems Corporation), to provide data entry and
other services from facilities located in India and the
Philippines to support our operations team. These services are
generally commercially available at comparable rates from other
service providers.
During 2010, we:
|
|
|
|
|
posted approximately $5.9 billion in physician collections;
|
|
|
|
processed over 47 million medical claims;
|
|
|
|
handled approximately 119 million charge postings; and
|
|
|
|
delivered 34.4 million automated calls to patients on
behalf of practices.
|
We depend on satisfied clients to succeed. Our client contracts
require minimum commitments by us on a range of tasks, including
claims submission, payment posting, claims tracking, and claims
denial management. We also commit to our clients that athenaNet
is accessible 99.7% of the time, excluding scheduled maintenance
windows. Each quarter, our management conducts a survey of
clients to identify client concerns and track progress against
client satisfaction objectives. In our most recent survey for
athenaCollector, 88% of the respondents reported that they would
recommend our services to a trusted friend or colleague.
In addition to the services described above, we also provide
client support services. There are several client support
service activities that take place on a regular basis, including
the following:
|
|
|
|
|
client support by our client services center, which is designed
to address client questions and concerns rapidly, whether those
questions and concerns are registered via a phone call or via an
online support case through our customized use of customer
relationship management technology;
|
9
|
|
|
|
|
account performance monitoring by the account management
organization to address open issues and focus clients on the
financial results of the co-sourcing relationship; these
activities are intended to aid in client performance and
retention, determine appropriate adjustments to service pricing
at renewal dates, inform clients of the full suite of our
services, and provide incremental services when
appropriate; and
|
|
|
|
relationship management by regional leaders of the client
services organization to ensure that decision-makers at client
practices are satisfied and that regional performance is managed
proactively with regard to client satisfaction, client margins,
client retention, renewal pricing, and added services.
|
The increased burden on patients to pay for a larger percentage
of their healthcare services, together with the need for
providers to have the ability to determine this patient payment
responsibility at the time of service, has led some payers to
develop the capability to accept and process claims in real
time. This capability is frequently referred to within the
industry as real time adjudication (or
RTA) because it avoids the processing time that
adjudication of claims by payers has historically involved.
Under an RTA system, payers notify physicians immediately upon
receipt of billing information if third-party claims are
accepted or rejected, the amount that will be paid by the payer,
and the amount that the patient may owe under the particular
health plan involved. Taking advantage of this payer capability,
we have designed a platform for transacting with payer RTA
systems that is payer-neutral and designed to integrate the
various payer RTA processes so that our clients experience the
same workflow regardless of payer. Using this platform, we have
collaborated with two major payers, Humana and United
Healthcare, to process RTA transactions with their systems.
Sales and
Marketing
We have developed sales and marketing capabilities aimed at
expanding our network of physician clients. We expect to expand
our network by selling our services to new clients and
cross-selling additional services into our client base. We have
a direct sales force, which we augment through our channel
partners and marketing initiatives.
Direct
Sales
We sell our services primarily through our direct sales force.
Our sales force is divided into three groups: the enterprise
team, which is dedicated to professionally managed physician
organizations with 150 or more physicians; the group team, which
is dedicated to physician practices with five to 149 physicians;
and the small group team, which is dedicated to physician
practices with one to four physicians. Our sales force is
supported by personnel in our marketing organization, who
provide specialized support for promotional and selling efforts.
Due to our ongoing service relationship with clients, we conduct
a consultative sales process. This process includes
understanding the needs of prospective clients, developing
service proposals, and negotiating contracts to enable the
commencement of services.
Channel
Partners
In addition to our direct sales force, we maintain business
relationships with third parties that promote or support our
sales or services within specific industries or geographic
regions. We refer to these third parties as channels
and the individuals and organizations involved as our
channel partners. In most cases, these relationships
are agreements that compensate channel partners for providing us
sales lead information that results in sales. These channel
partners generally do not make sales but instead provide us with
leads that we use to develop new business through our direct
sales force. Other channel relationships permit third parties to
act as an independent sales representative, purchasing agent (as
in the case of group purchasing organizations), or a joint
marketer of combined service offerings that we jointly develop
with that third party. In some instances, the channel
relationship involves endorsement or promotion of our services
by these third parties. In 2010, channel-based leads were
associated with approximately half of our new business. Our
channel relationships include state medical societies,
healthcare information technology product companies, healthcare
10
product distribution companies, consulting firms, group
purchasing organizations, regional extension centers, and
payers. Examples of these types of channel relationships include:
|
|
|
|
|
Humana Inc. (Humana). In August
2010, we entered into an alliance with Humana to promote a
program to reward quality, efficiency, and improved coordination
of care for Humanas Medicare beneficiaries. Under this
program, eligible physicians can receive a subsidy from Humana
for the purchase of our athenaClinicals service and earn
additional revenue above their current fee schedule for meeting
certain performance criteria. Humana is one of the nations
largest publicly traded health and supplemental benefits
companies.
|
|
|
|
WorldMed Shared Services, Inc. d/b/a PSS World Medical Shared
Services, Inc. (PSS). In October
2010, we entered into an agreement with PSS for the marketing
and sale of our revenue cycle, clinical cycle, and patient cycle
services. Under the terms of the agreement, PSS has a
non-exclusive right to distribute, sell, market, and promote our
services in the United States (excluding Hawaii) and we will pay
PSS commissions based upon the contract value of client orders
placed with PSS. According to PSS, they are the largest provider
of medical and surgical supplies to the physician market in the
United States, with a sales force consisting of more than 750
sales consultants who distribute medical supplies and equipment
to more than 100,000 offices in all 50 states.
|
Marketing
Initiatives
Since our service model is new to most physicians, our marketing
and sales objectives are designed to increase awareness of our
company, establish the benefits of our service model, and build
credibility with prospective clients so that they will view our
company as a trustworthy long-term service provider. To execute
on this strategy, we have designed and implemented specific
activities and programs aimed at converting leads to new clients.
Our marketing initiatives are generally targeted towards
specific segments of the physician practice market. These
marketing programs primarily consist of:
|
|
|
|
|
traditional print advertising;
|
|
|
|
sponsored
pay-per-click
search advertising and other Internet-focused awareness-
building efforts (such as social media, online videos, webinars,
and destination websites covering compliance and other issues of
interest to physician practices);
|
|
|
|
public relations activities aimed at generating media coverage;
|
|
|
|
campaigns to engage hospitals in discussions about their
approach to the affiliated physician market;
|
|
|
|
participation in industry-focused trade shows;
|
|
|
|
targeted mail,
e-mail, and
phone calls to physician practices;
|
|
|
|
informational meetings (such as strategic retreats with targeted
potential clients); and
|
|
|
|
dinner seminar series.
|
In June 2006, we introduced our annual PayerView rankings in
order to provide an industry-unique framework to systematically
address what we believe is administrative complexity existing
between payers and providers. PayerView is designed to look at
payers performance based on a number of categories, which
combine to provide an overall ranking aimed at quantifying the
ease of doing business with the payer. All data used
for the rankings come from actual claims performance data of our
clients and depict our experience in dealing with individual
payers across the nation. The rankings include payers that meet
a threshold of 3,500 claims per quarter in athenaNet.
11
Competition
We have experienced, and expect to continue to experience,
intense competition from a number of companies. Our primary
competition is the use of locally installed software to manage
revenue cycle, clinical cycle, and patient cycle workflow within
the physicians office. Other nationwide competitors have
begun introducing services that they refer to as
on-demand or software-as-a- service
models, under which software is centrally hosted and services
are provided from central locations. Software and service
companies that sell practice management and EHR software and
medical billing and collection services include GE Healthcare;
Sage Software Healthcare, Inc.; Allscripts-Misys Healthcare
Solutions, Inc.; Siemens Medical Solutions USA, Inc.;
eClinicalWorks, LLC; and Quality Systems, Inc. As a service
company that provides revenue cycle services, we also compete
against large billing companies such as McKesson Corp.; Ingenix,
a division of United Healthcare, Inc.; and regional billing
companies.
The principal competitive factors in our industry include:
|
|
|
|
|
ability to quickly adapt to increasing complexity of the
healthcare reimbursement system;
|
|
|
|
size and scope of payer rules knowledge;
|
|
|
|
ability to introduce only relevant rules into the workflow at
the point of care;
|
|
|
|
ease of use and rates of user adoption;
|
|
|
|
product functionality and scope of services;
|
|
|
|
scope of network connections to support electronic data
interactions;
|
|
|
|
performance, security, scalability, and reliability of service;
|
|
|
|
sale and marketing capabilities of the vendor; and
|
|
|
|
financial stability of the vendor.
|
We believe that we compete favorably with our competitors on the
basis of these factors. However, many of our competitors and
potential competitors have significantly greater financial,
technological, and other resources and name recognition than we
do, as well as more established distribution networks and
relationships with healthcare providers. As a result, many of
these companies may respond more quickly to new or emerging
technologies and standards and changes in customer requirements.
These companies may be able to invest more resources than we can
in research and development, strategic acquisitions, sales and
marketing, and patent prosecution and litigation and to finance
capital equipment acquisitions for their customers.
Government
Regulation
Although we generally do not contract with U.S. state or
local government entities, the services that we provide are
subject to a complex array of federal and state laws and
regulations, including regulation by the Centers for Medicare
and Medicaid Services, or CMS, of the U.S. Department of
Health and Human Services, as well as additional regulation.
Government
Regulation of Health Information
HIPAA Privacy and Security Rules. The Health
Insurance Portability and Accountability Act of 1996, as
amended, and the regulations that have been issued under it
(collectively, HIPAA) contain substantial
restrictions and requirements with respect to the use and
disclosure of individuals protected health information.
These are embodied in the Privacy Rule and Security Rule
portions of HIPAA. The HIPAA Privacy Rule prohibits a covered
entity from using or disclosing an individuals protected
health information unless the use or disclosure is authorized by
the individual or is specifically required or permitted under
the Privacy Rule. The Privacy Rule imposes a complex system of
requirements on covered entities for complying with this basic
standard. Under the HIPAA Security Rule, covered entities must
establish administrative, physical, and technical safeguards to
protect the confidentiality, integrity, and availability of
electronic protected health information maintained or
transmitted by them or by others on their behalf.
12
The HIPAA Privacy and Security Rules apply directly to covered
entities, such as healthcare providers who engage in
HIPAA-defined standard electronic transactions, health plans,
and healthcare clearinghouses. Because we translate electronic
transactions to and from the HIPAA-prescribed electronic forms
and other forms, we are considered a clearinghouse, and as such
are a covered entity. In addition, our clients are also covered
entities. In order to provide clients with services that involve
the use or disclosure of protected health information, the HIPAA
Privacy and Security Rules require us to enter into business
associate agreements with our clients. Such agreements must,
among other things, provide adequate written assurances:
|
|
|
|
|
as to how we will use and disclose the protected health
information;
|
|
|
|
that we will implement reasonable administrative, physical, and
technical safeguards to protect such information from misuse;
|
|
|
|
that we will enter into similar agreements with our agents and
subcontractors that have access to the information;
|
|
|
|
that we will report security incidents and other inappropriate
uses or disclosures of the information; and
|
|
|
|
that we will assist the client in question with certain of its
duties under the Privacy Rule.
|
HIPAA Transaction Requirements. In addition to
the Privacy and Security Rules, HIPAA also requires that certain
electronic transactions related to health care billing be
conducted using prescribed electronic formats. For example,
claims for reimbursement that are transmitted electronically to
payers must comply with specific formatting standards, and these
standards apply whether the payer is a government or a private
entity. As a covered entity subject to HIPAA, we must meet these
requirements, and moreover, we must structure and provide our
services in a way that supports our clients HIPAA
compliance obligations.
HITECH Act. The HITECH Act, which became law
in February 2009, and the regulations issued and to be issued
under it, have provided and are expected to provide, among other
things, clarification of certain aspects of both the Privacy and
Security Rules, expansion of the disclosure requirements for a
breach of the Security Rule, and strengthening of the civil and
criminal penalties for failure to comply with HIPAA. As these
additional requirements are adopted, we will be required to
comply with them.
State Laws. In addition to the HIPAA Privacy
and Security Rules and the requirements imposed by the HITECH
Act, most states have enacted patient confidentiality laws that
protect against the disclosure of confidential medical
information, and many states have adopted or are considering
further legislation in this area, including privacy safeguards,
security standards, and data security breach notification
requirements. Such state laws, if more stringent than HIPAA and
HITECH Act requirements, are not preempted by the federal
requirements, and we must comply with them. For example, the
Massachusetts Office of Consumer Affairs and Business
Regulations issued final data security regulations, which became
effective in March 2010 and establish minimum standards for
protecting and storing personal information about Massachusetts
residents contained in paper or electronic format.
Government
Regulation of Reimbursement
Our clients are subject to regulation by a number of
governmental agencies, including those that administer the
Medicare and Medicaid programs. Accordingly, our clients are
sensitive to legislative and regulatory changes in, and
limitations on, the government healthcare programs and changes
in reimbursement policies, processes, and payment rates. During
recent years, there have been numerous federal legislative and
administrative actions that have affected government programs,
including adjustments that have reduced or increased payments to
physicians and other healthcare providers and adjustments that
have affected the complexity of our work. It is possible that
the federal or state governments will implement future
reductions, increases, or changes in reimbursement under
government programs that adversely affect our client base or our
cost of providing our services. Any such changes could adversely
affect our own financial condition by reducing the reimbursement
rates of our clients or by increasing our cost of serving
clients.
13
Fraud
and Abuse
A number of federal and state laws, loosely referred to as
fraud and abuse laws, are used to prosecute
healthcare providers, physicians, and others that make, offer,
seek, or receive referrals or payments for products or services
that may be paid for through any federal or state healthcare
program and, in some instances, any private program. Given the
breadth of these laws and regulations, they are potentially
applicable to our business; the transactions that we undertake
on behalf of our clients; and the financial arrangements through
which we market, sell, and distribute our services. These laws
and regulations include:
Anti-Kickback Laws. There are numerous federal
and state laws that govern patient referrals, physician
financial relationships, and inducements to healthcare providers
and patients. The federal healthcare programs
anti-kickback law prohibits any person or entity from offering,
paying, soliciting, or receiving anything of value, directly or
indirectly, for the referral of patients covered by Medicare,
Medicaid, and other federal healthcare programs or the leasing,
purchasing, ordering, or arranging for or recommending the
lease, purchase, or order of any item, good, facility, or
service covered by these programs. Courts have construed this
anti-kickback law to mean that a financial arrangement may
violate this law if any one of the purposes of one of the
arrangements is to encourage patient referrals or other federal
healthcare program business, regardless of whether there are
other legitimate purposes for the arrangement. There are several
limited exclusions known as safe harbors that may protect some
arrangements from enforcement penalties. These safe harbors have
very limited application. Penalties for federal anti-kickback
violations are severe, and include imprisonment, criminal fines,
civil money penalties with triple damages, and exclusion from
participation in federal healthcare programs. Many states have
similar anti-kickback laws, some of which are not limited to
items or services for which payment is made by a government
healthcare program.
False or Fraudulent Claim Laws. There are
numerous federal and state laws that forbid submission of false
information or the failure to disclose information in connection
with the submission and payment of physician claims for
reimbursement. In some cases, these laws also forbid abuse of
existing systems for such submission and payment, for example,
by systematic over treatment or duplicate billing for the same
services to collect increased or duplicate payments. These laws
and regulations may change rapidly, and it is frequently unclear
how they apply to our business. For example, one federal false
claim law forbids knowing submission to government programs of
false claims for reimbursement for medical items or services.
Under this law, knowledge may consist of willful ignorance or
reckless disregard of falsity. How these concepts apply to
services such as ours that rely substantially on automated
processes has not been well defined in the regulations or
relevant case law. As a result, our errors with respect to the
formatting, preparation, or transmission of such claims and any
mishandling by us of claims information that is supplied by our
clients or other third parties may be determined to, or may be
alleged to, involve willful ignorance or reckless disregard of
any falsity that is later determined to exist.
In most cases where we are permitted to do so, we charge our
clients a percentage of the collections that they receive as a
result of our services. To the extent that liability under fraud
and abuse laws and regulations requires intent, it may be
alleged that this percentage calculation provides us or our
employees with incentive to commit or overlook fraud or abuse in
connection with submission and payment of reimbursement claims.
CMS has stated that it is concerned that percentage-based
billing services may encourage billing companies to commit or to
overlook fraudulent or abusive practices.
PPACA. In addition to the provisions relating
to healthcare access and delivery, the Patient Protection and
Affordable Care Act, or PPACA, made changes to healthcare fraud
and abuse laws. PPACA expands false claim laws, amends key
provisions of other anti-fraud and abuse statutes, provides the
government with new enforcement tools and funding for
enforcement, and enhances both criminal and administrative
penalties for noncompliance. PPACA may result in increased
anti-fraud enforcement activities.
Stark Law and Similar State Laws. The Ethics
in Patient Referrals Act, known as the Stark Law, prohibits
certain types of referral arrangements between physicians and
healthcare entities. Physicians are prohibited from referring
patients for certain designated health services reimbursed under
federally funded programs to entities with which they or their
immediate family members have a financial relationship or an
ownership interest, unless such referrals fall within a specific
exception. Violations of the statute can result in
14
civil monetary penalties
and/or
exclusion from the Medicare and Medicaid programs. Furthermore,
reimbursement claims for care rendered under forbidden referrals
may be deemed false or fraudulent, resulting in liability under
other fraud and abuse laws.
Laws in many states similarly forbid billing based on referrals
between individuals
and/or
entities that have various financial, ownership, or other
business relationships. These laws vary widely from state to
state.
Corporate
Practice of Medicine Laws, Fee-Splitting Laws, and
Anti-Assignment Laws
In many states, there are laws that prohibit non-licensed
practitioners from practicing medicine, prevent corporations
from being licensed as practitioners, and prohibit licensed
medical practitioners from practicing medicine in partnership
with non-physicians, such as business corporations. In some
states, these prohibitions take the form of laws or regulations
forbidding the splitting of physician fees with non-physicians
or others. In some cases, these laws have been interpreted to
prevent business service providers from charging their physician
clients on the basis of a percentage of collections or charges.
There are also federal and state laws that forbid or limit
assignment of claims for reimbursement from government-funded
programs. Some of these laws limit the manner in which business
service companies may handle payments for such claims and
prevent such companies from charging their physician clients on
the basis of a percentage of collections or charges. In
particular, the Medicare program specifically requires that
billing agents who receive Medicare payments on behalf of
medical care providers must meet the following requirements:
|
|
|
|
|
the agent must receive the payment under an agreement between
the provider and the agent;
|
|
|
|
the agents compensation may not be related in any way to
the dollar amount billed or collected;
|
|
|
|
the agents compensation may not depend upon the actual
collection of payment;
|
|
|
|
the agent must act under payment disposition instructions, which
the provider may modify or revoke at any time; and
|
|
|
|
in receiving the payment, the agent must act only on behalf of
the provider, except insofar as the agent uses part of that
payment to compensate the agent for the agents billing and
collection services.
|
Medicaid regulations similarly provide that payments may be
received by billing agents in the name of their clients without
violating anti-assignment requirements if payment to the agent
is related to the cost of the billing service, not related on a
percentage basis to the amount billed or collected, and not
dependent on collection of payment.
Electronic
Prescribing Laws
States have differing prescription format and signature
requirements. Many existing laws and regulations, when enacted,
did not anticipate the methods of
e-commerce
now being developed. However, due in part to recent industry
initiatives, federal law and the laws of all 50 states now
permit the electronic transmission of prescription orders. In
addition, on November 7, 2005, the Department of Health and
Human Services published its final
E-Prescribing
and the Prescription Drug Program regulations, referred to below
as the
E-Prescribing
Regulations. These regulations are required by the Medicare
Prescription Drug Improvement and Modernization Act of 2003
(MMA) and became effective beginning on
January 1, 2006. The
E-Prescribing
Regulations consist of detailed standards and requirements, in
addition to the HIPAA standards discussed previously, for
prescription and other information transmitted electronically in
connection with a drug benefit covered by the MMAs
Prescription Drug Benefit. These standards cover not only
transactions between prescribers and dispensers for
prescriptions but also electronic eligibility and benefits
inquiries and drug formulary and benefit coverage information.
The standards apply to prescription drug plans participating in
the MMAs Prescription Drug Benefit. Aspects of our
services are affected by such regulation, as our clients need to
comply with these requirements.
15
Anti-Tampering
Laws
For certain prescriptions that cannot or may not be transmitted
electronically from physician to pharmacy, both federal and
state laws require that the written forms used exhibit
anti-tampering features. For example, the U.S. Troop
Readiness, Veterans Care, Katrina Recovery, and Iraq
Accountability Appropriations Act of 2007 has since April 2008
required that most prescriptions covered by Medicaid must
demonstrate security features that prevent copying, erasing, or
counterfeiting of the written form. Because our clients will, on
occasion, need to use printed forms, we must take these laws
into consideration for purposes of the prescription functions of
our athenaClinicals service.
Electronic
Health Records Certification Requirements
The HITECH Act directs the Office of the National Coordinator
for Health Information Technology, or ONCHIT, to support and
promote meaningful use of certified EHR technology nationwide
through the adoption of standards, implementation
specifications, and certification criteria as well as the
establishment of certification programs for EHR technology. In
January 2011, HHS issued a final rule to establish a permanent
certification program for EHR technology, including how
organizations can become ONC-Authorized Testing and
Certification Bodies (ONC-ATCBs). ONC-ATCBs are required to test
and certify that EHR technology is compliant with the standards,
implementation specifications, and certification criteria
adopted by the Secretary and meet the definition of
certified EHR technology. In July 2010, the
Secretary published the final rule that adopted standards,
implementation specifications, and certification criteria for
EHR technology. Our athenaClinicals service was certified as a
2011/2012 compliant Complete EHR by CCHIT, an ONC-ATCB, in
accordance with the applicable eligible provider certification
criteria adopted by the Secretary. While we believe our system
is well designed in terms of function and interoperability, we
cannot be certain that it will meet future requirements.
United
States Food and Drug Administration
The U.S. Food and Drug Administration (FDA) has
promulgated a draft policy for the regulation of computer
software products as medical devices and a proposed rule for
reclassification of medical device data systems under the
Federal Food, Drug and Cosmetic Act, as amended, or FDCA. The
FDA has stated that health information technology software is a
medical device under the FDCA, and we expect that the FDA is
likely to become increasingly active in regulating computer
software intended for use in healthcare settings regardless of
whether the draft policy or proposed rule is finalized or
changed. If our computer software functionality is considered
medical device under the FDCA, we could be subject to the FDA
requirements discussed below.
Medical devices are subject to extensive regulation by the FDA
under the FDCA. Under the FDCA, medical devices include any
instrument, apparatus, machine, contrivance, or other similar or
related article that is intended for use in the diagnosis of
disease or other conditions or in the cure, mitigation,
treatment, or prevention of disease. FDA regulations govern,
among other things, product development, testing, manufacture,
packaging, labeling, storage, clearance or approval, advertising
and promotion, sales and distribution, and import and export.
FDA requirements with respect to devices that are determined to
pose lesser risk to the public include:
|
|
|
|
|
establishment registration and device listing with the FDA;
|
|
|
|
the Quality System Regulation, or QSR, which requires
manufacturers, including third-party or contract manufacturers,
to follow stringent design, testing, control, documentation, and
other quality assurance procedures during all aspects of
manufacturing;
|
|
|
|
labeling regulations and FDA prohibitions against the
advertising and promotion of products for uncleared, unapproved
off-label uses and other requirements related to advertising and
promotional activities;
|
16
|
|
|
|
|
medical device reporting regulations, which require that
manufacturers report to the FDA if their device may have caused
or contributed to a death or serious injury or malfunctioned in
a way that would likely cause or contribute to a death or
serious injury if the malfunction were to recur;
|
|
|
|
corrections and removal reporting regulations, which require
that manufacturers report to the FDA any field corrections and
product recalls or removals if undertaken to reduce a risk to
health posed by the device or to remedy a violation of the FDCA
that may present a risk to health; and
|
|
|
|
post-market surveillance regulations, which apply when necessary
to protect the public health or to provide additional safety and
effectiveness data for the device.
|
Non-compliance with applicable FDA requirements can result in,
among other things, public warning letters, fines, injunctions,
civil penalties, recall or seizure of products, total or partial
suspension of production, failure of the FDA to grant marketing
approvals, withdrawal of marketing approvals, a recommendation
by the FDA to disallow us from entering into government
contracts, and criminal prosecutions. The FDA also has the
authority to request repair, replacement, or refund of the cost
of any device.
Foreign
Regulations
Our subsidiary in Chennai, India, is subject to additional
regulations by the Government of India, as well as its regional
subdivisions. These regulations include Indian federal and local
corporation requirements, restrictions on exchange of funds,
employment-related laws, and qualification for tax status and
tax incentives.
Intellectual
Property
We rely on a combination of patent, trademark, copyright, and
trade secret laws in the United States as well as
confidentiality procedures and contractual provisions to protect
our proprietary technology, databases, and our brand. Despite
these reliances, we believe the following factors are more
essential to establishing and maintaining a competitive
advantage:
|
|
|
|
|
the statistical and technological skills of our service
operations and research and development teams;
|
|
|
|
the healthcare domain expertise and payer rules knowledge of our
service operations and research and development teams;
|
|
|
|
the real-time connectivity of our service offerings;
|
|
|
|
the continued expansion of our proprietary
Rules Engine; and
|
|
|
|
a continued focus on the improved financial results of our
clients.
|
As of December 31, 2010, we held two U.S. patents,
with twelve U.S. patent applications pending and two
foreign patent applications pending. Our first patent
application described and documented our unique patient workflow
process, including the Rules Engine, which applies
proprietary rules to practice and payer inputs on a live,
ongoing basis to produce cleaner healthcare claims, which can be
adjudicated more quickly and efficiently. This patent
application was granted in November 2009 and expires in December
2023. We will continue to file and prosecute patent applications
when and where appropriate to protect our rights in proprietary
technologies.
We also rely on a combination of registered and unregistered
service marks to protect our brand. Our registered service marks
include athenaClinicals, athenaCollector, athenaCommunicator,
athenahealth, athenaNet, PayerView, and the athenahealth logo.
Anodyne Analytics, Anodyne Intelligence, athenaEnterprise,
athenaRules, and ReminderCall are unregistered service marks.
This Annual Report on
Form 10-K
also includes the registered and unregistered trademarks and
service marks of other persons.
We have a policy of requiring key employees and consultants to
execute confidentiality agreements upon the commencement of an
employment or consulting relationship with us. Our employee
agreements also require relevant employees to assign to us all
rights to any inventions made or conceived during their
employment with us. In addition, we have a policy of requiring
individuals and entities with which we discuss
17
potential business relationships to sign non-disclosure
agreements. Our agreements with clients include confidentiality
and non-disclosure provisions.
Seasonality
There is moderate seasonality in the activity level of physician
practices. Typically, discretionary use of physician services
declines in the late summer and during the holiday season, which
leads to a decline in collections by our physician clients about
30 to 50 days later. In addition, as further explained in
Risk Factors in Item 1A of Part I of this
Annual Report on
Form 10-K,
our revenues and operating results may fluctuate from quarter to
quarter depending on a host of factors including, but not
limited to, the severity, length, and timing of seasonal and
pandemic illnesses.
Employees
As of December 31, 2010, we had 1,242 full-time
employees, with 691 in service operations, 199 in sales and
marketing, 211 in research and development, and 141 in general
and administrative functions. Of these full-time employees,
1,142 were located in the U.S. and 100 were located in
Chennai, India. We believe that we have good relationships with
our employees. None of our employees are subject to collective
bargaining agreements or are represented by a union.
Financial
Information
The financial information required under this Item 1 is
incorporated herein by reference to Item 8 of this Annual
Report on
Form 10-K.
Where You
Can Find More Information
Our Annual Reports on
Form 10-K,
Quarterly Reports on
Form 10-Q,
Current Reports on
Form 8-K,
and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of
1934 are available through the Investors portion of
our website ( www.athenahealth.com ) free of charge as
soon as reasonably practicable after we electronically file such
material with, or furnish it to, the Securities and Exchange
Commission, or SEC. Information on our website is not part of
this Annual Report on
Form 10-K
or any of our other securities filings unless specifically
incorporated herein by reference. In addition, our filings with
the SEC may be accessed through the SECs Interactive Data
Electronic Applications (IDEA) system at www.sec.gov. All
statements made in any of our securities filings, including all
forward-looking statements or information, are made as of the
date of the document in which the statement is included, and we
do not assume or undertake any obligation to update any of those
statements or documents unless we are required to do so by law.
Our operating results and financial condition have varied in
the past and may in the future vary significantly depending on a
number of factors. Except for the historical information in this
report, the matters contained in this report include
forward-looking statements that involve risks and uncertainties.
The following factors, among others, could cause actual results
to differ materially from those contained in forward-looking
statements made in this report and presented elsewhere by
management from time to time. Such factors, among others, may
have a material adverse effect upon our business, results of
operations, and financial condition.
18
RISKS
RELATED TO OUR BUSINESS
Our
operating results have in the past fluctuated and may continue
to fluctuate significantly, and if we fail to meet the
expectations of analysts or investors, our stock price and the
value of your investment could decline
substantially.
Our operating results are likely to fluctuate, and if we fail to
meet or exceed the expectations of securities analysts or
investors, the trading price of our common stock could decline.
Moreover, our stock price may be based on expectations of our
future performance that may be unrealistic or that may not be
met. Some of the important factors that could cause our revenues
and operating results to fluctuate from quarter to quarter
include:
|
|
|
|
|
the extent to which our services achieve or maintain market
acceptance;
|
|
|
|
our ability to introduce new services and enhancements to our
existing services on a timely basis;
|
|
|
|
new competitors and the introduction of enhanced products and
services from new or existing competitors;
|
|
|
|
the length of our contracting and implementation cycles;
|
|
|
|
changes in Client Days in Accounts Receivable;
|
|
|
|
the severity, length, and timing of seasonal and pandemic
illnesses;
|
|
|
|
seasonal declines in the use of physician services, generally in
the late summer and during the holiday season, which lead to a
decline in collections by our physician clients about 30 to
50 days later;
|
|
|
|
the financial condition of our current and potential clients;
|
|
|
|
changes in client budgets and procurement policies;
|
|
|
|
the amount and timing of our investment in research and
development activities;
|
|
|
|
the amount and timing of our investment in sales and marketing
activities;
|
|
|
|
technical difficulties or interruptions in our services;
|
|
|
|
our ability to hire and retain qualified personnel and maintain
an adequate rate of expansion of our sales force;
|
|
|
|
changes in the regulatory environment related to healthcare;
|
|
|
|
regulatory compliance costs;
|
|
|
|
the timing, size, and integration success of potential future
acquisitions; and
|
|
|
|
unforeseen legal expenses, including litigation and settlement
costs.
|
Many of these factors are not within our control, and the
occurrence of one or more of them might cause our operating
results to vary widely. As such, we believe that
quarter-to-quarter
comparisons of our revenues and operating results may not be
meaningful and should not be relied upon as an indication of
future performance.
A significant portion of our operating expense is relatively
fixed in nature, and planned expenditures are based in part on
expectations regarding future revenue and profitability.
Accordingly, unexpected revenue shortfalls, lower than expected
revenue increases as a result of planned expenditures, and
longer than expected impact on profitability and margins as a
result of planned revenue expenditures may decrease our gross
margins and profitability and could cause significant changes in
our operating results from quarter to quarter. In addition, our
future quarterly operating results may fluctuate and may not
meet the expectations of securities analysts or investors. If
this occurs, the trading price of our common stock could fall
substantially either suddenly or over time.
19
We
operate in a highly competitive industry, and if we are not able
to compete effectively, our business and operating results will
be harmed.
We have experienced, and expect to continue to experience,
intense competition from a number of companies. Some of our
current competitors have greater name recognition, longer
operating histories, and significantly greater resources than we
do. As a result, our competitors may be able to respond more
quickly and effectively than we can to new or changing
opportunities, technologies, standards, or client requirements.
In addition, current and potential competitors have established,
and may in the future establish, cooperative relationships with
vendors of complementary products, technologies, or services to
increase the availability of their products to the marketplace.
Current or future competitors may consolidate to improve the
breadth of their products, directly competing with our
integrated offerings. Accordingly, new competitors or alliances
may emerge that have greater market share, larger client bases,
more widely adopted proprietary technologies, broader offerings,
greater marketing expertise, greater financial resources, and
larger sales forces than we have, which could put us at a
competitive disadvantage.
Even if our services are more effective than the product or
service offerings of our competitors, current or potential
clients might accept competitive products and services in lieu
of purchasing our services. Increased competition is likely to
result in pricing pressures, which could negatively impact our
sales, profitability, or market share. In addition to new niche
vendors, who offer stand-alone products and services, we face
competition from existing enterprise vendors, including those
currently focused on software solutions, which have information
systems in place with clients in our target market. These
existing enterprise vendors may now, or in the future, offer or
promise products or services with less functionality than our
services, but that offer ease of integration with existing
systems and that leverage existing vendor relationships. If we
are unable to compete effectively against current or future
competitors, it may materially adversely affect our business,
financial condition, or results of operations.
The
market for our services is relatively immature and volatile, and
if it does not develop further or if it develops more slowly
than we expect, the growth of our business will be
harmed.
The market for cloud-based business services is still relatively
new and narrowly based, and it is uncertain whether these
services will achieve and sustain high levels of demand and
market acceptance. Our success will depend to a substantial
extent on the willingness of enterprises, large and small, to
increase their use of on-demand business services in general,
and for their revenue, clinical and patient cycles in
particular. Many enterprises have invested substantial personnel
and financial resources to integrate established enterprise
software into their businesses, and therefore may be reluctant
or unwilling to switch to an on-demand application service.
Furthermore, some enterprises may be reluctant or unwilling to
use on-demand application services, because they have concerns
regarding the risks associated with security capabilities, among
other things, of the technology delivery model associated with
these services. If enterprises do not perceive the benefits of
our services, then the market for these services may not expand
as much or develop as quickly as we expect, either of which
would significantly adversely affect our operating results. In
addition, as a relatively new company in the healthcare business
services market, we have limited insight into trends that may
develop and affect our business. We may make errors in
predicting and reacting to relevant business trends, which could
harm our business. If any of these risks occur, it could
materially adversely affect our business, financial condition,
or results of operations.
If we
do not continue to innovate and provide services that are useful
to users, we may not remain competitive, and our revenues and
operating results could suffer.
Our success depends on providing services that the medical
community uses to improve business performance and quality of
service to patients. Our competitors are constantly developing
products and services that may become more efficient or
appealing to our clients. As a result, we must continue to
invest significant resources in research and development in
order to enhance our existing services and introduce new
high-quality services that clients will want. If we are unable
to predict user preferences or industry changes, or if we are
unable to modify our services on a timely basis, we may lose
clients. Our operating results would also suffer if our
innovations are not responsive to the needs of our clients, are
not appropriately timed with
20
market opportunity, or are not effectively brought to market. As
technology continues to develop, our competitors may be able to
offer results that are, or that are perceived to be,
substantially similar to or better than those generated by our
services. This may force us to compete on additional service
attributes and to expend significant resources in order to
remain competitive.
As a
result of our variable sales and implementation cycles, we may
be unable to recognize revenue to offset expenditures, which
could result in fluctuations in our quarterly results of
operations or otherwise harm our future operating
results.
The sales cycle for our services can be variable, typically
ranging from three to five months from initial contact to
contract execution. During the sales cycle, we expend time and
resources, and we do not recognize any revenue to offset such
expenditures. Our implementation cycle is also variable,
typically ranging from three to five months from contract
execution to completion of implementation. Some of our
new-client
set-up
projects are complex and require a lengthy delay and significant
implementation work. Each clients situation is different,
and unanticipated difficulties and delays may arise as a result
of failure by us or by the client to meet our respective
implementation responsibilities. In some cases, especially those
involving larger clients, the sales cycle and the implementation
cycle may exceed the typical ranges by substantial margins.
During the implementation cycle, we expend substantial time,
effort, and financial resources implementing our services, but
accounting principles require us to defer revenue until the
service has been implemented, at which time we begin recognition
of implementation revenue over an expected attribution period of
the longer of the estimated expected customer life, currently
twelve years, or the contract term. This could harm our future
operating results.
After a client contract is signed, we provide an implementation
process for the client during which appropriate connections and
registrations are established and checked, data is loaded into
our athenaNet system, data tables are set up, and practice
personnel are given initial training. The length and details of
this implementation process vary widely from client to client.
Typically, implementation of larger clients takes longer than
implementation for smaller clients. Implementation for a given
client may be cancelled. Our contracts typically provide that
they can be terminated for any reason or for no reason in
90 days. Despite the fact that we typically require a
deposit in advance of implementation, some clients have
cancelled before our services have been started. In addition,
implementation may be delayed or the target dates for completion
may be extended into the future for a variety of reasons,
including the needs and requirements of the client, delays with
payer processing, and the volume and complexity of the
implementations awaiting our work. If implementation periods are
extended, our provision of the revenue cycle, clinical cycle, or
patient cycle services upon which we realize most of our
revenues will be delayed, and our financial condition may be
adversely affected. In addition, cancellation of any
implementation after it has begun may involve loss to us of
time, effort, and expenses invested in the cancelled
implementation process and lost opportunity for implementing
paying clients in that same period of time.
These factors may contribute to substantial fluctuations in our
quarterly operating results, particularly in the near term and
during any period in which our sales volume is relatively low.
As a result, in future quarters our operating results could fall
below the expectations of securities analysts or investors, in
which event our stock price would likely decrease.
If the
revenue of our clients decreases, or if our clients cancel or
elect not to renew their contracts, our revenue will
decrease.
Under most of our client contracts, we base our charges on a
percentage of the revenue that the client realizes while using
our services. Many factors may lead to decreases in client
revenue, including:
|
|
|
|
|
interruption of client access to our system for any reason;
|
|
|
|
our failure to provide services in a timely or high-quality
manner;
|
|
|
|
failure of our clients to adopt or maintain effective business
practices;
|
|
|
|
actions by third-party payers of medical claims to reduce
reimbursement;
|
21
|
|
|
|
|
government regulations and government or other payer actions
reducing or delaying reimbursement; and
|
|
|
|
reduction of client revenue resulting from increased competition
or other changes in the marketplace for physician services.
|
The current economic situation may give rise to several of these
factors. For example, patients who have lost health insurance
coverage due to unemployment or who face increased deductibles
imposed by financially struggling employers or insurers could
reduce the number of visits those patients make to our physician
clients. Patients without health insurance or with reduced
coverage may also default on their payment obligations at a
higher rate than patients with coverage. Added financial stress
on our clients could lead to their acquisition or bankruptcy,
which could cause the termination of some of our service
relationships. Further, despite the cost benefits that we
believe our services provide, prospective clients may wish to
delay contract decisions due to implementation costs or be
reluctant to make any material changes in their established
business methods in the current economic climate. With a
reduction in tax revenue, state and federal government health
care programs, including reimbursement programs such as
Medicaid, may be reduced or eliminated, which could negatively
impact the payments that our clients receive. In addition, both
public and private payers may introduce payment reform
initiatives, such as capitation or risk-sharing models, as a
cost-control measure that would limit the amounts paid to our
clients. Also, although we currently estimate our expected
customer life to be twelve years, this is only an estimate and
there can be no assurance that our clients will elect to renew
their contracts for this period of time. Our clients typically
purchase one-year contracts that, in most cases, may be
terminated on 90 days notice without cause. If our
clients revenue decreases for any of the above or other
reasons, or if our clients cancel or elect not to renew their
contracts, our revenue will decrease.
We may
not see the benefits of, or have our services approved under,
government programs initiated to counter the effects of the
current economic situation or foster the adoption of certain
health information technologies, which could reduce client
demand or affect our access to the market.
Although government programs have been initiated to counter the
effects of the current economic situation and foster the
adoption of certain health information technologies, we cannot
assure that we will receive any funds from, or have our services
approved under, those programs. For example, the HITECH Act has
authorized approximately $19 billion in expenditures to
further adoption of EHRs, and entities such as the Massachusetts
Healthcare Consortium have offered to subsidize such adoption,
as permitted by recent changes in federal regulations.
If our services are not approved or included as a preferred
solution under certain programs, our access to the market could
be reduced. For example, the Health Information Technology
Extension Program under the HITECH Act provides for 70 or more
regional centers that will assist local healthcare providers in
selecting and using EHR products and services. While
athenaClinicals has been approved, or included in a list of
preferred products and services, under a number of programs,
failure to obtain such approval or inclusion in one or more
additional programs could reduce demand for our services and our
access to the market, which could have a material adverse effect
on our business, including a material decrease in revenues and
possibly market share.
If
participants in our channel marketing and sales lead programs do
not maintain appropriate relationships with current and
potential clients, our sales accomplished with their help or
data may be unwound and our payments to them may be deemed
improper.
We maintain a series of relationships with third parties that we
term channel relationships. These relationships take
different forms under different contractual language. Some
relationships help us identify sales leads. Other relationships
permit third parties to act as value-added resellers or as
independent sales representatives for our services. In some
cases, for example in the case of some membership organizations,
these relationships involve endorsement of our services as well
as other marketing activities. In each of these cases, we
require contractually that the third party disclose information
to and/or
limit their relationships with
22
potential purchasers of our services for regulatory compliance
reasons. If these third parties do not comply with these
regulatory requirements or if our requirements are deemed
insufficient, sales accomplished with the data or help that they
have provided as well as the channel relationship themselves may
not be enforceable, may be unwound, and may be deemed to violate
relevant laws or regulations. Third parties that, despite our
requirements, exercise undue influence over decisions by current
and prospective clients, occupy positions with obligations of
fidelity or fiduciary obligations to current and prospective
clients, or who offer bribes or kickbacks to current and
prospective clients or their employees may be committing
wrongful or illegal acts that could render any resulting
contract between us and the client unenforceable or in violation
of relevant laws or regulations. Any misconduct by these third
parties with respect to current or prospective clients, any
failure to follow contractual requirements, or any insufficiency
of those contractual requirements may result in allegations that
we have encouraged or participated in wrongful or illegal
behavior and that payments to such third parties under our
channel contracts are improper. This misconduct could subject us
to civil or criminal claims and liabilities, require us to
change or terminate some portions of our business, require us to
refund portions of our services fees, and adversely affect our
revenue and operating margin. Even an unsuccessful challenge of
our activities could result in adverse publicity, require costly
response from us, impair our ability to attract and maintain
clients, and lead analysts or investors to reduce their
expectations of our performance, resulting in reduction in the
market price of our stock.
Failure
to manage our rapid growth effectively could increase our
expenses, decrease our revenue, and prevent us from implementing
our business strategy.
We have been experiencing a period of rapid growth. To manage
our anticipated future growth effectively, we must continue to
maintain, and may need to enhance, our information technology
infrastructure and financial and accounting systems and
controls, as well as manage expanded operations in
geographically distributed locations. We also must attract,
train, and retain a significant number of qualified sales and
marketing personnel, professional services personnel, software
engineers, technical personnel, and management personnel.
Failure to manage our rapid growth effectively could lead us to
over-invest or under-invest in technology and operations; result
in weaknesses in our infrastructure, systems, or controls; give
rise to operational mistakes, losses, or loss of productivity or
business opportunities; and result in loss of employees and
reduced productivity of remaining employees. Our growth could
require significant capital expenditures and may divert
financial resources from other projects, such as the development
of new services. If our management is unable to effectively
manage our growth, our expenses may increase more than expected,
our revenue could decline or may grow more slowly than expected,
and we may be unable to implement our business strategy.
We
depend upon two third-party service providers for important
processing functions. If either of these third-party providers
does not fulfill its contractual obligations or chooses to
discontinue its services, our business and operations could be
disrupted and our operating results would be
harmed.
We have entered into service agreements with International
Business Machines Corporation and Vision Business Process
Solutions Inc., a subsidiary of Dell, Inc. (formerly Perot
Systems Corporation), to provide data entry and other services
from facilities located in India and the Philippines to support
our client service operations. Among other things, these
providers process critical claims data and clinical documents.
If these services fail or are of poor quality, our business,
reputation, and operating results could be harmed. Failure of
either service provider to perform satisfactorily could result
in client dissatisfaction, disrupt our operations, and adversely
affect operating results. With respect to these service
providers, we have significantly less control over the systems
and processes involved than if we maintained and operated them
ourselves, which increases our risk. In some cases, functions
necessary to our business are performed on proprietary systems
and software to which we have no access. If we need to find an
alternative source for performing these functions, we may have
to expend significant money, resources, and time to develop the
alternative, and if this development is not accomplished in a
timely manner and without significant disruption to our
business, we may be unable to fulfill our responsibilities to
clients or the expectations of clients, with the attendant
potential for liability claims and a loss of business
reputation, loss of ability to attract or maintain clients, and
reduction of our revenue or operating margin.
23
Various
risks could affect our worldwide operations, exposing us to
significant costs.
We conduct operations throughout the world, including the United
States, India, and the Philippines, either directly or through
our service providers. Such worldwide operations expose us to
potential operational disruptions and costs as a result of a
wide variety of events, including local inflation or economic
downturn, currency exchange fluctuations, political turmoil,
terrorism, labor issues, natural disasters, and pandemics. Any
such disruptions or costs could have a negative effect on our
ability to provide our services or meet our contractual
obligations, the cost of our services, client satisfaction, our
ability to attract or maintain clients, and, ultimately, our
profits.
Because
competition for our target employees is intense, we may not be
able to attract and retain the highly skilled employees we need
to support our planned growth.
To continue to execute on our growth plan, we must attract and
retain highly qualified personnel. Competition for these
personnel is intense, especially for senior sales executives and
engineers with high levels of experience in designing and
developing software and Internet-related services. We may not be
successful in attracting and retaining qualified personnel. We
have from time to time in the past experienced, and we expect to
continue to experience in the future, difficulty in hiring and
retaining highly skilled employees with appropriate
qualifications. Many of the companies with which we compete for
experienced personnel have greater resources than we have. In
addition, in making employment decisions, particularly in the
Internet and high-technology industries, job candidates often
consider the value of the equity awards they are to receive in
connection with their employment. Volatility in the price of our
stock may, therefore, adversely affect our ability to attract or
retain key employees. Furthermore, the requirements to expense
equity awards may discourage us from granting the size or type
of equity awards that job candidates require to join our
company. If we fail to attract new personnel or fail to retain
and motivate our current personnel, our business and future
growth prospects could be severely harmed.
If we
acquire companies or technologies in the future, they could
prove difficult to integrate, disrupt our business, dilute
stockholder value, and adversely affect our operating results
and the value of our common stock.
As part of our business strategy, we may acquire, enter into
joint ventures with, or make investments in complementary
companies, services, and technologies in the future.
Acquisitions and investments involve numerous risks, including:
|
|
|
|
|
difficulties in identifying and acquiring products,
technologies, or businesses that will help our business;
|
|
|
|
difficulties in integrating operations, technologies, services,
and personnel;
|
|
|
|
diversion of financial and managerial resources from existing
operations;
|
|
|
|
the risk of entering new markets in which we have little to no
experience;
|
|
|
|
risks related to the assumption of known and unknown liabilities;
|
|
|
|
the risk of write-offs and the amortization of expenses related
intangible assets and
|
|
|
|
delays in client purchases due to uncertainty and the inability
to maintain relationships with clients of the acquired
businesses.
|
As a result, if we fail to properly evaluate acquisitions or
investments, we may not achieve the anticipated benefits of any
such acquisitions, we may incur costs in excess of what we
anticipate, and management resources and attention may be
diverted from other necessary or valuable activities.
We may
require additional capital to support business growth, and this
capital might not be available.
We intend to continue to make investments to support our
business growth and may require additional funds to respond to
business challenges or opportunities, including the need to
develop new services or
24
enhance our existing service, enhance our operating
infrastructure, or acquire complementary businesses and
technologies. Accordingly, we may need to engage in equity or
debt financings to secure additional funds. If we raise
additional funds through further issuances of equity or
convertible debt securities, our existing stockholders could
suffer significant dilution, and any new equity securities we
issue could have rights, preferences, and privileges superior to
those of holders of our common stock. Any debt financing secured
by us in the future could involve restrictive covenants relating
to our capital-raising activities and other financial and
operational matters, which may make it more difficult for us to
obtain additional capital and to pursue business opportunities,
including potential acquisitions. In addition, we may not be
able to obtain additional financing on terms favorable to us or
as a result of the current condition of the equity and debt
markets limited financing may be available, if at all. If we are
unable to obtain adequate financing or financing on terms
satisfactory to us when we require it, our ability to continue
to support our business growth and to respond to business
challenges could be significantly limited.
If we
are required to collect sales and use taxes on the services we
sell in additional jurisdictions, we may be subject to liability
for past sales and incur additional related costs and expenses,
and our future sales may decrease.
We may lose sales or incur significant expenses should states be
successful in imposing state sales and use taxes on our
services. A successful assertion by one or more states that we
should collect sales or other taxes on the sale of our services
could result in substantial tax liabilities for past sales,
decrease our ability to compete with traditional retailers, and
otherwise harm our business. Each state has different rules and
regulations governing sales and use taxes, and these rules and
regulations are subject to varying interpretations that may
change over time. We review these rules and regulations
periodically and, when we believe our services are subject to
sales and use taxes in a particular state, voluntarily engage
state tax authorities in order to determine how to comply with
their rules and regulations. We cannot assure you that we will
not be subject to sales and use taxes or related penalties for
past sales in states where we believe no compliance is necessary.
Vendors of services, like us, are typically held responsible by
taxing authorities for the collection and payment of any
applicable sales and similar taxes. If one or more taxing
authorities determines that taxes should have, but have not,
been paid with respect to our services, we may be liable for
past taxes in addition to taxes going forward. Liability for
past taxes may also include very substantial interest and
penalty charges. Our client contracts provide that our clients
must pay all applicable sales and similar taxes. Nevertheless,
clients may be reluctant to pay back taxes and may refuse
responsibility for interest or penalties associated with those
taxes. If we are required to collect and pay back taxes and the
associated interest and penalties, and if our clients fail or
refuse to reimburse us for all or a portion of these amounts, we
will have incurred unplanned expenses that may be substantial.
Moreover, imposition of such taxes on our services going forward
will effectively increase the cost of such services to our
clients and may adversely affect our ability to retain existing
clients or to gain new clients in the areas in which such taxes
are imposed.
We may also become subject to tax audits or similar procedures
in states where we already pay sales and use taxes. The
incurrence of additional accounting and legal costs and related
expenses in connection with, and the assessment of taxes,
interest, and penalties as a result of, audits, litigation, or
otherwise could be materially adverse to our current and future
results of operations and financial condition.
From
time to time we may become subject to income tax audits or
similar proceedings, and as a result we may incur additional
costs and expenses or owe additional taxes, interest, and
penalties in amounts that may be material.
We are subject to income taxes in the United States at both the
federal and state levels. In determining our provision for
income taxes, we are required to exercise judgment and make
estimates where the ultimate tax determination is uncertain.
While we believe that our estimates are reasonable, we cannot
assure you that the final determination of any tax audit or
tax-related litigation will not be materially different from
that reflected in our income tax provisions and accruals. The
incurrence of additional accounting and legal costs and related
expenses in connection with, and the assessment of taxes,
interest, and penalties as a result of,
25
audits, litigation, or otherwise could be materially adverse to
our current and future results of operations and financial
condition.
Unanticipated
changes in our tax rates or our exposure to additional income
tax liabilities could affect our operating results and financial
condition.
Our future effective tax rates could be favorably or unfavorably
affected by unanticipated changes in the valuation of our
deferred tax assets and liabilities, the geographic mix of our
revenue, or changes in tax laws or their interpretation.
Significant judgment is required in determining our provision
for income taxes. In addition, we are subject to the continuous
examination of our income tax returns by tax authorities. We
regularly assess the likelihood of adverse outcomes resulting
from these examinations to determine the adequacy of our
provision for income taxes. There can be no assurance, however,
that the outcomes from these continuous examinations will not
have an adverse effect on our operating results and financial
condition. Additionally, due to the evolving nature of tax rules
combined with the number of jurisdictions in which we operate,
it is possible that our estimates of our tax liability and our
ability to realize our deferred tax assets could change in the
future, which may result in additional tax liabilities and
adversely affect our results of operations, financial condition,
and cash flows.
The
results of our review of our revenue recognition practices and
resulting restatement may continue to have adverse effects on
our financial results.
Our review of our revenue recognition practices and our
restatement of our historical financial statements through
September 30, 2009, resulted in the deferral of previously
recognized revenue and required and may in the future require us
to expend significant management time and incur significant
accounting, legal, and other expenses, all of which may have an
adverse effect on our financial results.
For example, actions may be brought against us or our current or
former officers relating to a failure to apply generally
accepted accounting principles in the reporting of quarterly and
annual financial statements and securities prospectuses from the
time of our initial public offering to our filing with the SEC
on March 15, 2010. On March 19, 2010, one such action
was filed against us and certain of our current and former
officers in the United States District Court for the District of
Massachusetts alleging violation of the federal securities laws
by dissemination of false and misleading statements. For
additional information regarding this litigation, see
Part I, Item 3, Legal Proceedings. Such
actions could have a material adverse effect on our business,
financial condition, results of operations, and cash flows and
the trading price for our securities. Litigation would be
time-consuming, expensive, and disruptive to normal business
operations, and the outcome of litigation is difficult to
predict. The defense of any litigation would result in
significant expenditures and the continued diversion of our
managements time and attention from the operation of our
business, which could impede our business. In addition, while we
maintain standard directors and officers insurance, all or a
portion of any amount we may be required to pay to satisfy a
judgment or settlement of any or all of these claims may not be
covered by insurance.
We cannot be certain that the measures we have taken that
address this restatement will ensure that restatements will not
occur in the future. Execution of restatements like the one
described above could create a significant strain on our
internal resources, cause delays in our filing of quarterly or
annual financial results, increase our costs, and cause
management distraction.
We may
be unable to adequately protect, and we may incur significant
costs in enforcing, our intellectual property and other
proprietary rights.
Our success depends in part on our ability to enforce our
intellectual property and other proprietary rights. We rely upon
a combination of trademark, trade secret, copyright, patent, and
unfair competition laws, as well as license and access
agreements and other contractual provisions, to protect our
intellectual property and other proprietary rights. In addition,
we attempt to protect our intellectual property and proprietary
information by requiring certain of our employees and
consultants to enter into confidentiality, noncompetition, and
assignment of inventions agreements. Our attempts to protect our
intellectual property may be challenged
26
by others or invalidated through administrative process or
litigation. While we have two issued U.S. patent and have
twelve more U.S. patent applications and two foreign patent
applications pending as of December 31, 2010, we may be
unable to obtain further meaningful patent protection for our
technology. In addition, any patents issued in the future may
not provide us with any competitive advantages or may be
successfully challenged by third parties. Agreement terms that
address non-competition are difficult to enforce in many
jurisdictions and may not be enforceable in any particular case.
To the extent that our intellectual property and other
proprietary rights are not adequately protected, third parties
might gain access to our proprietary information, develop and
market products or services similar to ours, or use trademarks
similar to ours, each of which could materially harm our
business. Existing U.S. federal and state intellectual
property laws offer only limited protection. Moreover, the laws
of other countries in which we now or may in the future conduct
operations or contract for services may afford little or no
effective protection of our intellectual property. Further, our
platform incorporates open source software components that are
licensed to us under various public domain licenses. While we
believe that we have complied with our obligations under the
various applicable licenses for open source software that we
use, there is little or no legal precedent governing the
interpretation of many of the terms of certain of these
licenses, and therefore the potential impact of such terms on
our business is somewhat unknown. The failure to adequately
protect our intellectual property and other proprietary rights
could materially harm our business.
In addition, if we resort to legal proceedings to enforce our
intellectual property rights or to determine the validity and
scope of the intellectual property or other proprietary rights
of others, the proceedings could be burdensome and expensive,
even if we were to prevail. Any litigation that may be necessary
in the future could result in substantial costs and diversion of
resources and could have a material adverse effect on our
business, operating results, or financial condition.
We may
be sued by third parties for alleged infringement of their
proprietary rights.
The software and Internet industries are characterized by the
existence of a large number of patents, trademarks, and
copyrights and by frequent litigation based on allegations of
infringement or other violations of intellectual property
rights. Moreover, our business involves the systematic gathering
and analysis of data about the requirements and behaviors of
payers and other third parties, some or all of which may be
claimed to be confidential or proprietary. We have received in
the past, and may receive in the future, communications from
third parties claiming that we have infringed on the
intellectual property rights of others. For example, a complaint
was recently filed by Prompt Medical Systems, L.P. naming us and
several other defendants alleging infringement of its patent
with a listed issue date in 1996 entitled Method for
Computing Current Procedural Terminology Codes from Physician
Generated Documentation. For additional information
regarding this litigation, see Part I, Item 3,
Legal Proceedings. Our technologies may not be able
to withstand such third-party claims of rights against their
use. Any intellectual property claims, with or without merit,
could be time-consuming and expensive to resolve, divert
management attention from executing our business plan, and
require us to pay monetary damages or enter into royalty or
licensing agreements. In addition, many of our contracts contain
warranties with respect to intellectual property rights, and
some require us to indemnify our clients for third-party
intellectual property infringement claims, which would increase
the cost to us of an adverse ruling on such a claim.
Moreover, any settlement or adverse judgment resulting from such
a claim could require us to pay substantial amounts of money or
obtain a license to continue to use the technology or
information that is the subject of the claim, or otherwise
restrict or prohibit our use of the technology or information.
There can be no assurance that we would be able to obtain a
license on commercially reasonable terms, if at all, from third
parties asserting an infringement claim; that we would be able
to develop alternative technology on a timely basis, if at all;
or that we would be able to obtain a license to use a suitable
alternative technology to permit us to continue offering, and
our clients to continue using, our affected services.
Accordingly, an adverse determination could prevent us from
offering our services to others. In addition, we may be required
to indemnify our clients for third-party intellectual property
infringement claims, which would increase the cost to us of an
adverse ruling for such a claim.
27
Our
loan and capital lease agreements contain operating and
financial covenants that may restrict our business and financing
activities.
We have loan and capital lease agreements with $9.2 million
outstanding at December 31, 2010. Borrowings are secured by
substantially all of our assets, including our intellectual
property. Our loan agreements restrict our ability to:
|
|
|
|
|
incur additional indebtedness;
|
|
|
|
create liens;
|
|
|
|
make investments;
|
|
|
|
sell assets;
|
|
|
|
pay dividends or make distributions on and, in certain cases,
repurchase our stock; or
|
|
|
|
consolidate or merge with other entities.
|
In addition, our credit facilities require us to meet specified
minimum financial measurements. The operating and financial
restrictions and covenants in these credit facilities, as well
as any future financing agreements that we may enter into, may
restrict our ability to finance our operations, engage in
business activities, or expand or fully pursue our business
strategies. Our loan agreements also contain certain financial
and nonfinancial covenants, including limitations on our
consolidated leverage ratio and capital expenditures, as well as
defaults relating to non-payment, breach of covenants,
inaccuracy of representations and warranties, default under
other indebtedness (including a cross-default with our interest
rate swap), bankruptcy and insolvency, inability to pay debts,
attachment of assets, adverse judgments, ERISA violations,
invalidity of loan and collateral documents, and change of
control. Our ability to comply with these covenants may be
affected by events beyond our control, and we may not be able to
meet those covenants. A breach of any of these covenants could
result in a default under either or both of the loan agreements,
which could cause all of the outstanding indebtedness under both
credit facilities to become immediately due and payable and
terminate all commitments to extend further credit.
We
have entered into a derivative contract with a financial
counterparty, the effectiveness of which is dependent on the
continued viability of this financial counterparty, and its
nonperformance could harm our financial condition.
We have entered into an interest rate swap contract as part of
our strategy to mitigate risks related to fluctuations in cash
flow from movement in interest rates. The effectiveness of our
hedging programs using this instrument is dependent, in part,
upon the counterparty to this contract honoring its financial
obligations. The recent upheaval in the capital markets has
caused the viability of certain counterparties to be questioned.
While we have not experienced any losses due to counterparty
nonperformance, if our counterparty is unable to perform its
obligations in the future, we could be exposed to increased
earnings and cash flow volatility.
We may
incur additional costs as a result of continuing to operate as a
public company, and our management may be required to devote
substantial time to new compliance initiatives.
As a public company, we incur significant legal, accounting, and
other expenses that we did not incur as a private company, and
greater expenditures may be necessary in the future with the
advent of new laws and regulations pertaining to public
companies. In addition, the Sarbanes-Oxley Act of 2002, as well
as rules subsequently implemented by the Securities and Exchange
Commission and the NASDAQ Global Select Market, have imposed
various requirements on public companies, including requiring
changes in corporate governance practices. Our management and
other personnel continue to devote a substantial amount of time
to these compliance initiatives, and additional laws and
regulations may divert further management resources. Moreover,
if we are not able to comply with the requirements of new
compliance initiatives in a timely manner, the market price of
our stock could decline, and we could be subject to sanctions or
investigations by the NASDAQ Global Select Market, the
Securities and Exchange Commission, or other regulatory
authorities, which would require additional financial and
management resources.
28
Changes
in accounting standards issued by the Financial Accounting
Standards Board (FASB) or other standard-setting
bodies may adversely affect our financial
statements.
Our financial statements are subject to the application of
U.S. GAAP, which are periodically revised or expanded.
Accordingly, from time to time we are required to adopt new or
revised accounting standards issued by recognized authoritative
bodies, including the FASB and the SEC. It is possible that
future accounting standards we are required to adopt could
change the current accounting treatment that we apply to our
consolidated financial statements and that such changes could
have a material adverse impact on our results of operations and
financial condition.
Current
and future litigation against us could be costly and
time-consuming to defend.
We may from time to time be subject to legal proceedings and
claims that arise in the ordinary course of business, such as
claims brought by our clients in connection with commercial
disputes and employment claims made by our current or former
employees. Claims may also be asserted by or on behalf of a
variety of other parties, including patients of our physician
clients, government agencies, or stockholders. For example, on
March 19, 2010, a putative shareholder class action
complaint was filed against us and certain of our current and
former officers in the United States District Court for the
District of Massachusetts alleging violation of the federal
securities laws by dissemination of false and misleading
statements. For additional information regarding this
litigation, see Part I, Item 3, Legal
Proceedings.
Any litigation involving us may result in substantial costs and
may divert managements attention and resources, which may
seriously harm our business, overall financial condition, and
operating results. Insurance may not cover existing or future
claims, be sufficient to fully compensate us for one or more of
such claims, or continue to be available on terms acceptable to
us. A claim brought against us that is uninsured or underinsured
could result in unanticipated costs, thereby reducing our
operating results and leading analysts or potential investors to
reduce their expectations of our performance resulting in a
reduction in the trading price of our stock.
RISKS
RELATED TO OUR SERVICE OFFERINGS
Our
proprietary software or our services may not operate properly,
which could damage our reputation, give rise to claims against
us, or divert application of our resources from other purposes,
any of which could harm our business and operating
results.
Proprietary software development is time-consuming, expensive,
and complex. Unforeseen difficulties can arise. We may encounter
technical obstacles, and it is possible that we discover
additional problems that prevent our proprietary athenaNet
application from operating properly. If athenaNet does not
function reliably or fails to achieve client expectations in
terms of performance, clients could assert liability claims
against us
and/or
attempt to cancel their contracts with us. This could damage our
reputation and impair our ability to attract or maintain clients.
Moreover, information services as complex as those we offer have
in the past contained, and may in the future develop or contain,
undetected defects or errors. We cannot assure you that material
performance problems or defects in our services will not arise
in the future. Errors may result from receipt, entry, or
interpretation of patient information or from interface of our
services with legacy systems and data that we did not develop
and the function of which is outside of our control. Despite
testing, defects or errors may arise in our existing or new
software or service processes. Because changes in payer
requirements and practices are frequent and sometimes difficult
to determine except through trial and error, we are continuously
discovering defects and errors in our software and service
processes compared against these requirements and practices.
These defects and errors and any failure by us to identify and
address them could result in loss of revenue or market share,
liability to clients or others, failure to achieve market
acceptance or expansion, diversion of development resources,
injury to our reputation, and increased service and maintenance
costs. Defects or errors in our software and service processes
might discourage existing or potential clients from purchasing
services from us. Correction of defects or errors could prove to
be impossible or impracticable. The costs incurred in
29
correcting any defects or errors or in responding to resulting
claims or liability may be substantial and could adversely
affect our operating results.
In addition, clients relying on our services to collect, manage,
and report clinical, business, and administrative data may have
a greater sensitivity to service errors and security
vulnerabilities than clients of software products in general. We
market and sell services that, among other things, provide
information to assist care providers in tracking and treating
ill patients. Any operational delay in or failure of our
technology or service processes may result in the disruption of
patient care and could cause harm to patients and thereby harm
our business and operating results.
Our clients or their patients may assert claims against us
alleging that they suffered damages due to a defect, error, or
other failure of our software or service processes. A product
liability claim or errors or omissions claim could subject us to
significant legal defense costs and adverse publicity,
regardless of the merits or eventual outcome of such a claim.
If our
security measures are breached or fail, and unauthorized access
is obtained to a clients data, our services may be
perceived as not being secure, clients may curtail or stop using
our services, and we may incur significant
liabilities.
Our services involve the storage and transmission of
clients proprietary information and protected health
information of patients. Because of the sensitivity of this
information, security features of our software are very
important. If our security measures are breached or fail as a
result of third-party action, employee error, malfeasance,
insufficiency, defective design, or otherwise, someone may be
able to obtain unauthorized access to client or patient data. As
a result, our reputation could be damaged, our business may
suffer, and we could face damages for contract breach, penalties
for violation of applicable laws or regulations, and significant
costs for remediation and remediation efforts to prevent future
occurrences. We rely upon our clients as users of our system for
key activities to promote security of the system and the data
within it, such as administration of client-side access
credentialing and control of client-side display of data. On
occasion, our clients have failed to perform these activities.
Failure of clients to perform these activities may result in
claims against us that this reliance was misplaced, which could
expose us to significant expense and harm to our reputation.
Because techniques used to obtain unauthorized access or to
sabotage systems change frequently and generally are not
recognized until launched against a target, we may be unable to
anticipate these techniques or to implement adequate preventive
measures. If an actual or perceived breach of our security
occurs, the market perception of the effectiveness of our
security measures could be harmed and we could lose sales and
clients. In addition, our clients may authorize or enable third
parties to access their client data or the data of their
patients on our systems. Because we do not control such access,
we cannot ensure the complete propriety of that access or
integrity or security of such data in our systems.
Failure
by our clients to obtain proper permissions and waivers may
result in claims against us or may limit or prevent our use of
data, which could harm our business.
We require our clients to provide necessary notices and to
obtain necessary permissions and waivers for use and disclosure
of the information that we receive, and we require contractual
assurances from them that they have done so and will do so. If
they do not obtain necessary permissions and waivers, then our
use and disclosure of information that we receive from them or
on their behalf may be limited or prohibited by state or federal
privacy laws or other laws. This could impair our functions,
processes, and databases that reflect, contain, or are based
upon such data and may prevent use of such data. In addition,
this could interfere with or prevent creation or use of rules,
and analyses or limit other data-driven activities that benefit
us. Moreover, we may be subject to claims or liability for use
or disclosure of information by reason of lack of valid notice,
permission, or waiver. These claims or liabilities could subject
us to unexpected costs and adversely affect our operating
results.
30
Various
events could interrupt clients access to athenaNet,
exposing us to significant costs.
The ability to access athenaNet is critical to our clients
administering care, cash flow, and business viability. Our
operations and facilities are vulnerable to interruption
and/or
damage from a number of sources, many of which are beyond our
control, including, without limitation: (i) power loss and
telecommunications failures; (ii) fire, flood, hurricane,
and other natural disasters; (iii) software and hardware
errors, failures, or crashes in our own systems or in other
systems; and (iv) computer viruses, hacking, and similar
disruptive problems in our own systems and in other systems. We
attempt to mitigate these risks through various means, including
redundant infrastructure, disaster recovery plans, business
continuity plans, separate test systems, and change control and
system security measures, but our precautions will not protect
against all potential problems. If clients access is
interrupted because of problems in the operation of our
facilities, we could be exposed to significant claims by clients
or their patients, particularly if the access interruption is
associated with problems in the timely delivery of funds due to
clients or medical information relevant to patient care. Our
plans for disaster recovery and business continuity rely upon
third-party providers of related services, and if those vendors
fail us at a time that our systems are not operating correctly,
we could incur a loss of revenue and liability for failure to
fulfill our obligations. Any significant instances of system
downtime could negatively affect our reputation and ability to
retain clients and sell our services, which would adversely
impact our revenues.
In addition, retention and availability of patient care and
physician reimbursement data are subject to federal and state
laws governing record retention, accuracy, and access. Some laws
impose obligations on our clients and on us to produce
information to third parties and to amend or expunge data at
their direction. Our failure to meet these obligations may
result in liability that could increase our costs and reduce our
operating results.
Interruptions
or delays in service from our third-party data-hosting
facilities could impair the delivery of our services and harm
our business.
We currently serve our clients from a third-party data-hosting
facility located in Bedford, Massachusetts, operated by Digital
55 Middlesex, LLC (as successor to Sentinel Properties-Bedford,
LLC). In addition, in December 2009 we signed a contract with a
major provider of disaster recovery services, SunGard
Availability Services, LP, to store our disaster recovery plans,
deepen the resiliency of our technology recovery infrastructure,
and provide disaster recovery testing services. In the case of a
significant event at our primary data center, we could become
operational in a reasonable timeframe at our backup data center.
However, we do not control the operation of any of these
facilities, and they are vulnerable to damage or interruption
from earthquakes, floods, fires, power loss, telecommunications
failures, and similar events. They are also subject to
break-ins, sabotage, intentional acts of vandalism, and similar
misconduct. Despite precautions taken at these facilities, the
occurrence of a natural disaster or an act of terrorism, a
decision to close the facilities without adequate notice, or
other unanticipated problems at both facilities could result in
lengthy interruptions in our service. Even with the disaster
recovery arrangements, our services could be interrupted.
We
rely on Internet infrastructure, bandwidth providers, data
center providers, other third parties, and our own systems for
providing services to our users, and any failure or interruption
in the services provided by these third parties or our own
systems could expose us to litigation and negatively impact our
relationships with users, adversely affecting our brand and our
business.
Our ability to deliver our Internet- and
telecommunications-based services is dependent on the
development and maintenance of the infrastructure of the
Internet and other telecommunications services by third parties.
This includes maintenance of a reliable network backbone with
the necessary speed, data capacity, and security for providing
reliable Internet access and services and reliable telephone,
facsimile, and pager systems. Our services are designed to
operate without interruption in accordance with our service
level commitments. However, we have experienced and expect that
we will in the future experience interruptions and delays in
services and availability from time to time. We rely on internal
systems as well as third-party
31
vendors, including data center, bandwidth, and
telecommunications equipment providers, to provide our services.
We do not maintain redundant systems or facilities for some of
these services. In the event of a catastrophic event with
respect to one or more of these systems or facilities, we may
experience an extended period of system unavailability, which
could negatively impact our relationship with users. To operate
without interruption, both we and our service providers must
guard against:
|
|
|
|
|
damage from fire, power loss, and other natural disasters;
|
|
|
|
communications failures;
|
|
|
|
software and hardware errors, failures, and crashes;
|
|
|
|
security breaches, computer viruses, and similar disruptive
problems; and
|
|
|
|
other potential interruptions.
|
Any disruption in the network access, telecommunications, or
co-location services provided by these third-party providers or
any failure of or by these third-party providers or our own
systems to handle current or higher volume of use could
significantly harm our business. We exercise limited control
over these third-party vendors, which increases our
vulnerability to problems with services they provide.
Any errors, failures, interruptions, or delays experienced in
connection with these third-party technologies and information
services or our own systems could negatively impact our
relationships with users and adversely affect our business and
could expose us to third-party liabilities. Although we maintain
insurance for our business, the coverage under our policies may
not be adequate to compensate us for all losses that may occur.
In addition, we cannot provide assurance that we will continue
to be able to obtain adequate insurance coverage at an
acceptable cost.
The reliability and performance of the Internet may be harmed by
increased usage or by
denial-of-service
attacks. The Internet has experienced a variety of outages and
other delays as a result of damages to portions of its
infrastructure, and it could face outages and delays in the
future. These outages and delays could reduce the level of
Internet usage as well as the availability of the Internet to us
for delivery of our Internet-based services.
We
rely on third-party computer hardware and software that may be
difficult to replace or that could cause errors or failures of
our services, which could damage our reputation, harm our
ability to attract and maintain clients, and decrease our
revenue.
We rely on computer hardware purchased or leased and software
licensed from third parties in order to offer our services,
including database software from Oracle Corporation and storage
devices from International Business Machines Corporation and EMC
Corporation. These licenses are generally commercially available
on varying terms; however, it is possible that this hardware and
software may not continue to be available on commercially
reasonable terms, or at all. Any loss of the right to use any of
this hardware or software could result in delays in the
provisioning of our services until equivalent technology is
either developed by us, or, if available, is identified,
obtained, and integrated, which could harm our business. Any
errors or defects in third-party hardware or software could
result in errors or a failure of our services, which could
damage our reputation, harm our ability to attract and maintain
clients, and decrease our revenue.
We are
subject to the effect of payer and provider conduct that we
cannot control and that could damage our reputation with clients
and result in liability claims that increase our
expenses.
We offer certain electronic claims submission services for which
we rely on content from clients, payers, and others. While we
have implemented certain features and safeguards designed to
maximize the accuracy and completeness of claims content, these
features and safeguards may not be sufficient to prevent
inaccurate claims data from being submitted to payers. Should
inaccurate claims data be submitted to payers, we may experience
poor operational results and may be subject to liability claims,
which could damage our reputation with clients and result in
liability claims that increase our expenses.
32
If our
services fail to provide accurate and timely information, or if
our content or any other element of any of our services is
associated with faulty clinical decisions or treatment, we could
have liability to clients, clinicians, or patients, which could
adversely affect our results of operations.
Our software, content, and services are used to assist clinical
decision-making and provide information about patient medical
histories and treatment plans. If our software, content, or
services fail to provide accurate and timely information or are
associated with faulty clinical decisions or treatment, then
clients, clinicians, or their patients could assert claims
against us that could result in substantial costs to us, harm
our reputation in the industry, and cause demand for our
services to decline.
Our proprietary athenaClinicals service is utilized in clinical
decision-making, provides access to patient medical histories,
and assists in creating patient treatment plans, including the
issuance of prescription drugs. If our athenaClinicals service
fails to provide accurate and timely information, or if our
content or any other element of that service is associated with
faulty clinical decisions or treatment, we could have liability
to clients, clinicians, or patients.
The assertion of such claims and ensuing litigation, regardless
of its outcome, could result in substantial cost to us, divert
managements attention from operations, damage our
reputation, and decrease market acceptance of our services. We
attempt to limit by contract our liability for damages and to
require that our clients assume responsibility for medical care
and approve key system rules, protocols, and data. Despite these
precautions, the allocations of responsibility and limitations
of liability set forth in our contracts may not be enforceable,
be binding upon patients, or otherwise protect us from liability
for damages.
We maintain general liability and insurance coverage, but this
coverage may not continue to be available on acceptable terms or
may not be available in sufficient amounts to cover one or more
large claims against us. In addition, the insurer might disclaim
coverage as to any future claim. One or more large claims could
exceed our available insurance coverage.
Our proprietary software may contain errors or failures that are
not detected until after the software is introduced or updates
and new versions are released. It is challenging for us to test
our software for all potential problems because it is difficult
to simulate the wide variety of computing environments or
treatment methodologies that our clients may deploy or rely
upon. From time to time we have discovered defects or errors in
our software, and such defects or errors can be expected to
appear in the future. Defects and errors that are not timely
detected and remedied could expose us to risk of liability to
clients, clinicians, and patients and cause delays in
introduction of new services, result in increased costs and
diversion of development resources, require design
modifications, or decrease market acceptance or client
satisfaction with our services.
If any of these risks occur, they could materially adversely
affect our business, financial condition, or results of
operations.
We may
be liable for use of incorrect or incomplete data that we
provide, which could harm our business, financial condition, and
results of operations.
We store and display data for use by healthcare providers in
treating patients. Our clients or third parties provide us with
most of these data. If these data are incorrect or incomplete or
if we make mistakes in the capture or input of these data,
adverse consequences, including death, may occur and give rise
to product liability and other claims against us. In addition, a
court or government agency may take the position that our
storage and display of health information exposes us to personal
injury liability or other liability for wrongful delivery or
handling of healthcare services or erroneous health information.
While we maintain insurance coverage, we cannot assure that this
coverage will prove to be adequate or will continue to be
available on acceptable terms, if at all. Even unsuccessful
claims could result in substantial costs and diversion of
management resources. A claim brought against us that is
uninsured or under-insured could harm our business, financial
condition, and results of operations.
RISKS
RELATED TO REGULATION
33
Government
regulation of healthcare creates risks and challenges with
respect to our compliance efforts and our business
strategies.
The healthcare industry is highly regulated and is subject to
changing political, legislative, regulatory, and other
influences. Existing and new laws and regulations affecting the
healthcare industry could create unexpected liabilities for us,
cause us to incur additional costs, and restrict our operations.
Many healthcare laws are complex, and their application to
specific services and relationships may not be clear. In
particular, many existing healthcare laws and regulations, when
enacted, did not anticipate the healthcare information services
that we provide, and these laws and regulations may be applied
to our services in ways that we do not anticipate. Our failure
to accurately anticipate the application of these laws and
regulations, or our other failure to comply, could create
liability for us, result in adverse publicity, and negatively
affect our business. Some of the risks we face from healthcare
regulation are described below:
|
|
|
|
|
False or Fraudulent Claim Laws. There are
numerous federal and state laws that forbid submission of false
information or the failure to disclose information in connection
with submission and payment of physician claims for
reimbursement. In some cases, these laws also forbid abuse of
existing systems for such submission and payment. Any failure of
our services to comply with these laws and regulations could
result in substantial liability (including, but not limited to,
criminal liability), adversely affect demand for our services,
and force us to expend significant capital, research and
development, and other resources to address the failure. Errors
by us or our systems with respect to entry, formatting,
preparation, or transmission of claim information may be
determined or alleged to be in violation of these laws and
regulations. Any determination by a court or regulatory agency
that our services violate these laws could subject us to civil
or criminal penalties, invalidate all or portions of some of our
client contracts, require us to change or terminate some
portions of our business, require us to refund portions of our
services fees, cause us to be disqualified from serving clients
doing business with government payers, and have an adverse
effect on our business.
|
In most cases where we are permitted to do so, we calculate
charges for our services based on a percentage of the
collections that our clients receive as a result of our
services. To the extent that violations or liability for
violations of these laws and regulations require intent, it may
be alleged that this percentage calculation provides us or our
employees with incentive to commit or overlook fraud or abuse in
connection with submission and payment of reimbursement claims.
The U.S. Centers for Medicare and Medicaid Services has
stated that it is concerned that percentage-based billing
services may encourage billing companies to commit or to
overlook fraudulent or abusive practices.
In addition, we may contract with third parties that offer
software relating to the selection or verification of codes used
to identify and classify the services for which reimbursement is
sought. Submission of codes that do not accurately reflect the
services provided or the location or method of their provision
may constitute a violation of false or fraudulent claims laws.
Our ability to comply with these laws depends on the coding
decisions made by our clients and the accuracy of our
vendors software and services in suggesting possible codes
to our clients and verifying that proper codes have been
selected.
|
|
|
|
|
HIPAA and other Health Privacy
Regulations. There are numerous federal and state
laws related to patient privacy. In particular, the Health
Insurance Portability and Accountability Act of 1996, or HIPAA,
includes privacy standards that protect individual privacy by
limiting the uses and disclosures of individually identifiable
health information and implementing data security standards that
require covered entities to implement administrative, physical,
and technological safeguards to ensure the confidentiality,
integrity, availability, and security of individually
identifiable health information in electronic form. HIPAA also
specifies formats that must be used in certain electronic
transactions, such as claims, payment advice, and eligibility
inquiries. Because we translate electronic transactions to and
from HIPAA-prescribed electronic formats and other forms, we are
a clearinghouse and, as such, a covered entity. In addition, our
clients are also covered entities and are mandated by HIPAA to
enter into written agreements with us known as
business associate agreements that require us to
safeguard individually identifiable health information. Business
associate agreements typically include:
|
|
|
|
a description of our permitted uses of individually identifiable
health information;
|
34
|
|
|
|
|
a covenant not to disclose the information except as permitted
under the agreement and to make our subcontractors, if any,
subject to the same restrictions;
|
|
|
|
assurances that appropriate administrative, physical, and
technical safeguards are in place to prevent misuse of the
information;
|
|
|
|
an obligation to report to our client any use or disclosure of
the information other than as provided for in the agreement;
|
|
|
|
a prohibition against our use or disclosure of the information
if a similar use or disclosure by our client would violate the
HIPAA standards;
|
|
|
|
the ability of our clients to terminate the underlying support
agreement if we breach a material term of the business associate
agreement and are unable to cure the breach;
|
|
|
|
the requirement to return or destroy all individually
identifiable health information at the end of our support
agreement; and
|
|
|
|
access by the Department of Health and Human Services to our
internal practices, books, and records to validate that we are
safeguarding individually identifiable health information.
|
We may not be able to adequately address the business risks
created by HIPAA implementation. Furthermore, we are unable to
predict what changes to HIPAA or other laws or regulations might
be made in the future or how those changes could affect our
business or the costs of compliance. For example, the provisions
of the HITECH Act and the regulations issued under it have
provided and are expected to provide clarification of certain
aspects of both the Privacy and Security Rules, expansion of the
disclosure requirements for a breach of the Security Rule, and
strengthening of the civil and criminal penalties for failure to
comply with HIPAA. In addition, ONCHIT is coordinating the
ongoing development of national standards for creating an
interoperable health information technology infrastructure based
on the widespread adoption of electronic health records in the
healthcare sector. We are unable to predict what, if any, impact
the changes in such standards will have on our compliance costs
or our services.
In addition, some payers and clearinghouses with which we
conduct business interpret HIPAA transaction requirements
differently than we do. Where clearinghouses or payers require
conformity with their interpretations as a condition of
effecting transactions, we seek to comply with their
interpretations.
The HIPAA transaction standards include proper use of procedure
and diagnosis codes. Since these codes are selected or approved
by our clients, and since we do not verify their propriety, some
of our capability to comply with the transaction standards is
dependent on the proper conduct of our clients.
Among our services, we provide telephone reminder services to
patients, Internet- and telephone-based access to medical test
results, pager and email notification to practices of patient
calls, and patient call answering services. We believe that
reasonable efforts to prevent disclosure of individually
identifiable health information have been and are being taken in
connection with these services, including the use of
multiple-password security. However, any failure of our clients
to provide accurate contact information for their patients or
physicians or any breach of our telecommunications systems could
result in a disclosure of individually identifiable health
information.
In addition to the HIPAA Privacy and Security Rules and the
HITECH Act requirements, most states have enacted patient
confidentiality laws that protect against the disclosure of
confidential medical information, and many states have adopted
or are considering further legislation in this area, including
privacy safeguards, security standards, and data security breach
notification requirements. Such state laws, if more stringent
than HIPAA and HITECH Act requirements, are not preempted by the
federal requirements, and we are required to comply with them.
Failure by us to comply with any of the federal and state
standards regarding patient privacy may subject us to penalties,
including civil monetary penalties and, in some circumstances,
criminal penalties. In addition, such failure may injure our
reputation and adversely affect our ability to retain clients
and attract new clients.
35
We are subject to a variety of other regulatory schemes,
including:
|
|
|
|
|
Anti-Kickback and Anti-Bribery Laws. There are
federal and state laws that govern patient referrals, physician
financial relationships, and inducements to healthcare providers
and patients. For example, the federal healthcare programs
anti-kickback law prohibits any person or entity from offering,
paying, soliciting, or receiving anything of value, directly or
indirectly, for the referral of patients covered by Medicare,
Medicaid, and other federal healthcare programs or the leasing,
purchasing, ordering, or arranging for or recommending the
lease, purchase, or order of any item, good, facility, or
service covered by these programs. Many states also have similar
anti-kickback laws that are not necessarily limited to items or
services for which payment is made by a federal healthcare
program. Moreover, both federal and state laws forbid bribery
and similar behavior. Any determination by a state or federal
regulatory agency that any of our activities or those of our
clients, vendors, or channel partners violate any of these laws
could subject us to civil or criminal penalties, require us to
change or terminate some portions of our business, require us to
refund a portion of our service fees, disqualify us from
providing services to clients doing business with government
programs, and have an adverse effect on our business. Even an
unsuccessful challenge by regulatory authorities of our
activities could result in adverse publicity and could require a
costly response from us.
|
|
|
|
Anti-Referral Laws. There are federal and
state laws that forbid payment for patient referrals, patient
brokering, remuneration of patients, or billing based on
referrals between individuals
and/or
entities that have various financial, ownership, or other
business relationships with health care providers. In many
cases, billing for care arising from such actions is illegal.
These vary widely from state to state, and one of the federal
laws called the Stark Law is very
complex in its application. Any determination by a state or
federal regulatory agency that any of our clients violate or
have violated any of these laws may result in allegations that
claims that we have processed or forwarded are improper. This
could subject us to civil or criminal penalties, require us to
change or terminate some portions of our business, require us to
refund portions of our services fees, and have an adverse effect
on our business. Even an unsuccessful challenge by regulatory
authorities of our activities could result in adverse publicity
and could require a costly response from us.
|
|
|
|
Corporate Practice of Medicine Laws and Fee-Splitting
Laws. Many states have laws forbidding physicians
from practicing medicine in partnership with non-physicians,
such as business corporations. In some states, including New
York, these take the form of laws or regulations forbidding
splitting of physician fees with non-physicians or others. In
some cases, these laws have been interpreted to prevent business
service providers from charging their physician clients on the
basis of a percentage of collections or charges. We have varied
our charge structure in some states to comply with these laws,
which may make our services less desirable to potential clients.
Any determination by a state court or regulatory agency that our
service contracts with our clients violate these laws could
subject us to civil or criminal penalties, invalidate all or
portions of some of our client contracts, require us to change
or terminate some portions of our business, require us to refund
portions of our services fees, and have an adverse effect on our
business. Even an unsuccessful challenge by regulatory
authorities of our activities could result in adverse publicity
and could require a costly response from us.
|
|
|
|
Anti-Assignment Laws. There are federal and
state laws that prohibit or limit assignment of claims for
reimbursement from government-funded programs. In some cases,
these laws have been interpreted in regulations or policy
statements to limit the manner in which business service
companies may handle checks or other payments for such claims
and to limit or prevent such companies from charging their
physician clients on the basis of a percentage of collections or
charges. Any determination by a state court or regulatory agency
that our service contracts with our clients violate these laws
could subject us to civil or criminal penalties, invalidate all
or portions of some of our client contracts, require us to
change or terminate some portions of our business, require us to
refund portions of our services fees, and have an adverse effect
on our business. Even an unsuccessful challenge by regulatory
authorities of our activities could result in adverse publicity
and could require a costly response from us.
|
36
|
|
|
|
|
Prescribing Laws. The use of our software by
physicians to perform a variety of functions relating to
prescriptions, including electronic prescribing, electronic
routing of prescriptions to pharmacies, and dispensing of
medication, is governed by state and federal law, including
fraud and abuse laws, drug control regulations, and state
department of health regulations. States have differing
prescription format requirements, and, due in part to recent
industry initiatives, federal law and the laws of all
50 states now provide a regulatory framework for the
electronic transmission of prescription orders. Regulatory
authorities such as the U.S. Department of Health and Human
Services Centers for Medicare and Medicaid Services may
impose functionality standards with regard to electronic
prescribing and EHR technologies. Any determination that we or
our clients have violated prescribing laws may expose us to
liability, loss of reputation, and loss of business. These laws
and requirements may also increase the cost and time necessary
to market new services and could affect us in other respects not
presently foreseeable.
|
|
|
|
Electronic Medical Records Laws. A number of
federal and state laws govern the use and content of electronic
health record systems, including fraud and abuse laws that may
affect how such technology is provided. As a company that
provides EHR functionality, our systems and services must be
designed in a manner that facilitates our clients
compliance with these laws. Because this is a topic of
increasing state and federal regulation, we expect additional
and continuing modification of the current legal and regulatory
environment. We cannot predict the content or effect of possible
future regulation on our business activities. The software
component of our athenaClinicals service was certified as a
2011/2012 compliant Complete EHR by CCHIT, an ONC-ATCB, in
accordance with the applicable certification criteria adopted by
the Secretary of the U.S. Department of Health and Human
Services (HHS). The 2011/2012 criteria support the Stage 1
meaningful use measures required to qualify eligible providers
and hospitals for funding under the HITECH Act. However, such
certification does not represent an endorsement of our
athenaClinicals service by HHS or guarantee the receipt of
incentive payments. While we believe that our system is well
designed in terms of function and interoperability, we cannot be
certain that it will meet future requirements.
|
|
|
|
Claims Transmission Laws. Our services include
the manual and electronic transmission of our clients
claims for reimbursement from payers. Federal and various state
laws provide for civil and criminal penalties for any person who
submits, or causes to be submitted, a claim to any payer
(including, without limitation, Medicare, Medicaid, and any
private health plans and managed care plans) that is false or
that overbills or bills for items that have not been provided to
the patient. Although we do not determine what is billed to a
payer, to the extent that such laws apply to a service that
merely transmits claims on behalf of others, we could be subject
to the same civil and criminal penalties as our clients.
|
|
|
|
Prompt Pay Laws. Laws in many states govern
prompt payment obligations for healthcare services. These laws
generally define claims payment processes and set specific time
frames for submission, payment, and appeal steps. They
frequently also define and require clean claims. Failure to meet
these requirements and timeframes may result in rejection or
delay of claims. Failure of our services to comply may adversely
affect our business results and give rise to liability claims by
clients.
|
|
|
|
Medical Device Laws. The U.S. Food and
Drug Administration (FDA) has promulgated a draft policy for the
regulation of computer software products as medical devices
under the 1976 Medical Device Amendments to the Federal Food,
Drug and Cosmetic Act. To the extent that computer software is a
medical device under the policy, we, as a provider of
application functionality, could be required, depending on the
functionality, to:
|
|
|
|
register and list our products with the FDA;
|
|
|
|
notify the FDA and demonstrate substantial equivalence to other
products on the market before marketing our
functionality; or
|
|
|
|
obtain FDA approval by demonstrating safety and effectiveness
before marketing our functionality.
|
37
The FDA can impose extensive requirements governing pre- and
post-market conditions such as service investigation and others
relating to approval, labeling, and manufacturing. In addition,
the FDA can impose extensive requirements governing development
controls and quality assurance processes.
Potential
healthcare reform and new regulatory requirements placed on our
software, services, and content could impose increased costs on
us, delay or prevent our introduction of new services types, and
impair the function or value of our existing service
types.
Our services may be significantly impacted by healthcare reform
initiatives and are subject to increasing regulatory
requirements, either of which could affect our business in a
multitude of ways. If substantive healthcare reform or
applicable regulatory requirements are adopted, we may have to
change or adapt our services and software to comply. Reform or
changing regulatory requirements may render our services
obsolete or may block us from accomplishing our work or from
developing new services. This may in turn impose additional
costs upon us to adapt to the new operating environment or to
further develop services or software. It may also make
introduction of new service types more costly or more time
consuming than we currently anticipate. Such changes may even
prevent introduction by us of new services or make the
continuation of our existing services unprofitable or impossible.
Potential
additional regulation of the disclosure of health information
outside the United States may adversely affect our operations
and may increase our costs.
Federal or state governmental authorities may impose additional
data security standards or additional privacy or other
restrictions on the collection, use, transmission, and other
disclosures of health information. Legislation has been proposed
at various times at both the federal and the state level that
would limit, forbid, or regulate the use or transmission of
medical information outside of the United States. Such
legislation, if adopted, may render our use of our off-shore
partners, such as our data-entry and customer service providers,
International Business Machines Corporation and Vision Business
Process Solutions Inc., for work related to such data
impracticable or substantially more expensive. Alternative
processing of such information within the United States may
involve substantial delay in implementation and increased cost.
Changes
in the healthcare industry could affect the demand for our
services, cause our existing contracts to terminate, and
negatively impact the process of negotiating future
contracts.
As the healthcare industry evolves, changes in our client and
vendor bases may reduce the demand for our services, result in
the termination of existing contracts, and make it more
difficult to negotiate new contracts on terms that are
acceptable to us. For example, the current trend toward
consolidation of healthcare providers within hospital systems
may cause our existing client contracts to terminate as
independent practices are merged into hospital systems. Such
larger healthcare organizations may also have their own practice
management services and health IT systems, reducing demand for
our services. Similarly, client and vendor consolidation results
in fewer, larger entities with increased bargaining power and
the ability to demand terms that are unfavorable to us. If these
trends continue, we cannot assure you that we will be able to
continue to maintain or expand our client base, negotiate
contracts with acceptable terms, or maintain our current pricing
structure, and our revenues may decrease.
Errors
or illegal activity on the part of our clients may result in
claims against us.
We require our clients to provide us with accurate and
appropriate data and directives for our actions. We also rely
upon our clients as users of our system to perform key
activities in order to produce proper claims for reimbursement.
Failure of our clients to provide these data and directives or
to perform these activities may result in claims against us
alleging that our reliance was misplaced or unreasonable or that
we have facilitated or otherwise participated in submission of
false claims.
38
Our
services present the potential for embezzlement, identity theft,
or other similar illegal behavior by our employees or
subcontractors with respect to third parties.
Among other things, our services involve handling mail from
payers and from patients for many of our clients, and this mail
frequently includes original checks
and/or
credit card information and occasionally includes currency. Even
in those cases in which we do not handle original documents or
mail, our services also involve the use and disclosure of
personal and business information that could be used to
impersonate third parties or otherwise gain access to their data
or funds. If any of our employees or subcontractors takes,
converts, or misuses such funds, documents, or data, we could be
liable for damages, and our business reputation could be damaged
or destroyed. In addition, we could be perceived to have
facilitated or participated in illegal misappropriation of
funds, documents, or data and therefore be subject to civil or
criminal liability.
Potential
subsidy of services similar to ours may reduce client
demand.
Recently, entities such as the Massachusetts Healthcare
Consortium have offered to subsidize adoption by physicians of
EHR technology. In addition, federal regulations have been
changed to permit such subsidy from additional sources subject
to certain limitations, and the current administration has
passed the HITECH Act, which will provide federal support for
EHR initiatives. To the extent that we do not qualify or
participate in such subsidy programs, demand for our services
may be reduced, which may decrease our revenues.
RISKS
RELATED TO OWNERSHIP OF OUR COMMON STOCK
The
price of our common stock may continue to be
volatile.
The trading price of our common stock has been and is likely to
remain highly volatile and could be subject to wide fluctuations
in response to various factors, some of which are beyond our
control or unrelated to our operating performance. In addition
to the factors discussed in this Risk Factors
section and elsewhere in this Annual Report on
Form 10-K,
these factors include:
|
|
|
|
|
the operating performance of similar companies;
|
|
|
|
the overall performance of the equity markets;
|
|
|
|
announcements by us or our competitors of acquisitions, business
plans, or commercial relationships;
|
|
|
|
threatened or actual litigation;
|
|
|
|
changes in laws or regulations relating to the sale of health
insurance;
|
|
|
|
any major change in our board of directors or management;
|
|
|
|
publication of research reports or news stories about us, our
competitors, or our industry or positive or negative
recommendations or withdrawal of research coverage by securities
analysts;
|
|
|
|
large volumes of sales of our shares of common stock by existing
stockholders; and
|
|
|
|
general political and economic conditions.
|
In addition, the stock market in general, and the market for
Internet-related companies in particular, has experienced
extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of
those companies. Securities class action litigation has often
been instituted against companies following periods of
volatility in the overall market and in the market price of a
companys securities. This litigation, if instituted
against us, could result in very substantial costs; divert our
managements attention and resources; and harm our
business, operating results, and financial condition.
39
If a
substantial number of shares become available for sale and are
sold in a short period of time, the market price of our common
stock could decline.
If our existing stockholders sell a large number of shares of
our common stock or the public market perceives that these sales
may occur, the market price of our common stock could decline.
As of December 31, 2010, we had approximately
34.5 million shares of common stock outstanding. Moreover,
the holders of shares of common stock have rights, subject to
some conditions, to require us to file registration statements
covering the shares they currently hold, or to include these
shares in registration statements that we may file for ourselves
or other stockholders.
We have also registered all common stock that we may issue under
our 1997 Stock Plan, 2000 Stock Plan, 2007 Stock Option and
Incentive Plan, and 2007 Employee Stock Purchase Plan. As of
December 31, 2010, we had outstanding options to purchase
approximately 3.3 million shares of common stock
(approximately 1.6 million of which were exercisable at
December 31, 2010) that, if exercised, will result in
those shares becoming available for sale in the public market.
As of December 31, 2010, we had outstanding restricted
stock units totaling approximately 0.3 million that, if
vested, will result in those shares becoming available for sale
in the public market. If a large number of these shares are sold
in the public market, the sales could reduce the trading price
of our common stock.
Actual
or potential sales of our stock by our employees, including
members of our senior management team, pursuant to pre-arranged
stock trading plans could cause our stock price to fall or
prevent it from increasing for numerous reasons, and actual or
potential sales by such persons could be viewed negatively by
other investors.
In accordance with the guidelines specified under
Rule 10b5-1
of the Securities and Exchange Act of 1934 and our policies
regarding stock transactions, a number of our directors and
employees, including members of our senior management team, have
adopted and will continue to adopt pre-arranged stock trading
plans to sell a portion of our common stock. Generally, stock
sales under such plans by members of our senior management team
and directors require public filings. Actual or potential sales
of our stock by such persons could cause our stock price to fall
or prevent it from increasing for numerous reasons. For example,
a substantial amount of our common stock becoming available (or
being perceived to become available) for sale in the public
market could cause the market price of our common stock to fall
or prevent it from increasing. Also, actual or potential sales
by such persons could be viewed negatively by other investors.
Provisions
in our certificate of incorporation and by-laws or Delaware law
might discourage, delay, or prevent a change of control of our
company or changes in our management and, therefore, depress the
trading price of our common stock.
Provisions of our certificate of incorporation and by-laws and
Delaware law may discourage, delay, or prevent a merger,
acquisition, or other change in control that stockholders may
consider favorable, including transactions in which you might
otherwise receive a premium for your shares of our common stock.
These provisions may also prevent or frustrate attempts by our
stockholders to replace or remove our management. These
provisions include:
|
|
|
|
|
limitations on the removal of directors;
|
|
|
|
advance notice requirements for stockholder proposals and
nominations;
|
|
|
|
the inability of stockholders to act by written consent or to
call special meetings; and
|
|
|
|
the ability of our board of directors to make, alter, or repeal
our by-laws.
|
The affirmative vote of the holders of at least 75% of our
shares of capital stock entitled to vote is necessary to amend
or repeal the above provisions of our certificate of
incorporation. As our board of directors has the ability to
designate the terms of and issue new series of preferred stock
without stockholder approval, the effective number of votes
required to make such changes could increase. Also, absent
approval of our
40
board of directors, our by-laws may only be amended or repealed
by the affirmative vote of the holders of at least 75% of our
shares of capital stock entitled to vote.
In addition, Section 203 of the Delaware General
Corporation Law prohibits a publicly held Delaware corporation
from engaging in a business combination with an interested
stockholder (generally an entity that, together with its
affiliates, owns, or within the last three years has owned, 15%
or more of our voting stock) for a period of three years after
the date of the transaction in which the entity became an
interested stockholder, unless the business combination is
approved in a prescribed manner.
The existence of the foregoing provisions and anti-takeover
measures could limit the price that investors might be willing
to pay in the future for shares of our common stock. They could
also deter potential acquirers of our company, thereby reducing
the likelihood that you could receive a premium for your common
stock in an acquisition.
We do
not currently intend to pay dividends on our common stock, and,
consequently, your ability to achieve a return on your
investment will depend on appreciation in the price of our
common stock.
We have never declared or paid any cash dividends on our common
stock and do not currently intend to do so for the foreseeable
future. We currently intend to invest our future earnings, if
any, to fund our growth. Therefore, you are not likely to
receive any dividends on your common stock for the foreseeable
future, and the success of an investment in shares of our common
stock will depend upon any future appreciation in its value.
There is no guarantee that shares of our common stock will
appreciate in value or even maintain the price at which our
stockholders have purchased their shares.
|
|
Item 1B.
|
Unresolved
Staff Comments.
|
None.
As of December 31, 2010, we own a complex of buildings,
including approximately 133,000 square feet of office
space, on approximately 53 acres of land in Belfast, Maine.
We lease the remainder of our facilities. Our primary location
is 311 Arsenal Street in Watertown, Massachusetts, where we
lease 133,616 square feet, which is under lease until
July 1, 2015. We also lease 2,562 square feet in Rome,
Georgia, on a
month-to-month
basis; 11,936 square feet in Alpharetta, Georgia, through
October 31, 2012; and 22,295 square feet in Chennai,
India, through our Indian subsidiary, athenahealth Technology
Private Limited, until April 27, 2012, with the option to
extend the lease for up to two additional three-year periods.
Our servers are housed at our headquarters and our Belfast,
Maine, offices and also in data centers in Bedford,
Massachusetts, and Somerville, Massachusetts. Our owned property
in Belfast, Maine, is subject to a mortgage that secures any and
all amounts we may from time to time owe under our credit
facility or any other transaction with Bank of America, N.A.
|
|
Item 3.
|
Legal
Proceedings.
|
On March 2, 2010, a complaint was filed by Prompt Medical
Systems, L.P. naming the Company and several other defendants in
a patent infringement case (Prompt Medical Systems,
L.P. v. AllscriptsMisys Healthcare Solutions, Inc. et
al., Civil Action No. 6:2010cv00071, United States
District Court for the Eastern District of Texas). The complaint
alleges that the Company has infringed on U.S. Patent
No. 5,483,443 with a listed issue date of January 9,
1996, entitled Method for Computing Current Procedural
Terminology Codes from Physician Generated Documentation.
The complaint seeks an injunction enjoining infringement,
damages, and pre- and post-judgment costs and interest. The
Company and other several defendants filed motions to dismiss
the complaint. On February 11, 2011, the Court issued an
Order
granting-in-part
and
denying-in-part
the motions to dismiss. The Court ordered the plaintiff to
replead certain claims within fourteen days of the Order.
41
On November 24, 2010, several defendants filed (i) a
motion for summary judgment of invalidity against the
patent-in-suit
on the basis that it claims only non-patentable subject matter;
and (ii) a motion to stay all proceedings pending the
resolution of the motion for summary judgment. The Company filed
a motion to join in the motion to stay the proceedings. The
motions are fully briefed and awaiting a decision by the Court.
The case is currently in the discovery phase. A claim
construction hearing is scheduled for November 11, 2011.
Trial is scheduled for June 11, 2012.
The Company is being indemnified in this lawsuit from and
against any liability and reasonable costs, including attorneys
fees, incurred by the Company in its defense, pursuant to a
license agreement with its vendor.
The Company believes that it has meritorious defenses to the
lawsuit and continues to contest it vigorously.
On March 19, 2010, a putative shareholder class action
complaint was filed in the United States District Court for the
District of Massachusetts against the Company and certain of its
current and former officers entitled Casula v.
athenahealth, Inc. et al, Civil Action
No. 1:10-cv-10477.
On June 3, 2010, the court appointed Waterford Township
General Employees Retirement System as the lead plaintiff. On
August 2, 2010, the lead plaintiff filed an amended
complaint. The amended complaint alleges that the defendants
violated the federal securities laws by disseminating false and
misleading statements through press releases, statements by
senior management, and SEC filings. The alleged false and
misleading statements concern, among other things, the
amortization period for deferred implementation revenues. The
amended complaint seeks unspecified damages, costs, and
expenses. The defendants filed a motion to dismiss the amended
complaint on October 1, 2010, and a reply brief in further
support of the motion to dismiss the amended complaint on
December 30, 2010. We believe that we have meritorious
defenses to the amended complaint, and we will contest the
claims vigorously.
In addition, from time to time we may be subject to other legal
proceedings, claims, and litigation arising in the ordinary
course of business. We do not, however, currently expect that
the ultimate costs to resolve any pending matter will have a
material adverse effect on our consolidated financial position,
results of operations, or cash flows.
|
|
Item 4.
|
(Removed
and Reserved).
|
42
PART II
|
|
Item 5.
|
Market
for Registrants Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities.
|
Market
Information
Our common stock is listed on the NASDAQ Global Select Market
under the trading symbol ATHN. The following table
sets forth, for each of the periods indicated, the high and low
sales prices per share of our common stock as reported by the
NASDAQ Global Select Market.
|
|
|
|
|
|
|
|
|
Fiscal Year Ended December 31, 2010
|
|
High
|
|
Low
|
|
First Quarter
|
|
$
|
47.82
|
|
|
$
|
35.02
|
|
Second Quarter
|
|
$
|
38.77
|
|
|
$
|
22.30
|
|
Third Quarter
|
|
$
|
33.39
|
|
|
$
|
21.51
|
|
Fourth Quarter
|
|
$
|
46.25
|
|
|
$
|
29.98
|
|
Fiscal Year Ended December 31, 2009
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
39.29
|
|
|
$
|
23.15
|
|
Second Quarter
|
|
$
|
37.50
|
|
|
$
|
23.36
|
|
Third Quarter
|
|
$
|
41.13
|
|
|
$
|
31.52
|
|
Fourth Quarter
|
|
$
|
47.75
|
|
|
$
|
35.26
|
|
Holders
The last reported sale price of our common stock on the NASDAQ
Global Select Market on February 16, 2011, was
$47.55 per share. As of February 16, 2011, we had 146
holders of record of our common stock. Because many shares of
common stock are held by brokers and other institutions on
behalf of stockholders, we are unable to estimate the total
number of stockholders represented by these record holders.
Dividends
We have never declared or paid any dividends on our capital
stock, and our loan agreements restrict our ability to pay
dividends. We currently intend to retain any future earnings and
do not intend to declare or pay cash dividends on our common
stock in the foreseeable future. Any future determination to pay
dividends will be, subject to applicable law, at the discretion
of our board of directors and will depend upon, among other
factors, our results of operations, financial condition,
contractual restrictions, and capital requirements.
43
Performance
Graph
The following performance graph and related information shall
not be deemed soliciting material or to be
filed with the Securities and Exchange Commission,
nor shall such information be incorporated by reference into any
future filing under the Securities Act of 1933 or Securities
Exchange Act of 1934, each as amended, except to the extent that
we specifically incorporate it by reference into such filing.
Set forth below is a graph comparing the cumulative total
stockholder return on our common stock with the NASDAQ
Composite-Total Returns Index and the NASDAQ Computer and Data
Processing Index for the period starting with our initial public
offering on September 20, 2007, through the end of our
fiscal year ended December 31, 2010. The graph assumes an
investment of $100.00 made at the closing of trading on
September 20, 2007, in each of (i) our common stock,
(ii) the stocks comprising the NASDAQ Composite-Total
Returns Index, and (iii) stocks comprising the NASDAQ
Computer and Data Processing Index. All values assume
reinvestment of the full amount of all dividends, if any, into
additional shares of the same class of equity securities at the
frequency with which dividends are paid on such securities
during the applicable time period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 20,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2007
|
|
|
2008
|
|
|
2009
|
|
|
2010
|
athenahealth, Inc.
|
|
|
$
|
100
|
|
|
|
$
|
200
|
|
|
|
$
|
251
|
|
|
|
$
|
302
|
|
|
|
$
|
274
|
|
NASDAQ Composite-Total Returns
|
|
|
|
100
|
|
|
|
|
100
|
|
|
|
|
60
|
|
|
|
|
87
|
|
|
|
$
|
103
|
|
NASDAQ Computer and Data Processing Index
|
|
|
|
100
|
|
|
|
|
112
|
|
|
|
|
65
|
|
|
|
|
106
|
|
|
|
$
|
120
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recent
Sales of Unregistered Securities
None.
Use of
Proceeds from Registered Securities
We registered shares of our common stock in connection with our
initial public offering under the Securities Act of 1933, as
amended. Our Registration Statement on
Form S-1
(No. 333-143998)
in connection with our initial public offering was declared
effective by the SEC on September 20, 2007. The offering
commenced as of September 25, 2007, and did not terminate
before all securities were sold. The offering was co-managed by
the underwriters Goldman, Sachs & Co; Merrill Lynch,
Pierce, Fenner & Smith, Incorporated; Piper
Jaffray &Co.; and Jefferies & Company, Inc.
A total of 7,229,842 shares of common stock was registered
and sold in the initial public offering, including
943,023 shares of common stock sold upon exercise
44
of the underwriters over-allotment option, at a price to
the public of $18.00 per share. The offering closed on
September 25, 2007, and we received net proceeds of
approximately $81.3 million (after underwriters
discounts and commissions of approximately $6.3 million and
additional offering-related costs of approximately
$2.4 million). No underwriting discounts and commissions or
offering expenses were paid directly or indirectly to any of our
directors or officers (or their associates) or persons owning
ten percent or more of any class of our equity securities or to
any other affiliates.
There has been no material change in the planned use of proceeds
from our initial public offering as described in our final
prospectus filed with the SEC pursuant to Rule 424(b). We
expect to use the remaining net proceeds for capital
expenditures, working capital, and other general corporate
purposes. We may also use a portion of our net proceeds to fund
acquisitions of complementary businesses, products, or
technologies or to fund expansion of our operations facilities.
However, we do not have agreements or commitments for any
specific acquisitions at this time. Pending the uses described
above, we have invested the net proceeds in a variety of
short-term, interest-bearing, investment-grade securities.
At December 31, 2010, we had approximately
$35.9 million invested in cash and cash equivalents and
$80.2 million in short-term investments.
Issuer
Purchases of Equity Securities
During the quarter ended December 31, 2010, there were no
purchases made by us, on our behalf, or by any affiliated
purchasers of shares of our common stock.
45
|
|
Item 6.
|
Selected
Financial Data.
|
The following tables summarize our consolidated financial data
for the periods presented. You should read the following
financial information together with the information under
Managements Discussion and Analysis of Financial
Condition and Results of Operations and our consolidated
financial statements and the related notes to these consolidated
financial statements appearing elsewhere in this
Form 10-K.
Historical results are not necessarily indicative of the results
to be expected in future periods.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In thousands, except per share data)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
237,145
|
|
|
$
|
183,230
|
|
|
$
|
131,879
|
|
|
$
|
94,182
|
|
|
$
|
70,652
|
|
Implementation and other
|
|
|
8,393
|
|
|
|
5,297
|
|
|
|
4,403
|
|
|
|
3,436
|
|
|
|
2,665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
245,538
|
|
|
|
188,527
|
|
|
|
136,282
|
|
|
|
97,618
|
|
|
|
73,317
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses(1):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
96,582
|
|
|
|
79,017
|
|
|
|
59,947
|
|
|
|
46,978
|
|
|
|
37,172
|
|
Selling and marketing
|
|
|
52,675
|
|
|
|
34,072
|
|
|
|
22,827
|
|
|
|
17,212
|
|
|
|
15,645
|
|
Research and development
|
|
|
18,448
|
|
|
|
14,348
|
|
|
|
10,600
|
|
|
|
7,476
|
|
|
|
6,903
|
|
General and administrative
|
|
|
43,119
|
|
|
|
36,111
|
|
|
|
29,330
|
|
|
|
19,922
|
|
|
|
16,347
|
|
Depreciation and amortization
|
|
|
11,117
|
|
|
|
7,767
|
|
|
|
5,993
|
|
|
|
5,541
|
|
|
|
6,238
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
221,941
|
|
|
|
171,315
|
|
|
|
128,697
|
|
|
|
97,129
|
|
|
|
82,305
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
23,597
|
|
|
|
17,212
|
|
|
|
7,585
|
|
|
|
489
|
|
|
|
(8,988
|
)
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
309
|
|
|
|
1,016
|
|
|
|
1,942
|
|
|
|
1,415
|
|
|
|
372
|
|
Interest expense
|
|
|
(753
|
)
|
|
|
(968
|
)
|
|
|
(428
|
)
|
|
|
(3,682
|
)
|
|
|
(2,671
|
)
|
(Loss) gain on interest rate derivative contract
|
|
|
(199
|
)
|
|
|
590
|
|
|
|
(881
|
)
|
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
146
|
|
|
|
255
|
|
|
|
182
|
|
|
|
(5,689
|
)
|
|
|
(702
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (expense) income
|
|
|
(497
|
)
|
|
|
893
|
|
|
|
815
|
|
|
|
(7,956
|
)
|
|
|
(3,001
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax (provision) benefit and
cumulative effect of change in accounting principle
|
|
|
23,100
|
|
|
|
18,105
|
|
|
|
8,400
|
|
|
|
(7,467
|
)
|
|
|
(11,989
|
)
|
Income tax (provision) benefit(2)
|
|
|
(10,396
|
)
|
|
|
(8,829
|
)
|
|
|
23,202
|
|
|
|
(34
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before cumulative effect of change in accounting
principle
|
|
|
12,704
|
|
|
|
9,276
|
|
|
|
31,602
|
|
|
|
(7,501
|
)
|
|
|
(11,989
|
)
|
Cumulative effect of change in accounting principle(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(373
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
12,704
|
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
|
$
|
(7,501
|
)
|
|
$
|
(12,362
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before cumulative effect of change in accounting principle
|
|
$
|
0.37
|
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
$
|
(2.55
|
)
|
Cumulative effect of change in accounting principle(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
$
|
0.37
|
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
$
|
(2.63
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before cumulative effect of change in accounting principle
|
|
$
|
0.36
|
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
$
|
(2.55
|
)
|
Cumulative effect of change in accounting principle
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
$
|
0.36
|
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
$
|
(2.63
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in net income (loss) per
share basic
|
|
|
34,181
|
|
|
|
33,584
|
|
|
|
32,746
|
|
|
|
12,568
|
|
|
|
4,708
|
|
Weighted average shares used in net income (loss) per
share diluted
|
|
|
35,204
|
|
|
|
34,917
|
|
|
|
34,777
|
|
|
|
12,568
|
|
|
|
4,708
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
|
(In thousands)
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and short-term investments
|
|
$
|
116,175
|
|
|
$
|
82,849
|
|
|
$
|
86,994
|
|
|
$
|
71,891
|
|
|
$
|
9,736
|
|
Current assets
|
|
|
163,650
|
|
|
|
126,379
|
|
|
|
123,816
|
|
|
|
88,689
|
|
|
|
21,355
|
|
Total assets
|
|
|
261,170
|
|
|
|
211,077
|
|
|
|
169,571
|
|
|
|
103,636
|
|
|
|
39,973
|
|
Current liabilities
|
|
|
40,592
|
|
|
|
37,489
|
|
|
|
25,310
|
|
|
|
14,850
|
|
|
|
21,436
|
|
Total non-current liabilities
|
|
|
49,825
|
|
|
|
46,270
|
|
|
|
39,226
|
|
|
|
26,938
|
|
|
|
42,387
|
|
Total liabilities
|
|
|
90,417
|
|
|
|
83,759
|
|
|
|
64,536
|
|
|
|
41,788
|
|
|
|
63,823
|
|
Convertible preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,094
|
|
Total indebtedness including current portion
|
|
|
9,216
|
|
|
|
12,388
|
|
|
|
10,416
|
|
|
|
1,398
|
|
|
|
27,293
|
|
Total stockholders equity (deficit)
|
|
|
170,753
|
|
|
|
127,318
|
|
|
|
105,035
|
|
|
|
61,848
|
|
|
|
(73,944
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In thousands)
|
|
|
(1) Amounts include stock-based compensation expense as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
$
|
2,298
|
|
|
$
|
1,589
|
|
|
$
|
872
|
|
|
$
|
181
|
|
|
$
|
63
|
|
Selling and marketing
|
|
|
3,509
|
|
|
|
2,126
|
|
|
|
1,383
|
|
|
|
97
|
|
|
|
44
|
|
Research and development
|
|
|
2,014
|
|
|
|
1,015
|
|
|
|
1,086
|
|
|
|
260
|
|
|
|
53
|
|
General and administrative
|
|
|
6,656
|
|
|
|
3,584
|
|
|
|
2,217
|
|
|
|
773
|
|
|
|
196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
14,477
|
|
|
$
|
8,314
|
|
|
$
|
5,558
|
|
|
$
|
1,311
|
|
|
$
|
356
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
In the year ended December 31, 2008, we determined that a
valuation allowance was no longer needed on its deferred tax
assets. Accordingly, the 2008 results include the reversal of a
$23.9 million valuation allowance. |
|
(3) |
|
Change in accounting principle Effective
January 1, 2006, freestanding warrants and other similar
instruments related to shares that are redeemable are accounted
for in accordance with authoritative guidance on freestanding
warrants and other similar instruments on shares that are
redeemable. Under this guiadance, freestanding warrants
exercisable for shares of the Companys redeemable
convertible preferred stock are classified as a warrant
liability on the Companys balance sheet. The warrants
issued for the purchase of the Companys Series D and
Series E Preferred Stock are subject to the provisions of
this guidance. The Company accounted for the adoption of this
guidance as a cumulative effect of change in accounting
principle of $373 recorded on January 1, 2006, the date of
the Companys adoption of this guidance. The cumulative
effect adjustment was calculated as the difference in the fair
value of the warrants from the historical carrying value as of
January 1, 2006. The original carrying value of the
warrants, $1,229, was reclassified to liabilities from
additional paid-in capital at the date of adoption. |
|
|
Item 7.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations.
|
The following discussion and analysis should be read in
conjunction with our consolidated financial statements, the
accompanying notes to these financial statements, and the other
financial information that appear elsewhere in this Annual
Report on
Form 10-K.
This discussion contains predictions, estimates, and other
forward-looking statements that involve a number of risks and
uncertainties. In some cases, you can identify forward-looking
statements by terminology such as may,
will, should, expects,
plans, anticipates,
believes, estimates,
predicts, potential, or
continue; the negative of these terms; or other
comparable terminology. Actual results may differ materially
from those discussed in these forward-looking statements due to
a number of factors, including those set forth in the section
entitled Risk Factors and elsewhere in this Annual
Report on
Form 10-K.
47
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance, or
achievements. Except as required by law, we are under no duty to
update or revise any of the forward-looking statements, whether
as a result of new information, future events, or otherwise,
after the date of Annual Report on
Form 10-K.
Overview
athenahealth provides business services that help medical
practices achieve and sustain financial health by collecting
more money and exercising more control over their administrative
tasks. These services are designed to reduce the administrative
burden of complex billing rules, quality measurement and
reporting, clinical documentation and data exchange, patient
communication, and many of the related tasks that distract
medical providers and staff from the practice of medicine. Our
services are delivered and consumed through a single instance of
our cloud-based platform, athenaNet. We differentiate our
services by regularly deploying updates and improvements through
athenaNet to clients without any action on the part of the
client. athenaNet enables us to quickly implement our solution
at a low up-front cost and to seamlessly work in tandem with our
clients in real time.
The services provided through our single-instance cloud are
currently packaged as three integrated components:
athenaCollector for revenue cycle management, athenaClinicals
for clinical cycle management, and athenaCommunicator for
patient cycle management. The use of our single-instance
platform allows all clients to benefit from the collective
knowledge of all of our other clients through our patented
billing Rules Engine and our clinical Quality Management
Engine. Our clients use these rules engines to monitor and
benchmark their performance with peer practices across the
network. Our business intelligence application, Anodyne
Analytics, also supports our clients in their pursuit of
financial health by equipping users with data visualization
tools and insight into their practices performance.
Each service we provide is supported by a model comprised of
three distinct components: Software, Knowledge, and Work. The
cloud-based software is provided at no extra charge to users but
is the primary conduit through which we exchange information
between clients, payers, and our staff of experts. Knowledge is
infused into each of our services via our Rules Engine as
we work with clients, payers, and other partners to codify rules
associated with reimbursement, clinical quality measures, and
other factors related to our clients performance. The
third component to each of our services is the Work that we
perform on behalf of our clients. Wherever possible, we replace
manual processes with automation, but where automation is not
possible, we provide that manual labor rather than returning it
to clients to be completed. This unique service model of
Software, Knowledge, and Work has allowed us to align our
success with our clients performance, creating a continual
cycle of improvement and efficiency. We charge clients a
percentage of collections in most cases, so our financial
results are a direct reflection of our ability to drive revenue
to medical practices.
In 2010, we generated revenue of $245.5 million from the
sale of our services compared to $188.5 million in 2009 and
$136.3 million in 2008. Given the scope of our market
opportunity, we have increased our spending each year on growth,
innovation, and infrastructure. Despite increased spending in
these areas, higher revenue and lower direct operating expense
as a percentage of revenue have led to greater operating income.
Our revenues are predominately derived from business services
that we provide on an ongoing basis. This revenue is generally
determined as a percentage of our clients collections, so
the key drivers of our revenue include growth in the number of
physicians working within our client accounts and the
collections of these physicians. To provide these services, we
incur expense in several categories, including direct operating,
selling and marketing, research and development, general and
administrative, and depreciation and amortization expense. In
general, our direct operating expense increases as our volume of
work increases, whereas our selling and marketing expense
increases in proportion to our rate of adding new accounts to
our network of physician clients. Our other expense categories
are less directly related to growth of revenues and relate more
to our planning for the future, our overall business management
activities, and our infrastructure. As our revenues have grown,
the difference between our revenue and our direct operating
expense also has grown, which has afforded us the ability to
spend more in other categories of expense and to experience an
increase
48
in operating margin. We manage our cash and our use of credit
facilities to ensure adequate liquidity, in adherence to related
financial covenants.
Sources
of Revenue
We derive our revenue from two sources: from business services
which are primarily associated with our revenue, clinical and
patient cycle management services and from implementation and
other services. Implementation and other services consist
primarily of professional services fees related to assisting
clients with the initial implementation of our services and for
ongoing training and related support services. Business services
accounted for approximately 97% of our total revenues for each
of the years ended December 31, 2010, 2009, and 2008,
respectively. Business services fees are typically 2% to 8% of a
practices total collections depending upon the services
used and the size, complexity, and other characteristics of the
practice, plus a per-statement charge for billing statements
that are generated for patients of certain clients. Accordingly,
business services fees are largely driven by: the number of
physician practices we serve, the number of physicians and other
medical providers working in those physician practices, the
volume of activity and related collections of those physicians
and other medical providers, the services used by the practice
and our contracted rates. There is moderate seasonality in the
activity level of physician practices. Typically, discretionary
use of physician services declines in the late summer and during
the holiday season, which leads to a decline in collections by
our physician clients about 30 to 50 days later. None of
our clients accounted for more than 10% of our total revenues
for the years ended December 31, 2010, 2009, or 2008.
Operating
Expense
Direct Operating Expense. Direct operating
expense consists primarily of salaries, benefits, claim
processing costs, other direct costs, and stock-based
compensation related to personnel who provide services to
clients, including staff who implement new clients. We expense
implementation costs as incurred. Although we expect that direct
operating expense will increase in absolute terms for the
foreseeable future, the direct operating expense is expected to
decline as a percentage of revenues as we further increase the
percentage of transactions that are resolved on the first
attempt and as we decrease the cost of implementation for new
clients. In addition, over the longer term, we expect to
increase our overall level of automation and to reduce our
direct operating expense as a percentage of revenues as we
become a larger operation, with higher volumes of work in
particular functions, geographies, and medical specialties.
Included in direct operating expense are the service costs
associated with our athenaClinicals offering, which includes
transaction handling related to lab requisitions, lab results
entry, fax classification, and other services. We have also
included in direct operating expense the service costs
associated with our athenaCommunicator offering, which includes
costs based on telephone call volume, live operator answering
services, software licenses, and other services. We also expect
these costs to increase in absolute terms for the foreseeable
future but to decline as a percentage of revenue. This decrease
will be driven by increased levels of automation and by
economies of scale. Direct operating expense does not include
allocated amounts for rent, depreciation, and amortization,
except for amortization related to purchased intangible assets.
Selling and Marketing Expense. Selling and
marketing expense consists primarily of marketing programs
(including trade shows, brand messaging, and on-line
initiatives) and personnel-related expense for sales and
marketing employees (including salaries, benefits, commissions,
stock-based compensation, non-billable travel, lodging, and
other
out-of-pocket
employee-related expense). Although we recognize substantially
all of our revenue when services have been delivered, we
recognize a large portion of our sales commission expense at the
time of contract signature and at the time our services
commence. Accordingly, we incur a portion of our sales and
marketing expense prior to the recognition of the corresponding
revenue. We plan to continue to invest in sales and marketing by
hiring additional direct sales personnel to add new clients and
increase sales to our existing clients. We also plan to expand
our marketing activities in certain areas, such as attending
trade shows, expanding user groups, and creating new printed
materials as well as expand our external channel partner through
the addition of new key strategic partners. As a result, we
expect that, in the future, sales and marketing expense will
increase in absolute terms and will likely remain at current
levels as a percentage of total revenue in the near term.
49
Research and Development Expense. Research and
development expense consists primarily of personnel-related
expenses for research and development employees (including
salaries, benefits, stock-based compensation, non-billable
travel, lodging, and other
out-of-pocket
employee-related expense) and consulting fees for third-party
developers. We expect that, in the future, research and
development expense will increase in absolute terms but not as a
percentage of total revenue as new services and more mature
products require incrementally less new research and development
investment.
General and Administrative Expense. General
and administrative expense consists primarily of
personnel-related expense for administrative employees
(including salaries, benefits, stock-based compensation,
non-billable travel, lodging, and other
out-of-pocket
employee-related expense), occupancy and other indirect costs
(including building maintenance and utilities), and insurance,
as well as software license fees; outside professional fees for
accountants, lawyers, and consultants; and compensation for
temporary employees. We expect that general and administrative
expense will increase in absolute terms for the foreseeable
future as we invest in infrastructure to support our growth and
incur additional expense related to being a publicly traded
company. Though expenses are expected to continue to rise in
absolute terms, we expect general and administrative expense to
decline as a percentage of total revenues.
Depreciation and Amortization
Expense. Depreciation and amortization expense
consists primarily of depreciation of fixed assets and
amortization of capitalized software development costs, which we
amortize over a two-year period from the time of release of
related software code. Cost for our revenue cycle application
are considered maintenance and we expense those costs as
incurred, and, as a result, in 2010 approximately 83% of our
software development expenditures were expensed rather than
capitalized. In the years ended December 31, 2009 and 2008,
approximately 85% and 87%, respectively, were expensed rather
than capitalized. As we grow, we will continue to make capital
investments in the infrastructure of the business, and we will
continue to develop software that we capitalize. Therefore, we
expect related depreciation and amortization expense to increase
in absolute terms and increase as a percentage of total revenue
in the near term.
Other Income (Expense). Interest expense
consists primarily of interest costs related to our
equipment-related term leases, our term loan and revolving loans
under our credit facility, and our former subordinated term
loan, offset by interest income on investments. Interest income
represents earnings from our cash, cash equivalents, and
investments. The gain or loss on interest rate derivative
contract represents the change in the fair market value of a
derivative instrument that is not designated a hedge under the
authoritative accounting guidance. Although this derivative has
not been designated for hedge accounting, we believe that such
instrument is correlated with the underlying cash flow exposure
related to variability in interest rate movements on our term
loan.
Acquisitions
2009
Acquisition
In October 2009, we acquired Anodyne Health Partners, Inc., a
Software-as-a-Service (SaaS) business intelligence
company based in Alpharetta, Georgia. We believe that the
acquisition of Anodyne provides us with expanded service
offerings that will better enable us to compete in the large
medical group and enterprise markets. The Anodyne SaaS business
intelligence tool enhances customers ability to view all
facets of its revenue cycle information and to access and
extract critical operational and administrative information from
various data systems. Consideration for this transaction was
$22.3 million plus potential additional consideration of
$7.7 million which will be paid over a three-year period if
Anodyne achieves certain business and financial milestones. As
of December 31, 2010, we have paid $0.2 million of the
additional consideration.
2008
Acquisition
In September 2008, we acquired specified assets and assumed
specified liabilities of Crest Line Technologies, LLC (d.b.a.
MedicalMessaging.net). MedicalMessaging provided live and
automated calling services for healthcare professionals. The
purpose of the acquisition is to augment our core business
service offering with MedicalMessagings automated and live
communication services. We believe the purchase of
50
MedicalMessaging gave us access to a developed technology that
could speed the time to market versus internal development of
our own similar product. In addition, we plan to leverage its
existing customer base to increase revenues of the
MedicalMessaging services. Consideration for this transaction
was $7.7 million including potential additional
consideration of $1.0 million which will be paid over a
three-year period if MedicalMessaging achieves certain financial
milestones. As of December 31, 2010, we have paid
$0.7 million of the additional consideration.
Critical
Accounting Policies
Our discussion and analysis of our results of operations and
liquidity and capital resources are based on our consolidated
financial statements, which have been prepared in accordance
with generally accepted accounting principles in the United
States (GAAP). In connection with the preparation of our
consolidated financial statements, we are required to make
assumptions and estimates about future events, and apply
judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and the related disclosures. We
base our assumptions, estimates and judgments on historical
experience, current trends and other factors we believe to be
relevant at the time we prepared our consolidated financial
statements. On a regular basis, we review the accounting
policies, assumptions, estimates and judgments to ensure that
our consolidated financial statements are presented fairly and
in accordance with GAAP. However, because future events and
their effects cannot be determined with certainty, actual
results could differ from our assumptions and estimates, and
such differences could be material.
The preparation of our consolidated financial statements in
conformity with GAAP requires us to make estimates and
assumptions. These estimates and assumptions affect the reported
amounts of assets and liabilities and the disclosures of
contingent assets and liabilities as of the date of the
financial statements, and the reported amounts of revenues and
expenses during the reporting periods. Significant estimates and
assumptions are used for, but are not limited to:
(1) revenue recognition; including our estimated expected
customer life; (2) allowance for doubtful accounts;
(3) asset impairments; (4) depreciable lives of
assets; (5) economic lives and fair value of leased assets;
(6) income tax reserves; (7) fair value of stock
options; (8) allocation of direct and indirect cost of
sales; (9) fair value of contingent consideration; and
(10) litigation reserves. Future events and their effects
cannot be predicted with certainty, and accordingly, our
accounting estimates require the exercise of judgment. The
accounting estimates used in the preparation of our consolidated
financial statements will change as new events occur, as more
experience is acquired, as additional information is obtained
and as our operating environment changes. We evaluate and update
our assumptions and estimates on an ongoing basis and may employ
outside experts to assist in our evaluations. Actual results
could differ from the estimates we have used.
Our significant accounting policies are discussed in
Note 2, Summary of Significant Accounting Policies,
to our accompanying consolidated financial statements. We
believe the following accounting policies are the most critical
to aid in fully understanding and evaluating our reported
financial results, as they require management to make difficult,
subjective or complex judgments, and to make estimates about the
effect of
51
matters that are inherently uncertain. We have reviewed these
critical accounting policies and related disclosures with the
Audit Committee of our board of directors.
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
Revenue recognition
|
|
|
|
|
We derive our revenue from business services associated with our
revenue cycle, clinical cycle, patient cycle, and analytics
offerings and from implementation and other services.
|
|
We recognize revenue when all of the following conditions are satisfied:
there is evidence of an arrangement;
the service has been provided to the client;
the collection of the fees is reasonably assured; and
the amount of fees to be paid by the client is fixed or determinable.
|
|
Although we believe that our approach to estimates and judgments
as described herein is reasonable, actual results could differ
and we may be exposed to increases or decreases in revenue that
could be material.
|
|
|
|
|
|
|
|
Our arrangements do not contain general rights of return. All
revenue, other than implementation revenue, is recognized when
the service is performed. Relative to our business services
offering that is based on the collections of amounts by our
customers; we do not recognize revenue until our customers have
been paid. As the implementation service is not separable from
the ongoing business services, we record implementation fees as
deferred revenue until the implementation service is complete,
at which time we recognize revenue ratably on a monthly basis
over the longer of the estimated expected customer life or
contract life.
|
|
|
|
|
|
|
|
|
|
Our clients typically purchase one-year contracts that renew
automatically upon completion. In most cases, our clients may
terminate their agreements with 90 days notice without
cause. We typically retain the right to terminate client
agreements in a similar timeframe. Our clients are billed
monthly, in arrears, based either upon a percentage of
collections posted to athenaNet, minimum fees, flat fees, or
per-claim fees where applicable. Invoices are generated within
the first two weeks of the month and delivered to clients
primarily by email. For most of our clients, fees are then
deducted from a pre-defined bank account one week after invoice
receipt via an auto-debit transaction. Amounts that have been
invoiced are recorded as revenue or deferred revenue, as
appropriate, and are included in our accounts receivable
balances.
|
|
|
52
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
|
|
We maintain allowances for doubtful accounts based on an
assessment of the collectability of specific customer accounts,
the aging of accounts receivable, and other economic information
on both an historical and prospective basis. Customer account
balances are charged against the allowance when it is probable
the receivable will not be recovered. There are no off-balance
sheet credit exposure related to customer receivable balances.
|
|
|
|
|
|
|
|
We are required to recognize our non-refundable up-front fees
over the contract term or estimated expected customer life,
whichever is longer.
|
|
The determination of the amount of revenue we can recognize each accounting period requires management to make estimates and judgments on the estimated expected customer life. We considered all factors in the authoritative accounting literature and specifically focused on the following three factors in determining the estimated customer life:
Renewal rate considerations
Economic life of the product or service
Industry data
|
|
Our estimate of expected performance period may prove to be
inaccurate, in which case we may have understated or overstated
the revenue recognized in an accounting period. For example, if
in the future, we need to increase our estimated expected
performance period to a period longer than 12 years, the
amount we would recognize in each accounting period would
decrease. On the other hand, if in the future, we need to
decrease our estimated expected performance period to a period
shorter than 12 years, the amount we would recognize in
each accounting period would increase. The amount of deferred
revenue related to non-refundable up-front fees is $40.6 million
as of December 31, 2010. In the quarter when a customer
terminates, any unrecognized service fees associated with
implementation services before and after services have been
started are recognized as revenue in that quarter.
|
|
|
|
|
|
Income taxes
|
|
|
|
|
We account for income taxes using the asset and liability
method. Under this method, deferred tax assets and liabilities
are recognized for the estimated future tax consequences
attributable to differences between the financial statement
carrying values of existing assets and liabilities and their
respective tax bases. Deferred tax assets are also recorded with
respect to net operating losses and other tax attribute carry
forwards. Deferred tax assets and liabilities are measured using
enacted tax rates in effect for the years in which temporary
differences are expected to be recovered or settled. Valuation
allowances are established when it is more likely than not that
deferred tax assets will not be realized. The effect on deferred
tax assets and liabilities of a change in tax rates is
recognized in the income of the period that includes the
enactment date.
|
|
A high degree of judgment is required to determine if, and the
extent to which, valuation allowances should be recorded against
deferred tax assets.
Contingent tax liabilities are based on our assessment of the
likelihood that we have incurred a liability. Such liabilities
are reviewed based on recent changes in tax laws and
regulations, including judicial rulings.
|
|
Although we believe that our approach to estimates and judgments
as described herein is reasonable, actual results could differ
and we may be exposed to increases or decreases in income taxes
that could be material.
|
53
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
In addition, we are required to establish reserves for tax
contingencies.
|
|
|
|
|
|
|
|
|
|
Share-based Compensation
|
|
|
|
|
|
|
|
|
|
We grant various nonqualified stock-based compensation awards,
including stock options and restricted stock units. The
share-based compensation expense and related income tax benefit
recognized in the consolidated statement of operations in fiscal
year 2010 was $14.5 million and $9.2 million,
respectively. As of December 31, 2010, there was
$34.9 million of total unrecognized compensation cost
related to unvested stock options, which is expected to be
recognized through 2014.
|
|
We estimate the fair value of each stock option award on the
date of grant using the Black-Scholes valuation model, which
requires us to make estimates regarding expected option life,
stock price volatility and other assumptions. we have not had
sufficient history as a publicly traded company to evaluate its
volatility factor and expected term. As such, we analyzed the
volatilities and expected terms of a group of peer companies to
support the assumptions used in its calculations for the years
ended December 31, 2010, 2009, and 2008. We averaged the
volatilities of the peer companies with in-the-money options,
sufficient trading history and similar vesting terms to generate
the assumptions detailed above. We have not paid and do not
anticipate paying cash dividends on our shares of common stock;
therefore, the expected dividend yield is assumed to be zero. In
addition, we are required to utilize an estimated forfeiture
rate when calculating the expense for the period. We estimate
the fair value of the restricted stock units using the market
price of our common stock on the date of the grant. The fair
value of restricted stock units is amortized on a straight-line
basis over the vesting period.
|
|
We believe that there is a high degree of subjectivity involved
when using option-pricing models to estimate share-based
compensation under the authoritative guidance. If factors change
and we employ different assumptions in the application of the
authoritative guidance in future periods than those currently,
the compensation expense that we record in the future may differ
significantly from what we have historically reported for future
grants. If the volatility percentage used in calculating our
stock compensation expense had fluctuated by 10%, the total
stock compensation expense to be recognized over the stock
options four-year vesting period would have increased or
decreased by approximately $3 million. If the forfeiture rate
used in calculating our stock compensation expense had
fluctuated by 10%, the total stock compensation expense to be
recognized over the stock options four-year vesting period
would have decreased or increased by approximately $1 million.
|
Software Development Costs
|
|
|
|
|
|
|
|
|
|
Software development costs for internal use are expensed or
capitalized based on the stage of development for the software
and are amortized over the estimated economic life of the
software releases.
|
|
Under this guidance, costs related to the preliminary project
stage of subsequent versions of athenaNet and/or other
technology are expensed as incurred. Costs incurred in the
application development stage are capitalized. Such costs are
amortized over the softwares estimated economic life of
two years. In 2010, approximately 83% of our software
development expenditures were expensed rather than capitalized,
based upon the stage of development of the software. In the year
ended December 31, 2009, approximately 85% of our software
development expenditures were expensed rather than capitalized.
In the year ended December 31, 2008, approximately 87% of our
software development expenditures were expensed rather than
capitalized.
|
|
Although we believe that our approach to estimates and judgments
as described herein is reasonable, actual results could differ
and we may be exposed to increases or decreases in software
development costs that could be material.
|
54
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
Contingent consideration
|
|
|
|
|
Contingent consideration in a business combination after
January 1, 2009, is measured at fair value at the
acquisition date, with changes in the fair value after the
acquisition date affecting earnings.
|
|
Significant judgment is employed in determining the
appropriateness of these assumptions as of the acquisition date
and for each subsequent period. Accordingly, future business and
economic conditions, as well as changes in any of the
assumptions described above, can materially impact the amount of
contingent consideration expense we record in any given period.
Each period we revalue the contingent consideration obligations
associated with certain acquisitions to their then fair value
and record increases in the fair value as contingent
consideration expense and record decreases in the fair value as
a reduction of contingent consideration expense.
|
|
Increases or decreases in the fair value of the contingent
consideration obligations can result from changes in assumed
discount periods and rates, changes in the assumed timing and
amount of revenue and expense estimates. We recorded potential
contingent consideration of $7.7 million in the initial purchase
price allocation at its estimated fair value of $5.1 million
related to the Anodyne Health Partners, Inc acquisition in
October 2009. The change in the assumptions, and other factors,
resulted in a decrease of $0.3 million in the fair value of
the total contingent consideration during the year ended
December 31, 2010. The Company paid $0.2 million during the year
ended December 31, 2010, under the terms of the second potential
contingent consideration. The balance as of December 31, 2010,
was $4.7 million.
|
Consolidated
Results of Operations
The following table sets forth our consolidated results of
operations as a percentage of total revenue for the periods
shown:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
|
96.6
|
%
|
|
|
97.2
|
%
|
|
|
96.8
|
%
|
Implementation and other
|
|
|
3.4
|
|
|
|
2.8
|
|
|
|
3.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
39.3
|
|
|
|
41.9
|
|
|
|
44.0
|
|
Selling and marketing
|
|
|
21.5
|
|
|
|
18.1
|
|
|
|
16.7
|
|
Research and development
|
|
|
7.5
|
|
|
|
7.6
|
|
|
|
7.8
|
|
General and administrative
|
|
|
17.6
|
|
|
|
19.2
|
|
|
|
21.5
|
|
Depreciation and amortization
|
|
|
4.5
|
|
|
|
4.1
|
|
|
|
4.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
90.4
|
|
|
|
90.9
|
|
|
|
94.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
9.6
|
|
|
|
9.1
|
|
|
|
5.6
|
|
Other income (expenses):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
0.1
|
|
|
|
0.5
|
|
|
|
1.4
|
|
Interest expense
|
|
|
(0.3
|
)
|
|
|
(0.5
|
)
|
|
|
(0.3
|
)
|
(Loss) gain on interest rate derivative contract
|
|
|
(0.1
|
)
|
|
|
0.3
|
|
|
|
(0.6
|
)
|
Other income
|
|
|
0.1
|
|
|
|
0.2
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total (expense) other income
|
|
|
(0.2
|
)
|
|
|
0.5
|
|
|
|
0.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
9.4
|
|
|
|
9.6
|
|
|
|
6.2
|
|
Income tax (provision) benefit
|
|
|
(4.2
|
)
|
|
|
(4.7
|
)
|
|
|
17.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
5.2
|
%
|
|
|
4.9
|
%
|
|
|
23.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55
Comparison
of the Years Ended December 31, 2010 and 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Business services
|
|
$
|
237,145
|
|
|
$
|
183,230
|
|
|
$
|
53,915
|
|
|
|
29
|
%
|
Implementation and other
|
|
|
8,393
|
|
|
|
5,297
|
|
|
|
3,096
|
|
|
|
58
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
245,538
|
|
|
$
|
188,527
|
|
|
$
|
57,011
|
|
|
|
30
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue. Total revenue for the year ended
December 31, 2010, was $245.5 million, an increase of
$57.0 million, or 30%, over revenue of $188.5 million
for the year ended December 31, 2009. This increase was due
almost entirely to an increase in business services revenue.
Business Services Revenue. Revenue from
business services for the year ended December 31, 2010, was
$237.1 million, an increase of $53.9 million, or 29%,
over revenue of $183.2 million for the year ended
December 31, 2009. This increase was primarily due to the
growth in the number of physicians and other medical providers
using our services. The summary of changes in the physicians and
active medical providers using our revenue cycle management
service, athenaCollector, clinical cycle management service,
athenaClinicals, and patient cycle management service,
athenaCommunicator are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2010
|
|
2009
|
|
Change
|
|
|
Amount
|
|
Amount
|
|
Amount
|
|
Percent
|
|
Physicians revenue cycle management service
|
|
|
19,197
|
|
|
|
15,719
|
|
|
|
3,478
|
|
|
|
22
|
%
|
Active medical providers revenue cycle management
service
|
|
|
27,114
|
|
|
|
23,366
|
|
|
|
3,748
|
|
|
|
16
|
|
Physicians clinicals cycle management service
|
|
|
2,383
|
|
|
|
920
|
|
|
|
1,463
|
|
|
|
159
|
|
Active medical providers revenue cycle management
service
|
|
|
3,348
|
|
|
|
1,471
|
|
|
|
1,877
|
|
|
|
128
|
%
|
Physicians patient cycle management service
|
|
|
736
|
|
|
|
*
|
|
|
|
*
|
|
|
|
*
|
|
|
|
|
* |
|
Introduced in March 2010 therefore no comparative prior year data |
Also contributing to this increase was the growth in related
collections on behalf of these physicians and medical providers.
Total collections generated by these physicians and other
medical providers that were posted for the year ended
December 31, 2010, was $5.9 billion, an increase of
$1.0 billion over posted collections of $4.9 billion
for the year ended December 31, 2009.
Implementation and Other Revenue. Revenue from
implementations and other sources was $8.4 million for the
year ended December 31, 2010, an increase of
$3.1 million, or 58%, over revenue of $5.3 million for
the year ended December 31, 2009. This increase was driven
by new client implementations and increased professional
services for our larger client base. As of December 31,
2010, the number of accounts live on our revenue cycle
management service, athenaCollector, was 2,002, an increase of
410 accounts, from 1,592 accounts at December 31, 2009. As
of December 31, 2010, the numbers of accounts live on our
clinical cycle management service, athenaClinicals, was 552, an
increase of 302 accounts, from 250 accounts at December 31,
2009. The increase in implementation and other revenue is the
result of the increase in the volume of our business.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Direct operating costs
|
|
$
|
96,582
|
|
|
$
|
79,017
|
|
|
$
|
17,565
|
|
|
|
22
|
%
|
Direct Operating Costs. Direct operating costs
for the year ended December 31, 2010, was
$96.6 million, an increase of $17.6 million, or 22%,
over direct operating costs of $79.0 million for the year
ended December 31, 2009. This increase was primarily due to
an increase in the number of claims that we processed
56
on behalf of our clients and the related expense of providing
services, including transactions expense and salary and benefits
expense. The amount of collections processed for the year ended
December 31, 2010, was $5.9 billion, which was
$1.0 billion higher than the $4.9 billion of
collection processed for the year ended December 31, 2009.
The increase in collections increased at a higher rate than the
increase in the related direct operating expense as we benefited
from economies of scale. Direct operating employee-related
costs, excluding stock-based compensation, increased
$4.8 million from the year ended December 31, 2009, to
the year ended December 31, 2010. This increase is
primarily due to the 19% increase in headcount since
December 31, 2009. We increased the professional services
headcount as part of our redesign of our client services
organization and to meet the current and anticipated demand for
our services as our customer base has expanded and includes
larger medical groups. For the year ended December 31,
2010, direct operating expense includes $1.8 million of
amortization of purchased intangibles expense related to the
purchase of certain assets through acquisitions completed in
2009 and 2008, compared to $0.6 million in the year ended
December 31, 2009. Stock-based compensation expense also
increased $0.7 million from the year ended
December 31, 2009, to the year ended December 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Selling and marketing
|
|
$
|
52,675
|
|
|
$
|
34,072
|
|
|
$
|
18,603
|
|
|
|
55
|
%
|
Research and development
|
|
|
18,448
|
|
|
|
14,348
|
|
|
|
4,100
|
|
|
|
29
|
|
General and administrative
|
|
|
43,119
|
|
|
|
36,111
|
|
|
|
7,008
|
|
|
|
19
|
|
Depreciation and amortization
|
|
|
11,117
|
|
|
|
7,767
|
|
|
|
3,350
|
|
|
|
43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
125,359
|
|
|
$
|
92,298
|
|
|
$
|
33,061
|
|
|
|
36
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and Marketing Expense. Selling and
marketing expense for the year ended December 31, 2010, was
$52.7 million, an increase of $18.6 million, or 55%,
over costs of $34.1 million for the year ended
December 31, 2009. This increase was primarily due to an
increase in stock-based compensation expense of
$1.4 million and an increase in employee-related costs,
internal sales commissions and external partner channel
commission of $11.2 million due to an increase in headcount
and external channel partners. Our sales and marketing headcount
increased by 62% since December 31, 2009, as we hired
additional sales personnel to focus on adding new customers and
increasing penetration within our existing markets. The increase
was also due to a $6.0 million increase in travel related
expenses, consulting and other software licenses, online
marketing, offline marketing and other marketing events.
Research and Development Expense. Research and
development expense for the year ended December 31, 2010,
was $18.4 million, an increase of $4.1 million, or
29%, over research and development expense of $14.3 million
for the year ended December 31, 2009. This increase was
primarily due to a $3.1 million increase in
employee-related costs due to an increase in headcount and an
increase in stock-based compensation expense of
$1.0 million. Our research and development headcount
increased 19% since December 31, 2009, as we hired
additional research and development personnel in order to
upgrade and extend our service offerings and develop new
technologies.
General and Administrative Expense. General
and administrative expense for the year ended December 31,
2010, was $43.1 million, an increase of $7.0 million,
or 19%, over general and administrative expenses of
$36.1 million for the year ended December 31, 2009.
This increase was partially due to an increase in stock-based
compensation expense of $3.1 million, a $1.1 million
increase in facilities related expenses, and a $0.7 million
increase in bad debt expense. Our general and administrative
headcount increased by 6% since December 31, 2009, as we
added personnel to support our growth. Legal, audit, insurance
and consulting expenses increased $2.4 million primarily
due to our restatement and other additional costs of being a
public company. Additionally, under new authoritative guidance
on business combinations adopted January 1, 2009, any
changes in the fair value of contingent consideration after the
acquisition date affect earnings. The potential contingent
consideration of $7.7 million was recorded in the initial
purchase price allocation at its estimated fair value of
$5.1 million. A portion of the contingent consideration
relating to the Anodyne acquisition is expected to be paid in
2011 and 2012 totaling $1.0 million is presented in other
long-term
57
liabilities. The contingent consideration will be adjusted to
fair value to the amount payable when, and if, earned. The
difference between the estimated and earn-out amount will be
charged or credited to expense. For the year ended
December 31, 2010, approximately $0.3 million was
credited to expense relating to this contingent consideration
and $0.2 million was paid during the year.
Depreciation and Amortization. Depreciation
and amortization expense for the year ended December 31,
2010, was $11.1 million, an increase of $3.4 million,
or 43%, from depreciation and amortization of $7.8 million
for the year ended December 31, 2009. This increase was
primarily due to higher depreciation from fixed asset
expenditures in 2010 and 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Interest income
|
|
$
|
309
|
|
|
$
|
1,016
|
|
|
$
|
(707
|
)
|
|
|
(70
|
)%
|
Interest expense
|
|
|
(753
|
)
|
|
|
(968
|
)
|
|
|
215
|
|
|
|
(22
|
)
|
(Loss) gain on interest rate derivative contract
|
|
|
(199
|
)
|
|
|
590
|
|
|
|
(789
|
)
|
|
|
*
|
|
Other income
|
|
|
146
|
|
|
|
255
|
|
|
|
(109
|
)
|
|
|
(43
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (expense) income
|
|
$
|
(497
|
)
|
|
$
|
893
|
|
|
$
|
(1,390
|
)
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense). Interest income for
the year ended December 31, 2010, was $0.3 million, a
decrease of $0.7 million from interest income of
$1.0 million for the year ended December 31, 2009. The
decrease was directly related to the lower interest rates during
the year. Interest expense for the year ended December 31,
2010, was $0.8 million, a decrease of approximately
$0.2 million compared to interest expense of
$1.0 million for the year ended December 31, 2009. The
decrease is related to a decrease in the balance outstanding on
our capital leases during 2010. The loss on interest rate
derivative for the year ended December 31, 2010, was
$0.2 million, compared to a gain on interest rate
derivative for the year ended December 31, 2009, of
$0.6 million. The loss was the result of the change in the
fair market value of a derivative instrument that was not
designated as a hedge instrument under the authoritative
guidance. Although this derivative does not qualify for hedge
accounting, we believe that the instrument is closely correlated
with the underlying exposure, thus managing the associated risk.
The gains or losses from changes in the fair value of derivative
instruments that are not accounted for as hedges are recognized
in earnings.
Income Tax Provision. We recorded a provision
of $10.4 million for income taxes for the year ended
December 31, 2010, based upon an effective tax rate of 45%
compared to a provision of $8.8 million for the income
taxes for the year ended December 31, 2009, based upon an
effective tax rate of 49%. The decrease in our effective tax
rate was due to a decrease in our state tax rate and a decrease
in the effect of our permanent differences as percent of the
overall rate. The difference between our statutory tax rate and
our effective tax rate is due to permanent differences mostly
driven by stock-based compensation expense for incentive stock
options.
Comparison
of the Years Ended December 31, 2009 and 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Business services
|
|
$
|
183,230
|
|
|
$
|
131,879
|
|
|
$
|
51,351
|
|
|
|
39
|
%
|
Implementation and other
|
|
|
5,297
|
|
|
|
4,403
|
|
|
|
894
|
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
188,527
|
|
|
$
|
136,282
|
|
|
$
|
52,245
|
|
|
|
38
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue. Total revenue for the year ended
December 31, 2009, was $188.5 million, an increase of
$52.2 million, or 38%, over revenue of $136.3 million
for the year ended December 31, 2008. This increase was due
almost entirely to an increase in business services revenue.
58
Business Services Revenue. Revenue from
business services for the year ended December 31, 2009, was
$183.2 million, an increase of $51.4 million, or 39%,
over revenue of $131.9 million for the year ended
December 31, 2008. This increase was primarily due to the
growth in the number of physicians and other medical providers
using our services. The number of physicians using our revenue
cycle management service, athenaCollector, at December 31,
2009, was 15,719, an increase of 3,130, or 25%, from 12,589
physicians at December 31, 2008. The number of active
medical providers using our revenue cycle management service,
athenaCollector, at December 31, 2009, was 23,366, an
increase of 4,598, or 24%, from 18,768 active medical providers
at December 31, 2008. The number of physicians using our
clinical cycle management service, athenaClinicals, at
December 31, 2009, was 920, an increase of 435, or 90%,
from 485 physicians at December 31, 2008. The number of
active medical providers using our clinical cycle management
service, athenaClinicals, at December 31, 2009, was 1,471,
an increase of 673, or 84%, from 798 active medical providers at
December 31, 2008. Also contributing to this increase was
the growth in related collections on behalf of these physicians
and medical providers. Total collections generated by these
physicians and other medical providers that was posted for the
year ended December 31, 2009, was $4.9 billion, an
increase of $1.2 billion, or 32%, over posted collections
of $3.7 billion for the year ended December 31, 2008.
Implementation and Other Revenue. Revenue from
implementations and other sources was $5.3 million for the
year ended December 31, 2009, an increase of
$0.9 million, or 20%, over revenue of $4.4 million for
the year ended December 31, 2008. This increase was driven
by new client implementations and increased professional
services for our larger client base. As of December 31,
2009, the numbers of accounts live on our revenue cycle
management service, athenaCollector, increased by 366 accounts
since December 31, 2008. As of December 31, 2009, the
numbers of accounts live on our clinical cycle management
service, athenaClinicals, increased by 116 accounts since
December 31, 2008. The increase in implementation and other
revenue is the result of the increase in the volume of our
business.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2009
|
|
2008
|
|
Change
|
|
|
Amount
|
|
Amount
|
|
Amount
|
|
Percent
|
|
Direct operating costs
|
|
$
|
79,017
|
|
|
$
|
59,947
|
|
|
$
|
19,070
|
|
|
|
32
|
%
|
Direct Operating Costs. Direct operating costs
for the year ended December 31, 2009, was
$79.0 million, an increase of $19 million, or 32%,
over direct operating costs of $60.0 million for the year
ended December 31, 2008. This increase was primarily due to
an increase in the number of claims that we processed on behalf
of our clients and the related expense of providing services,
including transactions expense and salary and benefits expense.
The amount of collections processed for the year ended
December 31, 2009, was $4.9 billion, which was
$1.2 billion, or 32% higher than the $3.7 billion of
collection processed for the year ended December 31, 2008.
The increase in collections increased at a higher rate than the
increase in the related direct operating expense as we benefited
from economies of scale.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Selling and marketing
|
|
$
|
34,072
|
|
|
$
|
22,827
|
|
|
$
|
11,245
|
|
|
|
49
|
%
|
Research and development
|
|
|
14,348
|
|
|
|
10,600
|
|
|
|
3,748
|
|
|
|
35
|
|
General and administrative
|
|
|
36,111
|
|
|
|
29,330
|
|
|
|
6,781
|
|
|
|
23
|
|
Depreciation and amortization
|
|
|
7,767
|
|
|
|
5,993
|
|
|
|
1,774
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
92,298
|
|
|
$
|
68,750
|
|
|
$
|
23,548
|
|
|
|
34
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and Marketing Expense. Selling and
marketing expense for the year ended December 31, 2009, was
$34.1 million, an increase of $11.3 million, or 49%,
over costs of $22.8 million for the year ended
December 31, 2008. This increase was primarily due to
increases in external commissions of $1.5 million, a
$0.7 million increase in stock-based compensation expense,
and an increase in salaries, internal commissions and benefits
of $4.9 million. Additional increases were due to increases
in online and offline marketing-related
59
expenses totaling $3.3 million, a $0.5 million
increase in travel related expense, and a $0.4 million
increase in consulting costs.
Research and Development Expense. Research and
development expense for the year ended December 31, 2009,
was $14.3 million, an increase of $3.7 million, or
35%, over research and development expense of $10.6 million
for the year ended December 31, 2008. This increase was
primarily due to a $3.7 million increase in salaries and
benefits.
General and Administrative Expense. General
and administrative expense for the year ended December 31,
2009, was $36.1 million, an increase of $6.8 million,
or 23%, over general and administrative expenses of
$29.3 million for the year ended December 31, 2008.
This increase was primarily due to a $3.8 million increase
in employee-related costs due to an increase in headcount, a
$1.4 million increase in stock compensation expense, and a
$1.0 million increase in audit-related and legal fees due
to the costs of being a public company and acquisition related
costs. The remaining portion of the increase relates to an
increase in our bad debt expense.
Depreciation and Amortization. Depreciation
and amortization expense for the year ended December 31,
2009, was $7.8 million, an increase of $1.8 million,
or 30%, from depreciation and amortization of $6.0 million
for the year ended December 31, 2008. This increase was
primarily due to the addition of assets during 2009 and 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Interest income
|
|
$
|
1,016
|
|
|
$
|
1,942
|
|
|
$
|
(926
|
)
|
|
|
(48
|
)%
|
Interest expense
|
|
|
(968
|
)
|
|
|
(428
|
)
|
|
|
(540
|
)
|
|
|
*
|
|
Gain (loss) on interest rate derivative contract
|
|
|
590
|
|
|
|
(881
|
)
|
|
|
1,471
|
|
|
|
*
|
|
Other income
|
|
|
255
|
|
|
|
182
|
|
|
|
73
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income
|
|
$
|
893
|
|
|
$
|
815
|
|
|
$
|
78
|
|
|
|
10
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense). Interest income for
the year ended December 31, 2009, was $1.0 million, a
decrease of $0.9 million from interest income of
$1.9 million for the year ended December 31, 2008. The
decrease was directly related to the lower interest rates during
the year. Interest expense for the year ended December 31,
2009, was $1.0 million, an increase of approximately $0.6
million over interest expense of $0.4 million for the year
ended December 31, 2008. The increase is related to an
increase in the balance outstanding on our capital leases during
2009 and a full year of interest expense relating to our term
and revolving loans. The loss on interest rate derivative for
the year ended December 31, 2008, was $0.9 million,
compared to a gain on interest rate derivative for the year
ended December 31, 2009, of $0.6 million. The gain was
the result of the change in the fair market value of a
derivative instrument that was not designated a hedge instrument
under the authoritative guidance. Although this derivative does
not qualify for hedge accounting, we believe that the instrument
is closely correlated with the underlying exposure, thus
managing the associated risk. The gains or losses from changes
in the fair value of derivative instruments that are not
accounted for as hedges are recognized in earnings.
Income Tax Provision. We recorded a provision
of $8.8 million for the income taxes for the year ended
December 31, 2009, based upon an effective tax rate of 49%.
We recorded a benefit of $23.2 million for income taxes for
the period of December 31, 2008, which included a reversal
of the valuation allowance against the deferred tax assets of
the Company. We consider whether a valuation allowance is needed
on its deferred tax assets by evaluating all positive and
negative evidence relative to its ability to recover deferred
tax assets. Prior to the year ended December 31, 2008, we
had incurred losses and it is difficult to assert that deferred
tax assets are recoverable with this negative evidence. During
the fourth quarter of 2008, our results of operations generated
a cumulative profit as measured over the current and prior two
years. In addition, we had been profitable for six consecutive
quarters before releasing the allowance. Based on consideration
of the
60
weight of positive and negative evidence, including forecasted
operating results, we concluded that there was sufficient
positive evidence that our deferred tax assets were more likely
than not recoverable as of December 31, 2008. Accordingly,
the remaining valuation allowance was reversed as of
December 31, 2008.
Liquidity
and Capital Resources
Sources
of Liquidity
Since our inception, we have funded our growth primarily through
the private sale of equity securities, totaling approximately
$50.6 million, as well as through long-term debt, working
capital, equipment-financing loans, and, in September 2007, we
completed our initial public offering which provided net
proceeds of approximately $81.3 million.
As of December 31, 2010, our principal sources of liquidity
consisted of cash, cash equivalents and short-term investments
of $116.2 million. Our cash investments consist of
corporate debt securities, U.S. Treasury and government
agency securities, and commercial paper. As specified in our
investment policy, we place our investments in instruments that
meet high credit quality standards, the policy limits the amount
of our credit exposure to any one issue or issuer and seeks to
manage these assets to achieve our goals of preserving
principal, maintaining adequate liquidity at all times, and
maximizing returns.
Our total indebtedness was $9.2 million at
December 31, 2010. We have an unused revolving credit
facility in the amount of $15 million. The credit facility
may be extended by up to an additional $15 million on the
satisfaction of certain conditions. There was no balance
outstanding on the revolving credit facility during 2010. The
credit facility expires on September 30, 2011. We are
currently evaluating our options relating to our credit
facilities. In addition, we have a term loan facility used for
general working capital needs. At December 31, 2010, we
have $5.3 million outstanding on the term facility. The
term facility matures on September 30, 2013. At
December 31, 2010, there was a net present value of
$3.9 million in aggregate principal amount outstanding
under a series of capital leases with one finance company. Each
of the leases are payable on a monthly basis through December
2012.
The credit facility and term loan facility contains certain
financial and nonfinancial covenants, including limitations on
our consolidated leverage ratio and capital expenditures,
defaults relating to non-payment, breach of covenants,
inaccuracy of representations and warranties, default under
other indebtedness (including a cross-default with our interest
rate swap), bankruptcy and insolvency, inability to pay debts,
attachment of assets, adverse judgments, ERISA violations,
invalidity of loan and collateral documents, and change of
control. Upon an event of default, the lenders may terminate the
commitment to make loans and the obligation to extend letters of
credit, declare the unpaid principal amount of all outstanding
loans and interest accrued under the Credit Agreement to be
immediately due and payable, require us to provide cash and
deposit account collateral for our letter of credit obligations,
and exercise their security interests and other rights under the
Credit Agreement. As of December 31, 2010, we were in
compliance with all financial and non financial covenants under
this agreement.
We believe our sources of liquidity will be sufficient to
sustain operations, to finance our strategic initiatives, make
payments on our contractual obligations, and our purchases of
property and equipment for at least the next twelve months. Our
analysis is supported by the growth in our new customer base and
a high rate of renewal rates with our existing customers and the
corresponding increase in billings and collections. In addition,
we may pursue acquisitions or investments in complementary
businesses or technologies, in which case we may need to raise
additional funds sooner than expected. However, there can be no
assurance that we will continue to generate cash flows at or
above current levels or that we will be able to maintain our
ability to borrow under our existing credit facility or obtain
additional financing.
Commitments
We enter into various purchase commitments with vendors in the
normal course of business. We had no material purchase
commitments of capital assets at December 31, 2010. We
currently anticipate our aggregate capital expenditures to be
approximately $17 million to $20 million for the next
twelve months. We believe
61
that our existing sources of liquidity will be adequate to fund
these purchases during the year 2011. In the normal course of
business, we make representations and warranties that guarantee
the performance of services under service arrangements with
clients. Historically, there has been no material losses related
to such guarantees.
Operating
Cash Flow Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Net Income
|
|
$
|
12,704
|
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
Non-cash adjustments to net income
|
|
|
22,074
|
|
|
|
20,702
|
|
|
|
(12,366
|
)
|
Cash provided by changes in operating assets and liabilities
|
|
|
9,942
|
|
|
|
2,351
|
|
|
|
1,823
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
$
|
44,720
|
|
|
$
|
32,329
|
|
|
$
|
21,059
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operations increased by $12.4 million to
$44.7 million for the year ended December 31, 2010, as
compared to $32.3 million for the year ended
December 31, 2009. The increase is mainly attributable to
increases in net income, add-backs of non-cash expense items,
and increases in our changes in operating assets and
liabilities. The increase in net income is primarily due to the
growth in our customer base, stability in renewal rates with our
existing customer base, the associated increase in billings and
collections, and selling additional services into our existing
customer base. These increases are partially offset by an
increase in operating expenses that require cash outlays such as
salaries, higher commissions, direct operating expenses, and
marketing expenses. These expenses increased in absolute terms
but remain relatively consistent as a percentage of revenue. The
increase in add-backs of non-cash expenses during 2010 are
primarily due to increases in depreciation and amortization,
stock-based compensation expense, and our provision for
uncollectible accounts. The increases are off-set by an increase
in excess tax benefits from stock-based awards and a decrease in
our deferred income taxes. The increase in depreciation and
amortization was primarily attributed to capital expenditures of
$15.9 million during the year ended December 31, 2010,
and a full-year of the amortization of intangibles assets
purchased in our acquisition of Anodyne Health Partners, Inc. in
October of 2009. The increase in stock-based compensation
expense is primarily due to the increase in the volume and the
value of stock-based awards granted during 2010 over grants in
2009. The decrease in deferred income taxes was mainly
attributable to our use of Federal and State NOLs. The increase
to our changes in operating assets and liabilities during 2010
were due primarily to an increase in prepaid expenses and other
current assets and a smaller increase in accounts receivable.
The increase in prepaid expenses and other assets is mainly
attributable to purchases of software licenses during 2010 and
an increase in excess tax benefit from stock-based awards. We
have reclassed excess tax benefits to financing activities,
resulting in a corresponding decrease in our net cash provided
by operating activities. Accounts receivable increased
approximately 10% while revenue increased approximately 30%
during fiscal year 2010. This can be attributed to our DSO
decreasing to 49 days for the fourth quarter of 2010
compared to a DSO of 56 days for the fourth quarter of 2009.
Investing
Cash Flow Activities
The cash used by investing activities increased by
$20.4 million to $53.6 million from $33.2 million
for the years ended December 31, 2010 and 2009,
respectively. Cash flows from investing activities consist
primarily of purchases of property and equipment, capitalized
software development costs and our short-term investment
activities. We make investments in property and equipment and in
software development on an ongoing basis. Our investment in
equipment consists primarily of purchases of technology
infrastructure to provide service stability and additional
capacity to support our expanding client base. We purchased
$6.3 million of additions and upgrades to our technology
infrastructure during the year 2010. We plan on purchasing
approximately $8.0 million to $9.0 million on our
technology infrastructure for the year 2011. Our purchases of
property were primarily for adding additional space to our
existing leased and owned facilities and for new computers to
support our growth in the number of employees. The purchases for
facilities and other employee related growth was approximately
$3.6 million for the year ended December 31, 2010. We
62
plan on spending approximately $3.0 million of additional
facility expansion and other employee related growth items to
meet our hiring plans for the next twelve months. Our investment
in software development consist of company managed-design,
development, and testing of new application functionality with
our less mature service offerings, which primarily include our
athenaClinicals and athenaCommunicator service offerings. Our
capitalized software development amounted to $3.9 million
for the year ended December 31, 2010. We plan to spend
approximately $6.0 million to $7.0 million on software
development projects for the year 2011. During 2010, we
purchased an aircraft for $3.1 million to transport our
employees between our operational locations and for customer and
prospects visits.
Financing
Cash Flow Activities
The cash provided in financing activities increased by
$11.5 million to $14.1 million from $2.7 million
for the years ended December 31, 2010 and 2009,
respectively. The increase is attributable to an increase in the
proceeds from the exercise of stock options and the increase in
the excess tax benefit from stock-based awards. We recorded a
reduction in income tax liability of $9.2 related to excess tax
deductions received from employee stock option exercises. The
benefit was recorded as additional paid in capital. We also
recorded $0.2 million payment of contingent consideration
relating to the Anodyne acquisition that was recorded as of the
acquisition date.
Contractual
Obligations
We have contractual obligations under our equipment line of
credit, revolving and term loans and we also maintain operating
leases for property and certain office equipment. The following
table summarizes our long-term contractual obligations and
commitments as of December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period
|
|
|
|
|
|
|
Less than 1
|
|
|
2 - 3
|
|
|
4 -5
|
|
|
After 5
|
|
|
|
|
|
|
Total
|
|
|
Year
|
|
|
Years
|
|
|
Years
|
|
|
Years
|
|
|
Other
|
|
|
Long-term debt obligations
|
|
$
|
5,325
|
|
|
$
|
300
|
|
|
$
|
600
|
|
|
$
|
4,425
|
|
|
$
|
|
|
|
$
|
|
|
Capital lease obligations
|
|
|
3,891
|
|
|
|
2,609
|
|
|
|
1,282
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating lease obligations
|
|
|
26,125
|
|
|
|
5,699
|
|
|
|
10,874
|
|
|
|
8,477
|
|
|
|
1,075
|
|
|
|
|
|
Other
|
|
|
1,610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
36,951
|
|
|
$
|
8,608
|
|
|
$
|
12,756
|
|
|
$
|
12,902
|
|
|
$
|
1,075
|
|
|
$
|
1,610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
These amounts exclude interest payments of $0.3 million
that are due in the next three years on the capital lease
obligations and $1.0 million that are due in the next four
years on our long-term debt obligations.
The commitments under our operating leases shown above consist
primarily of lease payments for our Watertown, Massachusetts,
corporate headquarters; our Rome, Georgia, offices; our
Alpharetta, Georgia, subsidiary location; and our Chennai,
India, subsidiary location.
On February 15, 2008, we purchased a complex of buildings,
including approximately 133,000 square feet of office
space, on approximately 53 acres of land located in
Belfast, Maine, for a total purchase price of $6.2 million
from a wholly owned subsidiary of Bank of America Corporation.
We use this facility as a second operational service site and
intend to lease a small portion of the space to commercial
tenants.
Other amount consists of uncertain tax benefits. As of
December 31, 2010, we cannot reasonably estimate when any
future cash outlays would occur related to these uncertain tax
positions.
As of December 31, 2010, we have $4.7 million accrued
for contingent considerations estimated to be payable upon
Anodyne reaching specific performance metrics over the initial
three years of operations after acquisition.
63
Off-Balance
Sheet Arrangements
As of December 31, 2010, 2009, and 2008, we did not have
any relationships with unconsolidated entities or financial
partnerships, such as entities often referred to as
structured finance or special purpose
entities, which would have been established for the purpose of
facilitating off-balance sheet arrangements or other
contractually narrow or limited purposes. Other than our
operating leases for office space and computer equipment, we do
not engage in off-balance sheet financing arrangements.
Recent
Accounting Pronouncements
From time to time, new accounting pronouncements are issued by
FASB and are adopted by us as of the specified effective date.
Unless otherwise discussed, we believe that the impact of
recently issued accounting pronouncements will not have a
material impact on consolidated financial position, results of
operations, and cash flows, or do not apply to our operations.
|
|
Item 7A.
|
Quantitative
and Qualitative Disclosures About Market Risk.
|
Foreign Currency Exchange Risk. Our results of
operations and cash flows are subject to fluctuations due to
changes in the Indian rupee. None of our consolidated revenues
are generated outside the United States. None of our vendor
relationships, including our contracts with our offshore service
providers, International Business Machines Corporation and
Vision Process Business Solutions Inc., for work performed in
India or the Philippines, is denominated in any currency other
than the U.S. dollar. Although the contracts are
denominated in U.S. dollars, the fees in one of our vendor
contracts are subject to adjustment based upon fluctuation in
exchange rates between the India Rupees and the
U.S. dollar. In 2010 and 2009, 1.0% and 0.9%, respectively,
of our expenses occurred in our direct subsidiary in Chennai,
India, and were incurred in Indian rupees. We therefore believe
that the risk of a significant impact on our operating income
from foreign currency fluctuations is not substantial.
Interest Rate Sensitivity. We had unrestricted
cash and cash equivalents totaling $35.9 million at
December 31, 2010. These amounts are held for working
capital purposes and were invested primarily in deposits, money
market funds, and short-term, interest-bearing, investment-grade
securities. Due to the short-term nature of these investments,
we believe that we do not have any material exposure to changes
in the fair value of our investment portfolio as a result of
changes in interest rates. The value of these securities,
however, will be subject to interest rate risk and could fall in
value if interest rates rise.
Interest
Rate Risk
As of December 31, 2010, we had long-term debt and capital
lease obligations totaling $9.2 million, which have both
variable and fixed interest rate components. We have entered
into interest rate swaps as a hedge relating to variability in
interest rate movements on our term loan. For floating rate
debt, interest rate changes generally do not affect the fair
market value, but do impact future earnings and cash flows,
assuming other factors are held constant.
The table below summarizes the principal terms of our interest
rate swap transaction, including the notional amount of the
swap, the interest rate payment we receive from and pay to our
swap counterparty, the term of the transaction, and its fair
market value at December 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Market
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year
|
|
|
|
Value at
|
|
|
|
|
Notional
|
|
|
|
|
|
Entered
|
|
Maturity
|
|
December 31,
|
Description
|
|
Borrowing
|
|
Amount
|
|
Receive
|
|
Pay
|
|
Into
|
|
(Fiscal Year)
|
|
2010
|
|
Interest rate swap
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
variable to fixed
|
|
Interest on
Term Loan
|
|
$5,325
|
|
LIBOR
|
|
4.55%
Fixed
|
|
2008
|
|
2028
|
|
$(490)
|
64
|
|
Item 8.
|
Financial
Statements and Supplementary Data.
|
The financial statements required by this Item are located
beginning on
page F-1
of this report.
|
|
Item 9.
|
Changes
in and Disagreements with Accountants on Accounting and
Financial Disclosure.
|
None.
|
|
Item 9A.
|
Controls
and Procedures.
|
Evaluation
of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed
to ensure that information required to be disclosed in the
reports that we file or submit under the Securities and Exchange
Act of 1934 is (1) recorded, processed, summarized, and
reported within the time periods specified in the SECs
rules and forms and (2) accumulated and communicated to our
management, including our Chief Executive Officer and Chief
Financial Officer, to allow timely decisions regarding required
disclosure. As of December 31, 2010 (the Evaluation
Date), our management, with the participation of our Chief
Executive Officer and Chief Financial Officer, evaluated the
effectiveness of our disclosure controls and procedures (as
defined in
Rules 13a-15(e)
and
15d-15(e)
under the Securities and Exchange Act of 1934). Our management
recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of
achieving their objectives, and management necessarily applies
its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Our Chief Executive Officer
and Chief Financial Officer have concluded based upon the
evaluation described above that, as of the Evaluation Date, our
disclosure controls and procedures were effective at the
reasonable assurance level.
Managements
Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining
adequate internal control over financial reporting for our
company. Internal control over financial reporting is defined in
Rules 13a-15(f)
and 15(d)-15(f) promulgated under the Securities Exchange Act of
1934, as amended, as a process designed by, or under the
supervision of, our Chief Executive and Chief Financial Officers
and effected by our board of directors, management, and other
personnel to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles and includes those
policies and procedures that:
|
|
|
|
|
pertain to the maintenance of records that in reasonable detail
accurately and fairly reflect the transactions and disposition
of our assets;
|
|
|
|
provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles;
|
|
|
|
provide reasonable assurance that our receipts and expenditures
are being made only in accordance with authorization of our
management and directors; and
|
|
|
|
provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of
our assets that could have a material effect on the financial
statements.
|
Because of inherent limitations, internal controls over
financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods
are subject to the risks that controls may become inadequate
because of changes in conditions or that the degree of
compliance with the policies or procedures may deteriorate.
Our management, including our Chief Executive and Chief
Financial Officers, has conducted an evaluation of the
effectiveness of our internal control over financial reporting
as of December 31, 2010. In conducting this evaluation, we
used the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO), in Internal
Control-Integrated Framework.
65
Based upon this evaluation and those criteria, management
believes that, as of December 31, 2010, our internal
controls over financial reporting were effective.
Deloitte and Touche LLP, our independent registered public
accounting firm, has audited our consolidated financial
statements and the effectiveness of our internal control over
financial reporting as of December 31, 2010. This report
appears below.
Changes
in Internal Control over Financial Reporting
There were no changes in our internal control over financial
reporting during the fourth quarter of 2010 that have materially
affected, or are reasonably likely to materially affect, our
internal control over financial reporting.
66
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of athenahealth, Inc
Watertown, Massachusetts
We have audited the internal control over financial reporting of
athenahealth, Inc. and subsidiaries (the Company) as
of December 31, 2010, based on criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission. The Companys management is responsible for
maintaining effective internal control over financial reporting
and for its assessment of the effectiveness of internal control
over financial reporting, included in the accompanying
Managements Report on Internal Control over Financial
Reporting. Our responsibility is to express an opinion on the
Companys internal control over financial reporting based
on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk, and performing such other procedures as we
considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a
process designed by, or under the supervision of, the
companys principal executive and principal financial
officers, or persons performing similar functions, and effected
by the companys board of directors, management, and other
personnel to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of the inherent limitations of internal control over
financial reporting, including the possibility of collusion or
improper management override of controls, material misstatements
due to error or fraud may not be prevented or detected on a
timely basis. Also, projections of any evaluation of the
effectiveness of the internal control over financial reporting
to future periods are subject to the risk that the controls may
become inadequate because of changes in conditions, or that the
degree of compliance with the policies or procedures may
deteriorate.
In our opinion, the Company maintained, in all material
respects, effective internal control over financial reporting as
of December 31, 2010, based on the criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission.
We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated financial statements as of and for the year ended
December 31, 2010, of the Company and our report dated
February 18, 2011, expressed an unqualified opinion on
those financial statements and included an explanatory paragraph
relating to the change in the Companys method of
accounting for business combinations on January 1, 2009.
/s/ Deloitte &
Touche LLP
Boston, Massachusetts
February 18, 2011
67
|
|
Item 9B.
|
Other
Information.
|
Entry
into
Rule 10b5-1
Trading Plans
Our policy governing transactions in our securities by our
directors, officers, and employees permits our officers,
directors, and certain other persons to enter into trading plans
complying with
Rule 10b5-1
under the Securities Exchange Act of 1934, as amended. We have
been advised that a number of our directors and employees,
including members of our senior management team, have entered
into trading plans in accordance with
Rule 10b5-1
and our policy governing transactions in our securities. We
undertake no obligation to update or revise the information
provided herein, including for revision or termination of an
established trading plan.
PART III
Certain information required by Part III of
Form 10-K
is omitted from this report because we expect to file a
definitive proxy statement for our 2011 Annual Meeting of
Stockholders (2011 Proxy Statement) within
120 days after the end of our fiscal year pursuant to
Regulation 14A promulgated under the Securities Exchange
Act of 1934, as amended, and the information included in our
2011 Proxy Statement is incorporated herein by reference to the
extent provided below.
|
|
Item 10.
|
Directors,
Executive Officers and Corporate Governance.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2011 Proxy
Statement.
We have adopted a code of ethics that applies to all of our
directors, officers, and employees. This code is publicly
available on our website at www.athenahealth.com.
Amendments to the code of ethics or any grant of a waiver
from a provision of the code requiring disclosure under
applicable SEC and NASDAQ Global Select Market rules will be
disclosed on our website or, if so required, disclosed in a
Current Report on
Form 8-K.
|
|
Item 11.
|
Executive
Compensation.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2011 Proxy
Statement.
|
|
Item 12.
|
Security
Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2011 Proxy
Statement.
|
|
Item 13.
|
Certain
Relationships and Related Transactions, and Director
Independence.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2011 Proxy
Statement.
|
|
Item 14.
|
Principal
Accounting Fees and Services.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2011 Proxy
Statement.
68
PART IV
|
|
Item 15.
|
Exhibits,
Financial Statement Schedules.
|
a) Documents filed as part of this Report.
(1) The following consolidated financial statements are
filed herewith in Item 8 of Part II above.
(i) Report of Independent Registered Public Accounting Firm
(ii) Consolidated Balance Sheets
(iii) Consolidated Statements of Operations
(iv) Consolidated Statements of Changes in
Stockholders Equity
(v) Consolidated Statements of Cash Flows
(vi) Notes to Consolidated Financial Statements
(2) Financial Statement Schedules
All other supplemental schedules are omitted because of the
absence of conditions under which they are required or because
the required information is given in the financial statements or
notes thereto.
(3) Exhibits
|
|
|
Exhibit
|
|
|
No.
|
|
Exhibit Index
|
|
2.1(viii)
|
|
Agreement and Plan of Merger by and among athenahealth, Inc.,
Aries Acquisition Corporation, Anodyne Health Partners, Inc.,
and the Securityholders Representatives named therein,
dated October 5, 2009
|
3.1(i)
|
|
Amended and Restated Certificate of Incorporation of the
Registrant
|
3.2(i)
|
|
Amended and Restated Bylaws of the Registrant
|
4.1(i)
|
|
Specimen Certificate evidencing shares of common stock
|
10.1(i)
|
|
Form of Indemnification Agreement, to be entered into between
the Registrant and each of its directors and officers
|
10.2(i)
|
|
1997 Stock Plan of the Registrant and form of agreements
thereunder
|
10.3(i)
|
|
2000 Stock Option and Incentive Plan of the Registrant, as
amended, and form of agreements thereunder
|
10.4*
|
|
2007 Stock Option and Incentive Plan of the Registrant, and form
of agreements thereunder
|
10.5(xii)
|
|
2007 Employee Stock Purchase Plan, as amended
|
10.6(xii)
|
|
Employment Agreement by and between the Registrant and Timothy
M. Adams, dated January 11, 2010
|
10.7(i)
|
|
Employment Agreement by and between the Registrant and Jonathan
Bush, dated November 1, 1999, as amended
|
10.8(iii)
|
|
Employment Agreement by and between the Registrant and Robert L.
Cosinuke, dated December 3, 2007
|
10.9*
|
|
Employment Agreement by and between the Registrant and Derek
Hedges, dated January 31, 2005
|
10.10(vi)
|
|
Employment Agreement by and between the Registrant and Robert M.
Hueber, dated September 16, 2002, as amended
|
10.11(xiv)
|
|
Employment Agreement by and between the Registrant and Daniel H.
Orenstein, dated July 1, 2010
|
10.12(xiv)
|
|
Employment Agreement by and between the Registrant and Ed Park,
dated July 1, 2010
|
10.13(xi)
|
|
The athenahealth Executive Incentive Plan, adopted March 30,
2010
|
69
|
|
|
Exhibit
|
|
|
No.
|
|
Exhibit Index
|
|
10.14(xiii)
|
|
Director Compensation Plan of the Registrant, dated June 17, 2010
|
10.15(i)
|
|
Warrant to Purchase 32,468 Shares of the Registrants
Series D Convertible Preferred Stock, issued to GATX Ventures,
Inc. on May 31, 2001
|
#10.16(i)
|
|
Lease between President and Fellows of Harvard College and the
Registrant, dated November 8, 2004, for space at the premises
located at 300 North Beacon Street, Watertown, MA 02472 and 311
Arsenal Street, Watertown, MA 02472
|
10.17(vii)
|
|
Deed of Lease by and between RMZ Infotech Private Limited and
Athena Net India Private Limited, dated April 28, 2009, for
space at the premises located at Unit No. 701, Campus 3B, RMZ
Millenia Tech Park, 143, Dr.MGR Road, Perungudi, Chennai 600 113
|
#10.18(i)
|
|
Agreement of Lease by and between Sentinel
Properties Bedford, LLC and the Registrant, dated
May 8, 2007
|
10.19(v)(ix)
|
|
Credit Agreement by and between the Registrant and Bank of
America, N.A., as Administrative Agent, Swing Line Lender and
L/C Issuer, dated September 30, 2008, and exhibits and schedules
thereunder
|
10.20(v)
|
|
Security Agreement by and between the Registrant and Bank of
America, N.A., as Administrative Agent, dated September 30, 2008
|
10.21(v)
|
|
Term Note by and between the Registrant and Bank of America,
N.A., dated September 30, 2008
|
10.22(ix)
|
|
First Amendment to Credit Agreement by and between the
Registrant and Bank of America, N.A., as Administrative Agent,
Swing Line Lender and L/C Issuer, dated December 12, 2008
|
10.23(viii)
|
|
Second Amendment to Credit Agreement and Limited Waiver by and
between the Registrant and Bank of America, N.A., as
Administrative Agent, Swing Line Lender and L/C Issuer, dated
October 5, 2009
|
10.24*
|
|
Master Equipment Lease Agreement by and between CIT Technologies
Corporation and the Registrant, dated June 1, 2007
|
10.25(ii)
|
|
Purchase Agreement dated November 28, 2007, between the
Registrant and Bracebridge Corporation
|
#10.26(iv)
|
|
Master Agreement by and between the Registrant and Vision
Business Process Solutions Inc., dated June 30, 2008
|
#10.27(x)
|
|
Professional Services Agreement by and between the Registrant
and International Business Machines Corporation dated as of
October 2, 2009
|
#10.28(x)
|
|
Master Agreement for U.S. Availability Services between SunGard
Availability Services LP and the Registrant, dated December 1,
2009, as amended
|
#10.29*
|
|
Second Amended and Restated Marketing and Sales Agreement by and
between the Registrant and WorldMed Shared Services, Inc. (d/b/a
PSS World Medical Shared Services, Inc.), dated October 21, 2010
|
21.1*
|
|
Subsidiaries of the Registrant
|
23.1*
|
|
Consent of Independent Registered Public Accounting Firm
|
31.1*
|
|
Rule 13a-14(a) or 15d-14 Certification of Chief Executive Officer
|
31.2*
|
|
Rule 13a-14(a) or 15d-14 Certification of Chief Financial Officer
|
32.1*
|
|
Certifications of Chief Executive Officer and Chief Financial
Officer pursuant to Exchange Act rules 13a-14(b) or 15d-14(b)
and 18 U.S.C. Section 1350
|
70
|
|
|
Exhibit
|
|
|
No.
|
|
Exhibit Index
|
|
101.INS**
|
|
XBRL Instance Document
|
101.SCH**
|
|
XBRL Schema Document
|
101.CAL**
|
|
XBRL Calculation Linkbase Document
|
101.DEF**
|
|
XBRL Extension Definition Document
|
101.LAB**
|
|
XBRL Labels Linkbase Document
|
101.PRE**
|
|
XBRL Presentation Linkbase Document
|
|
|
|
Indicates a management contract or any compensatory plan,
contract, or arrangement.
|
|
#
|
Application has been made to the Securities and Exchange
Commission for confidential treatment of certain provisions.
Omitted material for which confidential treatment has been
requested has been filed separately with the Securities and
Exchange Commission.
|
|
(i)
|
Incorporated by reference to the Registrants registration
statement on
Form S-1
(File
No. 333-143998).
|
|
(ii)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed November 29, 2007.
|
|
(iii)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed May 6, 2008.
|
|
(iv)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed August 5, 2008.
|
|
(v)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed November 7, 2008.
|
|
(vi)
|
Incorporated by reference to the Registrants annual report
on
Form 10-K,
filed March 2, 2009.
|
|
(vii)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed August 6, 2009.
|
|
(viii)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed October 5, 2009.
|
|
(ix)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed October 30, 2009.
|
|
(x)
|
Incorporated by reference to the Registrants annual report
on
Form 10-K,
filed March 15, 2010.
|
|
(xi)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed April 5, 2010.
|
|
(xii)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed May 3, 2010.
|
|
(xiii)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed July 23, 2010.
|
|
(xiv)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed October 22, 2010.
|
|
*
|
Filed herewith.
|
|
**
|
Extensible Business Reporting Language (XBRL) information is
furnished and deemed not filed or a part of a registration
statement or prospectus for purposes of sections 11 or 12
of the Securities Act of 1933, is deemed not filed for purposes
of section 18 of the Securities Exchange Act of 1934, and
otherwise is not subject to liability under these sections.
|
71
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
ATHENAHEALTH, INC.
Jonathan Bush
Chief Executive Officer, President, and Chairman
Timothy M. Adams
Chief Financial Officer,
Senior Vice President and Treasurer
Date: February 18, 2011
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the
dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Jonathan
Bush
(Jonathan
Bush)
|
|
Chief Executive Officer, President, and Chairman (Principal
Executive Officer)
|
|
February 18, 2011
|
|
|
|
|
|
/s/ Timothy
M. Adams
(Timothy
M. Adams)
|
|
Chief Financial Officer, Senior Vice President and Treasurer
(Principal Financial Officer & Principal Accounting
Officer)
|
|
February 18, 2011
|
|
|
|
|
|
/s/ Ruben
J. King-Shaw, Jr.
(Ruben
J. King-Shaw, Jr.)
|
|
Lead Director
|
|
February 18, 2011
|
|
|
|
|
|
/s/ Richard
N. Foster
(Richard
N. Foster)
|
|
Director
|
|
February 18, 2011
|
|
|
|
|
|
/s/ Brandon
H. Hull
(Brandon
H. Hull)
|
|
Director
|
|
February 18, 2011
|
|
|
|
|
|
/s/ Dev
Ittycheria
(Dev
Ittycheria)
|
|
Director
|
|
February 18, 2011
|
|
|
|
|
|
/s/ John
A. Kane
(John
A. Kane)
|
|
Director
|
|
February 18, 2011
|
|
|
|
|
|
/s/ James
L. Mann
(James
L. Mann)
|
|
Director
|
|
February 18, 2011
|
72
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ David
E. Robinson
(David
E. Robinson)
|
|
Director
|
|
February 18, 2011
|
|
|
|
|
|
/s/ William
Winkenwerder, Jr., M.D.
(William
Winkenwerder, Jr., M.D.)
|
|
Director
|
|
February 18, 2011
|
73
Financial
Statements and Supplementary Data
athenahealth,
Inc.
INDEX TO
CONSOLIDATED FINANCIAL STATEMENTS
Contents
|
|
|
|
|
|
|
|
F-2
|
|
Financial Statements
|
|
|
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
F-1
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
athenahealth, Inc.
Watertown, Massachusetts
We have audited the accompanying consolidated balance sheets of
athenahealth, Inc. and subsidiaries (the Company) as
of December 31, 2010 and 2009, and the related consolidated
statements of operations, stockholders equity, and cash
flows for each of the three years in the period ended
December 31, 2010. These financial statements are the
responsibility of the Companys management. Our
responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, such consolidated financial statements present
fairly, in all material respects, the financial position of
athenahealth, Inc. and subsidiaries as of December 31, 2010
and 2009, and the results of their operations and their cash
flows for each of the three years in the period ended
December 31, 2010, in conformity with accounting principles
generally accepted in the United States of America.
As discussed in Note 2 to the consolidated financial
statements, the Company changed its method of accounting for
business combinations on January 1, 2009.
We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
Companys internal control over financial reporting as of
December 31, 2010, based on the criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission and our report dated February 18, 2011,
expressed an unqualified opinion on the Companys internal
control over financial reporting.
/s/ Deloitte &
Touche LLP
Boston, Massachusetts
February 18, 2011
F-2
athenahealth,
Inc.
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(Amounts in thousands,
|
|
|
|
except per share amounts)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
35,944
|
|
|
$
|
30,526
|
|
Short-term investments
|
|
|
80,231
|
|
|
|
52,323
|
|
Accounts receivable net
|
|
|
36,870
|
|
|
|
33,323
|
|
Deferred tax assets
|
|
|
3,856
|
|
|
|
5,544
|
|
Prepaid expenses and other current assets
|
|
|
6,749
|
|
|
|
4,663
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
163,650
|
|
|
|
126,379
|
|
Property and equipment net
|
|
|
31,899
|
|
|
|
24,871
|
|
Restricted cash
|
|
|
8,691
|
|
|
|
9,216
|
|
Software development costs net
|
|
|
3,642
|
|
|
|
2,324
|
|
Purchased intangibles net
|
|
|
12,651
|
|
|
|
14,490
|
|
Goodwill
|
|
|
22,450
|
|
|
|
22,120
|
|
Deferred tax assets
|
|
|
10,959
|
|
|
|
10,284
|
|
Investments and other assets
|
|
|
7,228
|
|
|
|
1,393
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
261,170
|
|
|
$
|
211,077
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Current portion of long-term debt and capital lease obligations
|
|
$
|
2,909
|
|
|
$
|
3,437
|
|
Accounts payable
|
|
|
559
|
|
|
|
1,880
|
|
Accrued compensation
|
|
|
19,178
|
|
|
|
15,774
|
|
Accrued expenses
|
|
|
10,981
|
|
|
|
10,781
|
|
Current portion of deferred revenue
|
|
|
4,978
|
|
|
|
4,038
|
|
Interest rate derivative liability
|
|
|
490
|
|
|
|
291
|
|
Current portion of deferred rent
|
|
|
1,497
|
|
|
|
1,288
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
40,592
|
|
|
|
37,489
|
|
Deferred rent, net of current portion
|
|
|
5,960
|
|
|
|
7,444
|
|
Deferred revenue, net of current portion
|
|
|
35,661
|
|
|
|
28,684
|
|
Other long-term liabilities
|
|
|
1,897
|
|
|
|
1,191
|
|
Debt and capital lease obligations, net of current portion
|
|
|
6,307
|
|
|
|
8,951
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
90,417
|
|
|
|
83,759
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (see notes to financial statements)
|
|
|
|
|
|
|
|
|
Preferred stock; $0.01 par value: 5,000 shares
authorized and no shares issued and outstanding at
December 31, 2010 and 2009, respectively
|
|
|
|
|
|
|
|
|
Common stock; $0.01 par value per share;
125,000 shares authorized; 35,808 shares issued and
34,530 shares outstanding at December 31, 2010
35,166 shares issued and 33,888 shares outstanding at
December 31, 2009
|
|
|
358
|
|
|
|
352
|
|
Additional paid-in capital
|
|
|
200,339
|
|
|
|
169,715
|
|
Treasury stock, at cost, 1,278 shares
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
Accumulated other comprehensive income (loss)
|
|
|
28
|
|
|
|
(73
|
)
|
Accumulated deficit
|
|
|
(28,772
|
)
|
|
|
(41,476
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
170,753
|
|
|
|
127,318
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
261,170
|
|
|
$
|
211,077
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated
financial statements
F-3
athenahealth,
Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(Amounts in thousands,
|
|
|
|
except per share amounts)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
237,145
|
|
|
$
|
183,230
|
|
|
$
|
131,879
|
|
Implementation and other
|
|
|
8,393
|
|
|
|
5,297
|
|
|
|
4,403
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
245,538
|
|
|
|
188,527
|
|
|
|
136,282
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
96,582
|
|
|
|
79,017
|
|
|
|
59,947
|
|
Selling and marketing
|
|
|
52,675
|
|
|
|
34,072
|
|
|
|
22,827
|
|
Research and development
|
|
|
18,448
|
|
|
|
14,348
|
|
|
|
10,600
|
|
General and administrative
|
|
|
43,119
|
|
|
|
36,111
|
|
|
|
29,330
|
|
Depreciation and amortization
|
|
|
11,117
|
|
|
|
7,767
|
|
|
|
5,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
221,941
|
|
|
|
171,315
|
|
|
|
128,697
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
23,597
|
|
|
|
17,212
|
|
|
|
7,585
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
309
|
|
|
|
1,016
|
|
|
|
1,942
|
|
Interest expense
|
|
|
(753
|
)
|
|
|
(968
|
)
|
|
|
(428
|
)
|
(Loss) gain on interest rate derivative contract
|
|
|
(199
|
)
|
|
|
590
|
|
|
|
(881
|
)
|
Other income
|
|
|
146
|
|
|
|
255
|
|
|
|
182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (expense) income
|
|
|
(497
|
)
|
|
|
893
|
|
|
|
815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax (provision) benefit
|
|
|
23,100
|
|
|
|
18,105
|
|
|
|
8,400
|
|
Income tax (provision) benefit
|
|
|
(10,396
|
)
|
|
|
(8,829
|
)
|
|
|
23,202
|
|
Net income
|
|
|
12,704
|
|
|
|
9,276
|
|
|
|
31,602
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.37
|
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.36
|
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
34,181
|
|
|
|
33,584
|
|
|
|
32,746
|
|
Diluted
|
|
|
35,204
|
|
|
|
34,917
|
|
|
|
34,777
|
|
The accompanying notes are an integral part of the consolidated
financial statements
F-4
athenahealth,
Inc.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
Total
|
|
|
Total
|
|
|
|
Common Stock
|
|
|
Paid-In
|
|
|
Treasury Stock
|
|
|
Comprehensive
|
|
|
Accumulated
|
|
|
Stockholders
|
|
|
Comprehensive
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Shares
|
|
|
Amount
|
|
|
Income
|
|
|
Deficit
|
|
|
Equity
|
|
|
Income
|
|
|
|
(Amounts in thousands)
|
|
|
BALANCE January 1, 2008
|
|
|
33,613
|
|
|
$
|
336
|
|
|
$
|
144,994
|
|
|
|
(1,278
|
)
|
|
$
|
(1,200
|
)
|
|
$
|
72
|
|
|
$
|
(82,354
|
)
|
|
$
|
61,848
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
5,558
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,558
|
|
|
|
|
|
Stock options and warrants exercised
|
|
|
1,021
|
|
|
|
10
|
|
|
|
4,908
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,918
|
|
|
|
|
|
Common stock issued under employee stock purchase plan
|
|
|
11
|
|
|
|
|
|
|
|
317
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
317
|
|
|
|
|
|
Tax benefit realized from stock-based awards
|
|
|
|
|
|
|
|
|
|
|
526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
526
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,602
|
|
|
|
31,602
|
|
|
$
|
31,602
|
|
Unrealized holding gain on
available-for-sale-
investments, net of $188 tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
288
|
|
|
|
|
|
|
|
288
|
|
|
|
288
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(22
|
)
|
|
|
|
|
|
|
(22
|
)
|
|
|
(22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE December 31, 2008
|
|
|
34,645
|
|
|
|
346
|
|
|
|
156,303
|
|
|
|
(1,278
|
)
|
|
|
(1,200
|
)
|
|
|
338
|
|
|
|
(50,752
|
)
|
|
|
105,035
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
8,314
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,314
|
|
|
|
|
|
Stock options exercised
|
|
|
488
|
|
|
|
5
|
|
|
|
1,890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,895
|
|
|
|
|
|
Common stock issued under employee stock purchase plan
|
|
|
33
|
|
|
|
1
|
|
|
|
780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
781
|
|
|
|
|
|
Tax benefit realized from stock-based awards
|
|
|
|
|
|
|
|
|
|
|
2,428
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,428
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,276
|
|
|
|
9,276
|
|
|
|
9,276
|
|
Unrealized holding gain on
available-for-sale-
investments, net of $17 tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(262
|
)
|
|
|
|
|
|
|
(262
|
)
|
|
|
(262
|
)
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(149
|
)
|
|
|
|
|
|
|
(149
|
)
|
|
|
(149
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
8,865
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE December 31, 2009
|
|
|
35,166
|
|
|
|
352
|
|
|
|
169,715
|
|
|
|
(1,278
|
)
|
|
|
(1,200
|
)
|
|
|
(73
|
)
|
|
|
(41,476
|
)
|
|
|
127,318
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
14,477
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,477
|
|
|
|
|
|
Stock options exercised and restricted stock units vested
|
|
|
605
|
|
|
|
5
|
|
|
|
7,522
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,527
|
|
|
|
|
|
Common stock issued under employee stock purchase plan
|
|
|
37
|
|
|
|
1
|
|
|
|
1,078
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,079
|
|
|
|
|
|
Tax benefit realized from stock-based awards
|
|
|
|
|
|
|
|
|
|
|
7,547
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,547
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,704
|
|
|
|
12,704
|
|
|
|
12,704
|
|
Unrealized holding gain on
available-for-sale-
investments, net of $7 tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(52
|
)
|
|
|
|
|
|
|
(52
|
)
|
|
|
(52
|
)
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
153
|
|
|
|
|
|
|
|
153
|
|
|
|
153
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
12,805
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE December 31, 2010
|
|
|
35,808
|
|
|
$
|
358
|
|
|
$
|
200,339
|
|
|
|
(1,278
|
)
|
|
$
|
(1,200
|
)
|
|
$
|
28
|
|
|
$
|
(28,772
|
)
|
|
$
|
170,753
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated
financial statements
F-5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(Amounts in thousands)
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
12,704
|
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
12,956
|
|
|
|
8,403
|
|
|
|
6,095
|
|
Amortization of premiums (discounts) on investments
|
|
|
1,152
|
|
|
|
(113
|
)
|
|
|
(899
|
)
|
Provision for uncollectible accounts
|
|
|
1,772
|
|
|
|
999
|
|
|
|
405
|
|
Decrease in fair value of contingent consideration
|
|
|
(250
|
)
|
|
|
|
|
|
|
|
|
Loss (gain) on interest rate derivative contract
|
|
|
199
|
|
|
|
(590
|
)
|
|
|
881
|
|
Deferred income taxes
|
|
|
1,013
|
|
|
|
5,918
|
|
|
|
(23,833
|
)
|
Excess tax benefit from stock-based awards
|
|
|
(9,245
|
)
|
|
|
(2,505
|
)
|
|
|
(526
|
)
|
Stock-based compensation expense
|
|
|
14,477
|
|
|
|
8,314
|
|
|
|
5,558
|
|
Loss (gain) on disposal of property and equipment
|
|
|
|
|
|
|
276
|
|
|
|
(47
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(5,319
|
)
|
|
|
(10,489
|
)
|
|
|
(9,254
|
)
|
Prepaid expenses and other current assets
|
|
|
5,461
|
|
|
|
(887
|
)
|
|
|
(912
|
)
|
Other assets
|
|
|
(243
|
)
|
|
|
(173
|
)
|
|
|
86
|
|
Accounts payable
|
|
|
(1,024
|
)
|
|
|
1,379
|
|
|
|
(1,195
|
)
|
Accrued expenses
|
|
|
4,425
|
|
|
|
6,201
|
|
|
|
7,424
|
|
Deferred revenue
|
|
|
7,917
|
|
|
|
7,438
|
|
|
|
7,120
|
|
Deferred rent
|
|
|
(1,275
|
)
|
|
|
(1,118
|
)
|
|
|
(1,446
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
44,720
|
|
|
|
32,329
|
|
|
|
21,059
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Capitalized software development costs
|
|
|
(3,881
|
)
|
|
|
(2,555
|
)
|
|
|
(1,393
|
)
|
Purchases of property and equipment
|
|
|
(15,932
|
)
|
|
|
(10,277
|
)
|
|
|
(13,452
|
)
|
Proceeds from sales and disposals of property and equipment
|
|
|
363
|
|
|
|
4,538
|
|
|
|
4,112
|
|
Purchase in long-term investment in unconsolidated company
|
|
|
|
|
|
|
(550
|
)
|
|
|
(550
|
)
|
Proceeds from sales and maturities of investments
|
|
|
110,741
|
|
|
|
84,014
|
|
|
|
73,250
|
|
Purchases of short term and long-term investments
|
|
|
(145,443
|
)
|
|
|
(78,588
|
)
|
|
|
(129,935
|
)
|
Payments for acquisitions net of cash acquired
|
|
|
|
|
|
|
(22,391
|
)
|
|
|
(6,680
|
)
|
Decrease (increase) in restricted cash
|
|
|
525
|
|
|
|
(7,368
|
)
|
|
|
(136
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(53,627
|
)
|
|
|
(33,177
|
)
|
|
|
(74,784
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options
|
|
|
8,606
|
|
|
|
2,676
|
|
|
|
5,235
|
|
Debt issuance costs
|
|
|
|
|
|
|
|
|
|
|
(177
|
)
|
Excess tax benefit from stock-based awards
|
|
|
9,245
|
|
|
|
2,505
|
|
|
|
526
|
|
Proceeds from long-term debt
|
|
|
|
|
|
|
|
|
|
|
6,000
|
|
Payment of contingent consideration accrued at acquisition date
|
|
|
(195
|
)
|
|
|
|
|
|
|
|
|
Payments on long term debt and capital lease obligations
|
|
|
(3,535
|
)
|
|
|
(2,514
|
)
|
|
|
(777
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
14,121
|
|
|
|
2,667
|
|
|
|
10,807
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effects of exchange rate changes on cash and cash equivalents
|
|
|
204
|
|
|
|
(226
|
)
|
|
|
(40
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
5,418
|
|
|
|
1,593
|
|
|
|
(42,958
|
)
|
Cash and cash equivalents at beginning of year
|
|
|
30,526
|
|
|
|
28,933
|
|
|
|
71,891
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
35,944
|
|
|
$
|
30,526
|
|
|
$
|
28,933
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of non-cash investing
activities Property and equipment recorded in
accounts payable and accrued expenses
|
|
$
|
214
|
|
|
$
|
510
|
|
|
$
|
998
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure Cash paid for interest
|
|
$
|
873
|
|
|
$
|
836
|
|
|
$
|
324
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure Non-cash investing
activities Contingent Consideration
|
|
$
|
|
|
|
$
|
5,100
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure Cash paid for taxes
|
|
$
|
1,636
|
|
|
$
|
514
|
|
|
$
|
403
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment acquired under capital leases
|
|
$
|
363
|
|
|
$
|
4,538
|
|
|
$
|
3,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated
financial statements
F-6
athenahealth,
Inc.
(Amounts in thousands, except per-share amounts)
|
|
1.
|
BUSINESS
AND ORGANIZATION
|
General athenahealth, Inc. (the
Company, we, us, or
our) is a business services company that provides
ongoing billing, clinical-related, and other related services to
its customers. The Company provides these services with the use
of athenaNet, a proprietary Internet-based practice management
application. The Companys customers consist of medical
group practices ranging in size throughout the United States of
America.
In August 2005, the Company established a subsidiary in Chennai,
India, athenahealth Technology Private Limited, to conduct
research and development activities. On April 10, 2009, the
Company established a Massachusetts corporation, athenahealth
MA, Inc., to hold a share of common stock of athenahealth
Technology Private Limited. On December 23, 2010, the
Company established a subsidiary, athenahealth Security
Corporation, to hold the Companys investments.
On October 16, 2009, the Company acquired Anodyne Health
Partners, Inc. (Anodyne). The Company paid cash for
Anodyne. For financial reporting purposes, the acquisition was
accounted for using the acquisition method of accounting in
accordance with the guidance on business combinations.
Risks and Uncertainties The Company is
subject to risks common to companies in similar industries and
stages of development, including, but not limited to,
competition from larger companies, a volatile market for its
services, new technological innovations, dependence on key
personnel, third-party service providers and vendors, protection
of proprietary technology, fluctuations in operating results,
dependence on market acceptance of its products, and compliance
with government regulations.
|
|
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
|
Principles of Consolidation The accompanying
consolidated financial statements include the results of
operations of the Company and its majority owned subsidiaries.
All intercompany balances and transactions have been eliminated
in consolidation.
Comprehensive Income (Loss) Comprehensive
income includes net income, foreign currency translation
adjustments, and unrealized holding gains (losses) on
available-for-sale
securities.
Use of Estimates The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States of America requires management to
make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements,
as well as the reported amounts of revenues and expenses during
the reporting period. Significant estimates and assumptions are
used for, but are not limited to: (1) revenue recognition;
including the estimated expected customer life;
(2) allowance for doubtful accounts; (3) asset
impairments; (4) depreciable lives of assets;
(5) economic lives and fair value of leased assets;
(6) income tax reserves and valuation allowances;
(7) fair value of stock-based compensation;
(8) allocation of direct and indirect cost of sales;
(9) fair value of contingent consideration; and
(10) litigation reserves. Actual results could
significantly differ from those estimates.
Recent Accounting Pronouncements From time to
time, new accounting pronouncements are issued by FASB and are
adopted by us as of the specified effective date. Unless
otherwise discussed, the Company believes that the impact of
other recently issued accounting pronouncements will not have a
material impact on consolidated financial position, results of
operations, and cash flows, or do not apply to the
Companys operations. See discussion below relating to the
adoption of new authoritative guidance relating to revenue
recognition.
F-7
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Revenue Recognition The Company recognizes
revenue when there is evidence of an arrangement, the service
has been provided to the customer, the collection of the fees is
reasonably assured, and the amount of fees to be paid by the
customer are fixed or determinable.
The Company derives its revenue from business services fees,
implementation fees, and other services. Business services fees
include amounts charged for ongoing billing, clinical-related,
and other related services and are generally billed to the
customer as a percentage of total collections. Business services
fees also include amounts charged to customers for generating
and mailing patient statements and are recognized as the related
services are performed. The Company does not recognize revenue
for business services fees until these collections are made, as
the services fees are not fixed and determinable until such time.
Implementation revenue consists primarily of professional
services fees related to assisting customers with the
implementation of the Companys services and are generally
billed upfront and recorded as deferred revenue until the
implementation is complete and then recognized ratably over the
longer of the life of the agreement or the estimated expected
customer life, which is currently estimated to be twelve years.
The Company evaluates the length of the amortization period of
the implementation fees based on our experience with customer
contract renewals and consideration of the period over which
those customers will receive benefits from our current portfolio
of services. Certain expenses related to the implementation of a
customer, such as
out-of-pocket
travel, are typically reimbursed by the customer. This is
accounted for as both revenue and expense in the period the cost
is incurred. Other services consist primarily of training,
consulting services and interface fees and are recognized as the
services are performed.
Effective January 1, 2010, the Company adopted the new
accounting standards for revenue recognition for multiple
deliverable revenue arrangements. This new authoritative
guidance amends previously issued guidance to eliminate the
residual method of allocation for multiple deliverable revenue
arrangements, and requires that arrangement consideration be
allocated at the inception of an arrangement to all deliverables
using the relative selling price method. The new authoritative
guidance also establishes a selling price hierarchy for
determining the selling price of a deliverable, which includes
(1) vendor-specific objective evidence (VSOE),
if available, (2) third-party evidence (TPE),
if vendor-specific objective evidence is not available, and
(3) estimated selling price (ESP), if neither
vendor-specific nor third party evidence is available.
Additionally, it expands the disclosure requirements related to
a vendors multiple-deliverable revenue arrangements.
During the second quarter of 2010 the Company elected to adopt
early, as permitted by the guidance. As such, the Company has
prospectively (retroactive to January 1, 2010) applied
the provisions of the new authoritative guidance to all revenue
arrangements entered into or materially modified after
January 1, 2010. Adopting the new standard will require the
Company to allocate the arrangement consideration if multiple
service offerings are sold at the same time. A sale of multiple
services offerings could include any combination of the
Companys services.
In accordance with the new authoritative guidance, the Company
allocates arrangement consideration to each deliverable in an
arrangement based on its relative selling price. The Company
determines selling price using VSOE, if it exists; otherwise,
the Company uses TPE. If neither VSOE nor TPE of selling price
exists for a unit of accounting, the Company uses ESP.
VSOE is generally limited to the price charged when the same or
similar product is sold separately. If a product or service is
seldom sold separately, it is unlikely that the Company can
determine VSOE for the product or service. The Company defines
VSOE as a median price of recent standalone transactions that
are priced within a narrow range, as defined by the Company. TPE
is determined based on the prices charged by our competitors for
a similar deliverable when sold separately. It may be difficult
for the Company to obtain sufficient information on competitor
pricing to substantiate TPE and therefore the Company may not
always be able to use TPE.
F-8
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
If the Company is unable to establish selling price using VSOE
or TPE, and the order was received or materially modified after
the implementation date of January 1, 2010, for the new
authoritative guidance, the Company will use ESP in our
allocation of arrangement consideration. The objective of ESP is
to determine the price at which the Company would transact if
the product or service were sold by us on a standalone basis.
The Companys determination of ESP involves a weighting of
several factors based on the specific facts and circumstances of
the arrangement. The Company considered the selling price for
similar services, our ongoing pricing strategy and policies, the
value of any enhancements that have been built into the
deliverable and the characteristics of the varying markets in
which the deliverable is sold.
The Company analyzes the selling prices used in our allocation
of arrangement consideration at a minimum on an annual basis.
Selling prices will be analyzed on a more frequent basis if a
significant change in our business necessitates a more timely
analysis or if we experience significant variances in the
Companys selling prices.
Each deliverable within a multiple-deliverable revenue
arrangement is accounted for as a separate unit of accounting
under the new authoritative literature if both of the following
criteria are met: (1) the delivered item or items have
value to the customer on a standalone basis and (2) for an
arrangement that includes a general right of return relative to
the delivered item(s), delivery or performance of the
undelivered item(s) is considered probable and substantially in
our control. The Company considers a deliverable to have
standalone value if we sell this item separately or if the item
is sold by another vendor or could be resold by the customer.
Further, the Companys revenue arrangements generally do
not include a general right of return relative to delivered
products. Deliverables not meeting the criteria for being a
separate unit of accounting are combined with a deliverable that
does meet that criterion. The appropriate allocation of
arrangement consideration and recognition of revenue is then
determined for the combined unit of accounting.
During the year ended December 31, 2010, the adoption of
this guidance had no material impact. The new accounting
standards for revenue recognition, if applied in the same manner
to the year ended December 31, 2009, would not have had a
material impact on total net revenue for that fiscal year. In
terms of the timing and pattern of revenue recognition, the new
accounting guidance is not expected to have a significant effect
on total net revenue in periods immediately after the initial
adoption.
Direct Operating Expenses Direct operating
expenses consist primarily of salaries, benefits, and
stock-based compensation related to personnel who provide
services to clients; claims processing costs; implementing new
clients; and other direct costs related to collection and
business services. Costs associated with the implementation of
new clients are expensed as incurred. The reported amounts of
direct operating expenses do not include allocated amounts for
rent and overhead costs (which are included in general and
administrative costs), and depreciation, amortization (which are
broken out separately on the statement of operations), except
for the amortization of certain purchased intangible assets.
Research and Development Expenses Research
and development expenses consist primarily of personnel-related
costs and consulting fees for third-party developers. All such
costs are expensed as incurred.
Cash and Cash Equivalents Cash and cash
equivalents consist of deposits, money market funds, commercial
paper, and other liquid securities with remaining maturities of
three months or less at the date of purchase.
Investments Management determines the
appropriate classification of investments at the time of
purchase based upon managements intent with regard to such
investments. All investments have been classified as
available-for-sale
and are recorded at fair value with unrealized holding gains and
losses included in accumulated other comprehensive income
(loss). The Company classifies its investments on the
consolidated balance sheet as current or noncurrent based on the
maturity of the instrument. The Company determines realized
gains and losses based on the specific identification method.
F-9
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Accounts Receivable Accounts receivable
represents amounts due from customers for services and
implementation services. Accounts receivable are stated net of
an allowance for uncollectible accounts, which is determined by
establishing reserves for specific accounts and consideration of
historical and estimated probable losses.
Activity in the allowance for doubtful accounts is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Beginning balance
|
|
$
|
1,271
|
|
|
$
|
726
|
|
|
$
|
437
|
|
Provision
|
|
|
1,772
|
|
|
|
999
|
|
|
|
405
|
|
Write-offs and adjustments
|
|
|
(1,098
|
)
|
|
|
(454
|
)
|
|
|
(116
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
1,945
|
|
|
$
|
1,271
|
|
|
$
|
726
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial Instruments Certain financial
instruments are required to be recorded at fair value. The other
financial instruments approximate their fair value, primarily
because of their short-term nature which include cash
equivalents, accounts receivable, accounts payable, and accrued
expenses. The carrying amounts of the Companys debt
obligations approximate fair value based upon our best estimate
of interest rates that would be available to the Company for
similar debt obligations. All highly liquid debt instruments
purchased with a maturity of three months or less at the date of
acquisition are included in cash and cash equivalents.
Derivative financial instruments are used to manage certain of
the Companys interest rate exposures. The Company does not
enter into derivatives for speculative purposes, nor does the
Company hold or issue any financial instruments for trading
purposes. In October 2008, the Company entered into a derivative
instrument that is not designated as hedge. The Company entered
into the derivative instrument to offset the cash flow exposure
associated with its interest payments on certain outstanding
debt. Derivatives are carried at fair value, as determined using
standard valuation models and adjusted, when necessary, for
credit risk and are separately presented on the balance sheet.
The gains or losses from changes in the fair value of derivative
instruments that are not accounted for as hedges are recognized
in earnings and are separately presented.
Property and Equipment Property and equipment
are stated at cost. Equipment, furniture and, fixtures are
depreciated using the straight-line method over their estimated
useful lives, generally ranging from three to five years.
Leasehold improvements are depreciated using the straight-line
method over the lesser of the useful life of the improvements or
the applicable lease terms, excluding renewal periods. Buildings
are depreciated using the straight-line method over
30 years. Building improvements are depreciated using the
straight-line method over the lesser of the useful life of the
improvement or the remaining life of the building. Costs
associated with maintenance and repairs are expensed as
incurred. The airplane is depreciated using the straight-line
method over 20 years.
Long-Lived Assets Long-lived assets to be
held and used are reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of
recoverability of long-lived assets is based on an estimate of
undiscounted future cash flows resulting from the use of the
asset and its eventual disposition, as compared with the asset
carrying value. Measurement of an impairment loss for long-lived
assets that management expects to hold and use is based on the
fair value of the asset. Long-lived assets to be disposed of are
reported at the lower of carrying amount or fair value, less
costs to sell. No impairment losses have been recognized in the
years ended December 31, 2010, 2009, or 2008.
Restricted Cash Restricted cash consists of
funds held under a letter of credit as a condition of the
Companys operating lease for its corporate headquarters
(see Note 9). The letter of credit was reduced in 2008 to
$856. The letter of credit will remain in effect during the term
of the lease agreement. The remaining restricted cash balance as
of December 31, 2010, consists of escrowed amounts relating
to the purchase of
F-10
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
MedicalMessaging and Anodyne (see Note 7). Of the remaining
balance, $330 relates to MedicalMessaging and will be paid in
the first quarter of 2011 as MedicalMessaging achieved the final
financial milestone set forth in the purchase agreement during
2010. Restricted cash relating to the purchase of Anodyne at
December 31, 2010, was $7,505, and may be paid over a
three-year period starting in 2010 if Anodyne achieves certain
business and financial milestones or may be released to the
Company to cover indemnification claims.
Software Development Costs The Company
accounts for software development costs based on required
criteria and timing. Costs related to the preliminary project
stage of subsequent versions of athenaNet or other technologies
are expensed as incurred. Costs incurred in the application
development stage are capitalized, and such costs are amortized
over the softwares estimated economic life. The estimated
useful life of the software release is two years. Amortization
expense was $2,563, $2,110, and $1,395 for the years ended
December 31, 2010, 2009, and 2008, respectively. Future
amortization expense for all software development costs
capitalized as of December 31, 2010, is estimated to be
$2,597 and $1,045 for the years ending December 31, 2011
and 2012, respectively.
Goodwill Goodwill is recorded as the
difference, if any, between the aggregate consideration paid for
an acquisition and the fair value of the net tangible and
intangible assets acquired. Goodwill is not amortized but is
evaluated for impairment annually or more frequently if
indicators of impairment are present or changes in circumstances
suggest that impairment may exist. The Company evaluates the
carrying value of its goodwill annually on November 30. The
first step of the goodwill impairment test compares the fair
value of the reporting unit with its carrying amount, including
goodwill. If the fair value of the Companys reporting unit
exceeds its carrying amount, the goodwill of the reporting unit
is considered not impaired. If the carrying amount of the
Companys reporting unit exceeds its fair value, the second
step of the goodwill impairment test is performed to measure the
amount of impairment loss, if any. The second step of the
goodwill impairment test, used to measure the amount of
impairment loss, compares the implied fair value of the affected
reporting units goodwill with the carrying value of that
goodwill. No impairment losses have been recognized in the years
ended December 31, 2010, 2009, and 2008.
Other Intangible Assets Other intangible
assets consist of technology and customer relationships acquired
in connection with business acquisitions and are amortized over
their estimated useful lives on a straight-line basis. The
Company concluded that use of the straight-line method was
appropriate as the majority of the cash flows will be recognized
ratably over the estimated useful lives and there is no
significant degradation of the cash flows over time.
Accrued expenses and accrued compensation
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Accrued bonus
|
|
$
|
9,599
|
|
|
$
|
8,030
|
|
Accrued vacation
|
|
|
2,342
|
|
|
|
1,884
|
|
Accrued payroll
|
|
|
4,895
|
|
|
|
4,081
|
|
Accrued commissions
|
|
|
2,342
|
|
|
|
1,779
|
|
|
|
|
|
|
|
|
|
|
Accrued compensation expenses
|
|
$
|
19,178
|
|
|
$
|
15,774
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
$
|
7,301
|
|
|
$
|
6,468
|
|
Current portion of accrued contingent consideration
|
|
|
3,680
|
|
|
|
4,313
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
$
|
10,981
|
|
|
$
|
10,781
|
|
|
|
|
|
|
|
|
|
|
Deferred Rent Deferred rent consists of rent
escalation payment terms, tenant improvement allowances and
other incentives received from landlords related to the
Companys operating leases for its facilities. Rent
F-11
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
escalation represents the difference between actual operating
lease payments due and straight-line rent expense, which is
recorded by the Company over the term of the lease, including
any construction period. The excess is recorded as a deferred
credit in the early periods of the lease, when cash payments are
generally lower than straight-line rent expense, and is reduced
in the later periods of the lease when payments begin to exceed
the straight-line expense. Tenant allowances from landlords for
tenant improvements are generally comprised of cash received
from the landlord as part of the negotiated terms of the lease
or reimbursements of moving costs. These cash payments are
recorded as deferred rent from landlords and are amortized as a
reduction of periodic rent expense, over the term of the
applicable lease.
Deferred Revenue Deferred revenue primarily
consists of billings or payments received in advance of the
revenue recognition criteria being met. Deferred revenue
includes certain deferred implementation services fees which are
recognized as revenue ratably over the longer of the life of the
agreement or the estimated expected customer life, which is
currently estimated to be twelve years. Deferred revenue that
will be recognized during the succeeding
12-month
period is recorded as current deferred revenue and the remaining
portion is recorded as noncurrent. In the quarter when a
customer terminates, any unrecognized service fees associated
with implementation services before and after services have been
started are recognized as revenue in that quarter.
Business Combinations On January 1,
2009, the Company adopted the new authoritative guidance on
business combinations. This guidance establishes principles and
requirements for how an acquirer recognizes and measures in its
financial statements significant aspects of a business
combination. Under this guidance, acquisition costs are
generally expensed as incurred; non-controlling interests are
reflected at fair value at the acquisition date; in-process
research and development (IPR&D) is recorded at
fair value as an intangible asset at the acquisition date;
restructuring costs associated with a business combination are
generally expensed rather than capitalized; contingent
consideration is measured at fair value at the acquisition date,
with changes in the fair value after the acquisition date
affecting earnings; and changes in deferred tax asset valuation
allowances and income tax uncertainties after the measurement
period will affect income tax expense.
In connection with a 2009 acquisition discussed in Note 7,
the Company expensed $751 of acquisition costs that, prior to
the change in accounting, would have been included as part of
the purchase price. In addition, the potential contingent
consideration of $7,700 was recorded in the initial purchase
price allocation at its estimated fair value of $5,100. The
difference between the estimated and earn-out amount will be
charged or credited to expense. The contingent consideration for
acquisitions which occurred prior to this change are recorded as
additional goodwill when the contingent consideration is earned.
In addition, under the provisions of this guidance, future
reversal of the Companys acquisition-related tax reserves
of $680 (excluding interest and penalties) will be recorded in
earnings, rather than as an adjustment to goodwill or
acquisition related other intangible assets and will affect the
Companys annual effective income tax rate.
Concentrations of Credit Risk Financial
instruments that potentially subject the Company to
concentrations of credit risk are cash equivalents, investments,
derivatives, and accounts receivable. The Company attempts to
limit its credit risk associated with cash equivalents and
investments by investing in highly rated corporate and financial
institutions, and engages with highly rated financial
institutions as a counterparty to its derivative transaction.
With respect to customer accounts receivable, the Company
manages its credit risk by performing ongoing credit evaluations
of its customers. No customer accounted for more than 10% of
revenues or accounts receivable as of or for the years ended
December 31, 2010, 2009, or 2008.
Income Taxes Deferred tax assets and
liabilities relate to temporary differences between the
financial reporting and income tax bases of assets and
liabilities and are measured using enacted tax rates and laws
expected to be in effect at the time of their reversal. A
valuation allowance is established to reduce net deferred tax
assets if, based on the available positive and negative
evidence, it is more likely than not that some or all of the
deferred tax assets will not be realized. In making such
determination, the Company
F-12
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
considers all available positive and negative evidence,
including future reversals of existing taxable temporary
differences, projected future taxable income, tax planning
strategies, and recent financial results.
The Company recognizes a tax benefit from an uncertain tax
position when it is more likely than not that the position will
be sustained upon examination, including resolutions of any
related appeals or litigation processes, based on the technical
merits. Our income tax positions must meet a
more-likely-than-not recognition threshold at the balance sheet
date to be recognized in the related period.
The Companys policy is to record interest and penalties
related to unrecognized tax benefits in income tax expense. As
of December 31, 2010, the Company has no accrued interest
or penalties related to uncertain tax positions.
Sales and Use Taxes the Companys
services are subject to sales and use taxes in certain
jurisdictions. The Companys contractual agreements with
its customers provide that payment of any sales or use taxes
assessments are the responsibility of the customer. In certain
jurisdictions sales taxes are collected from the customer and
remitted to the respective agencies. These taxes are recorded on
a net basis and excluded from revenue and expense in our
financial statements as presented.
Segment Reporting Operating segments are
identified as components of an enterprise about which separate
discrete financial information is evaluated by the chief
decision-maker, or decision-making group, in making decisions
regarding resource allocation and assessing performance. The
Company, which uses consolidated financial information in
determining how to allocate resources and assess performance,
has determined that it operates in one segment.
Stock-Based Compensation The Company accounts
for share-based awards, including shares issued under employee
stock purchase plans, stock options, and restricted stock units
with compensation cost measured using the fair value of the
awards issued.
Foreign Currency Translation The financial
position and results of operations of the Companys foreign
subsidiary are measured using local currency as the functional
currency. Assets and liabilities are translated at the rate of
exchange in effect at the end of each reporting period. Revenues
and expenses are translated at the average exchange rate for the
period. Foreign currency translation gains and losses are
recorded within other comprehensive income.
Basic net income per share is computed by dividing net income by
the weighted average number of common shares outstanding during
the period. Diluted net income per share is computed by dividing
net income by the weighted average number of common shares
outstanding and potentially dilutive securities outstanding
during the period under the treasury stock method. Potentially
dilutive securities include stock options and warrants. Under
the treasury stock method, dilutive securities are assumed to be
exercised at the beginning of the periods and as if funds
obtained thereby were used to purchase common stock at the
average market price during the period. Securities are excluded
from the computations of diluted net income per share if their
effect would be anti-dilutive to earnings per share.
F-13
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table reconciles the weighted average shares
outstanding for basic and diluted net income per share for the
periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Net income
|
|
$
|
12,704
|
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
Weighted average shares used in computing basic net income per
share
|
|
|
34,181
|
|
|
|
33,584
|
|
|
|
32,746
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.37
|
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
12,704
|
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
Weighted average shares used in computing basic net income per
share
|
|
|
34,181
|
|
|
|
33,584
|
|
|
|
32,746
|
|
Effect of dilutive securities
|
|
|
1,023
|
|
|
|
1,333
|
|
|
|
2,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing diluted net income per
share
|
|
|
35,204
|
|
|
|
34,917
|
|
|
|
34,777
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.36
|
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The computation of diluted net income per share does not include
844 stock options and restricted stock units for the year ended
December 31, 2010, because their inclusion would have an
anti-dilutive effect on net income per share. The computation of
diluted net income per share does not include 1,021 and 1,088
stock options for the year ended December 31, 2009 and
2008, respectively, because their inclusion would have an
anti-dilutive effect on net income per share.
|
|
4.
|
FAIR
VALUE OF FINANCIAL INSTRUMENTS
|
As of December 31, 2010 and 2009, the carrying amounts of
cash and cash equivalents, restricted cash, receivables,
accounts payable, and accrued expenses approximated their
estimated fair values because of the
short-term
nature of these financial instruments. All highly liquid debt
instruments purchased with a maturity of three months or less at
the date of acquisition are included in cash and cash
equivalents. Included in cash and cash equivalents as of
December 31, 2010 and 2009, are money market fund
investments of $10,799 and $10,081, respectively, which are
reported at fair value.
The carrying amounts of the Companys debt obligations
approximate fair value based upon our best estimate of interest
rates that would be available to the Company for similar debt
obligations. The estimated fair value of our long-term debt was
determined using quoted market prices and other inputs that were
derived from available market information and may not be
representative of actual values that could have been or will be
realized in the future.
The following table presents information about the
Companys financial assets and liabilities that are
measured at fair value on a recurring basis as of
December 31, 2010 and 2009, and indicates the fair value
hierarchy of the valuation techniques the Company utilized to
determine such fair value. In general, fair values determined by
Level 1 inputs utilize quoted prices (unadjusted) in active
markets for identical assets or liabilities and fair values
determined by Level 2 inputs utilize quoted prices
(unadjusted) in inactive markets for identical assets or
liabilities obtained from readily available pricing sources for
similar instruments. The fair values determined by Level 3
inputs are unobservable values which are supported by little or
no market activity. Investments includes $3,500 of
long term U.S. government backed securities and
$2,081 of long-term corporate bonds that have been classified in
investments and other assets on the consolidated balance
F-14
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
sheet as of December 31, 2010. At December 31, 2009,
there were no
long-term
investments held by the Company.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of December 31, 2010 Using
|
|
|
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market
|
|
$
|
10,799
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
10,799
|
|
Corporate bonds
|
|
|
|
|
|
|
577
|
|
|
|
|
|
|
|
577
|
|
Available-for-sale
investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial paper
|
|
|
|
|
|
|
29,642
|
|
|
|
|
|
|
|
29,642
|
|
Corporate bonds
|
|
|
|
|
|
|
40,676
|
|
|
|
|
|
|
|
40,676
|
|
U.S. government backed securities
|
|
|
|
|
|
|
15,494
|
|
|
|
|
|
|
|
15,494
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
10,799
|
|
|
$
|
86,389
|
|
|
$
|
|
|
|
$
|
97,188
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued contingent consideration
|
|
$
|
|
|
|
$
|
|
|
|
$
|
(4,655
|
)
|
|
$
|
(4,655
|
)
|
Interest rate swap derivative contract
|
|
|
|
|
|
|
(490
|
)
|
|
|
|
|
|
|
(490
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
|
|
|
$
|
(490
|
)
|
|
$
|
(4,655
|
)
|
|
$
|
(5,145
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of December 31, 2009 Using
|
|
|
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market
|
|
$
|
10,081
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
10,081
|
|
Available-for-sale
investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government backed securities
|
|
|
|
|
|
|
52,323
|
|
|
|
|
|
|
|
52,323
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
10,081
|
|
|
$
|
52,323
|
|
|
$
|
|
|
|
$
|
62,404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued contingent consideration
|
|
$
|
|
|
|
$
|
|
|
|
$
|
(5,100
|
)
|
|
$
|
(5,100
|
)
|
Interest rate swap derivative contract
|
|
|
|
|
|
|
(291
|
)
|
|
|
|
|
|
|
(291
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
|
|
|
$
|
(291
|
)
|
|
$
|
(5,100
|
)
|
|
$
|
(5,391
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government backed securities, corporate bonds, and
commercial paper are valued using a market approach based upon
the quoted market prices of identical instruments when available
or other observable inputs such as trading prices of identical
instruments in inactive markets or similar securities. The
interest rate swap derivative is valued using observable inputs
at the reporting date. It is the Companys policy to
recognize transfers between levels of the fair value hierarchy,
if any, at the end of the reporting period however there have
been no such transfers during the year ended December 31,
2010.
Contingent consideration is recorded at fair value as an element
of purchase price with subsequent adjustments recognized in the
consolidated statement of operations. At the acquisition date
and reporting date, the fair value of the accrued contingent
consideration was determined using a probability-weighted income
approach based on upside, downside and base case scenarios. This
approach is based on significant inputs that are not observable
in the market, which are referred to as Level 3 inputs. As
of December 31, 2010 and 2009, the Company has accrued a
liability of $4,655 and $5,100, respectively, for the estimated
fair value of contingent considerations estimated to be payable
upon the acquired company reaching specific performance metrics
over the initial three years of operation after acquisition.
There are two separate elements that make up the contingent
consideration. The first potential contingent consideration
ranges from zero to $4,800 and is
F-15
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
payable in one installment based upon operational performance
for the year ended December 31, 2010. Based on the actual
operational performance for the year ended December 31,
2010, the Company has accrued $2,400 relating to the first
potential contingent consideration which will be paid in the
first half of 2011.
The second potential contingent consideration ranges from zero
to $2,900 and is payable in quarterly installments based upon
the cross selling of the Companys services into the
Anodyne customer base for the years ended December 31, 2010
and 2011, and the six-month period ending June 30, 2012.
Any amounts not earned in the first potential contingent
consideration can be earned under the second potential
contingent consideration in excess of the initial $2,900
bringing the total potential contingent consideration to $5,300.
At December 31, 2010, key assumptions relating to the
second potential contingent consideration include a discount
rate of 21% and a probability adjusted level of 50% for the base
case scenario and 25% for the upside and downside scenarios. At
December 31, 2009, key assumptions relating to the second
potential contingent consideration include a discount rate of
21% and a probability adjusted level of 50% for the base case
scenario, 40% for the upside scenario and 10% downside scenario.
The change in these assumptions were caused by the results from
2010 operations and expected results from 2011 and 2012
operations and resulted in a decrease of $250 in the fair value
of the total contingent consideration during the year ended
December 31, 2010. The Company paid $195 during the year
ended December 31, 2010, under the terms of the second
potential contingent consideration.
|
|
|
|
|
Balance as of January 1, 2010
|
|
$
|
5,100
|
|
Decrease in fair value of contingent consideration
|
|
|
(250
|
)
|
Payments of contingent consideration
|
|
|
(195
|
)
|
|
|
|
|
|
Balance as of December 31, 2010
|
|
$
|
4,655
|
|
|
|
|
|
|
The summary of
available-for-sale
securities as of December 31, 2010, is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
|
|
|
|
|
|
|
|
Unrealized
|
|
|
|
|
|
|
Amortized
|
|
|
Gains
|
|
|
|
|
|
|
Cost
|
|
|
(Losses)
|
|
|
Fair Value
|
|
|
Commercial paper
|
|
$
|
29,635
|
|
|
$
|
7
|
|
|
$
|
29,642
|
|
Corporate bonds
|
|
|
40,694
|
|
|
|
(18
|
)
|
|
|
40,676
|
|
U.S. government backed securities
|
|
|
15,500
|
|
|
|
(6
|
)
|
|
|
15,494
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
85,829
|
|
|
$
|
(17
|
)
|
|
$
|
85,812
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments include $3,500 of long-term U.S. government
backed securities and $2,081 of long-term corporate bonds that
have been classified in investments and other assets on the
condensed consolidated balance sheet at December 31, 2010.
At December 31, 2009, there were no long-term investments
held by the Company.
The summary of
available-for-sale
securities as of December 31, 2009, is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
|
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
|
|
|
|
Cost
|
|
|
Gains
|
|
|
Fair Value
|
|
|
U.S. government backed securities
|
|
$
|
52,280
|
|
|
$
|
43
|
|
|
$
|
52,323
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scheduled maturity dates of U.S. government backed
securities, corporate bonds and commercial paper as of
December 31, 2010 and 2009, within one year of that date
are classified as short-term. Scheduled maturity dates of
U.S. government backed securities, corporate bonds and
commercial paper as of December 31, 2010
F-16
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and 2009, in excess of one year are classified as long-term.
There were no material realized gains and losses on sales of
these investments for the periods presented. Unrealized gains
and losses are included in other accumulated comprehensive
income (loss).
|
|
6.
|
PROPERTY
AND EQUIPMENT
|
On March 11, 2010, the Company purchased an airplane for a
total price of $3,154. The airplane is being depreciated over
20 years and has an estimated residual value of $800. The
gross amount of the Company assets under capital leases as of
December 31, 2010, was $7,292 of equipment, $1,051 of
leasehold and building improvements, and $300 of furniture. The
gross amount of the Company assets under capital leases as of
December 31, 2009, was $8,551 of equipment, $1,249 of
leasehold improvements, and $300 of furniture. Property and
equipment consist of the following:
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Equipment
|
|
$
|
26,889
|
|
|
$
|
17,063
|
|
Furniture and fixtures
|
|
|
1,672
|
|
|
|
804
|
|
Leasehold improvements
|
|
|
10,569
|
|
|
|
9,854
|
|
Airplane
|
|
|
3,154
|
|
|
|
|
|
Building and improvements
|
|
|
9,075
|
|
|
|
8,515
|
|
Land
|
|
|
800
|
|
|
|
800
|
|
|
|
|
|
|
|
|
|
|
Total property and equipment, at cost
|
|
|
52,159
|
|
|
|
37,036
|
|
Accumulated depreciation and amortization
|
|
|
(21,861
|
)
|
|
|
(13,897
|
)
|
Construction in progress
|
|
|
1,601
|
|
|
|
1,732
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
31,899
|
|
|
$
|
24,871
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense on property and equipment was $8,554,
$5,658, and $4,598 for the years ended December 31, 2010,
2009, and 2008, respectively.
Acquisition
of Anodyne Health Partners, Inc.
On October 16, 2009, the Company acquired Anodyne Health
Partners, Inc. (Anodyne), a software enabled service
business intelligence company based in Alpharetta, Georgia. The
Company believes that the acquisition of Anodyne provides the
Company with expanded service offerings that will better enable
it to compete in the large medical group market. The Anodyne
software as a service business intelligence tool enhances
customers ability to view all facets of its revenue cycle
information and to access and extract critical operational and
administrative information from various data systems. The
Company used existing cash to fund the acquisition of Anodyne,
following which Anodyne became a wholly owned subsidiary of the
Company.
The Company has accounted for the acquisition as a business
combination using the acquisition method. The Company incurred
legal costs and professional fees in connection with the
acquisition of $751 which are included in general and
administrative expenses. The results of Anodynes
operations are included in the statement of operations of the
combined entity since the date of acquisition.
F-17
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table summarizes the total consideration on the
acquisition date:
|
|
|
|
|
Cash payments
|
|
$
|
22,300
|
|
Contingent consideration
|
|
|
5,100
|
|
Cash acquired
|
|
|
(50
|
)
|
|
|
|
|
|
Fair value of total consideration
|
|
$
|
27,350
|
|
|
|
|
|
|
The fair values assigned to tangible and intangible assets
acquired and liabilities assumed are based on managements
estimates and assumptions, as well as other information compiled
by management, including valuations that utilize customary
valuation procedures and techniques.
The following table summarizes the recognized amounts of
identifiable assets acquired and liabilities assumed:
|
|
|
|
|
Current assets and other assets
|
|
$
|
757
|
|
Property and equipment
|
|
|
128
|
|
Intangible assets:
|
|
|
|
|
Technology
|
|
|
2,000
|
|
Customer relationships
|
|
|
11,200
|
|
Deferred tax liability
|
|
|
(2,206
|
)
|
Accrued expenses and other liabilities
|
|
|
(1,041
|
)
|
Deferred revenue
|
|
|
(250
|
)
|
|
|
|
|
|
Total identifiable net assets
|
|
|
10,588
|
|
Goodwill
|
|
|
16,762
|
|
|
|
|
|
|
|
|
$
|
27,350
|
|
|
|
|
|
|
Revenue from the date of acquisition of Anodyne,
October 16, 2009, to December 31, 2009, was $906. The
Company has determined that the presentation of Anodynes
net income is impracticable for the period ended
December 31, 2009, due to the integration of Anodyne
operations into the Company upon acquisition.
Contingent consideration is recorded at fair value as an element
of purchase price with subsequent adjustments recognized in the
consolidated statement of operations. The contingent
consideration is discussed in Note 4.
The intangibles are being amortized over 5-10 years, with
customer lists being amortized over 10 years. The goodwill
of $16,762 resulting from the acquisition arises largely from
the synergies expected from combining the operations of the
acquisitions with our existing services operations, as well as
from the benefits derived from the assembled workforce of the
acquisitions. The goodwill recognized is not deductible for tax
purposes.
Acquisition
of Crest Line Technologies, Inc. (d.b.a.
MedicalMessaging.net)
On September 5, 2008, the Company acquired specified assets
and assumed specified liabilities of Crest Line Technologies,
LLC (d.b.a. MedicalMessaging.net)
(MedicalMessaging). MedicalMessaging provided live
and automated calling services for healthcare professionals. The
purpose of the acquisition is to augment the Companys core
business service offering with MedicalMessagings automated
and live communication services. The Company believes the
purchase of MedicalMessaging gave access to a developed
technology that could speed the time to market versus internal
development of our own similar product. In addition, the Company
plans to leverage its existing customer base to increase
revenues of the MedicalMessaging services.
F-18
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Consideration for this transaction was approximately $7,700,
including potential additional consideration of $992 which was
to be paid over a three-year period if MedicalMessaging achieves
certain financial milestones. If the contingent consideration is
paid, it will result in an increase in the goodwill based on the
accounting required at acquisition date. The final payment will
include accrued interest on the escrowed amounts. At the date of
acquisition, the Company determined that $241 of the $992
potential contingent consideration was met and recorded the
obligation. At December 31, 2009 and 2008, the Company
determined that $330 of the potential consideration was met
during each period and recorded to the obligation. This amount
was paid out in March 2010 and 2009, respectively, from a
restricted cash account. During 2009, the Company paid a working
capital adjustment of $141. As of December 31, 2010, the
Company determined that an additional $330 of the potential
consideration was met and recorded to the obligation and is
expected to be paid in March 2011. The excess of the purchase
price over the fair value of the acquired net assets has been
allocated to goodwill, all of which is tax deductible.
Allocation of the purchase price for the acquisition was based
on estimates of the fair value of the net assets acquired, and
is subject to adjustment upon finalization of the contingent
consideration. The fair values assigned to tangible and
intangible assets acquired and liabilities assumed are based on
managements estimates and assumptions, as well as other
information compiled by management, including valuations that
utilize customary valuation procedures and techniques.
|
|
8.
|
GOODWILL
AND OTHER PURCHASED INTANGABLE ASSETS
|
Goodwill
The following table summarizes the activity relating to the
carrying value of the Companys goodwill during the years
ended December 31, 2010 and 2009:
|
|
|
|
|
Balance as of January 1, 2009
|
|
$
|
4,887
|
|
|
|
|
|
|
Contingent consideration recorded in connection with Medical
Messaging
|
|
|
330
|
|
Net working capital adjustment recorded in connection with
Medical Messaging
|
|
|
141
|
|
Goodwill recorded in connection with Anodyne
|
|
|
16,762
|
|
|
|
|
|
|
Balance as of December 31, 2009
|
|
|
22,120
|
|
|
|
|
|
|
Contingent consideration recorded in connection with Medical
Messaging
|
|
|
330
|
|
|
|
|
|
|
Balance as of December 31, 2010
|
|
$
|
22,450
|
|
|
|
|
|
|
Purchased
Intangible Assets
Intangible assets acquired as of December 31, 2010 and
2009, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Weighted Average Remaining
|
|
|
|
Gross
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life (years)
|
|
|
Developed technology
|
|
$
|
3,161
|
|
|
$
|
(1,022
|
)
|
|
$
|
2,139
|
|
|
|
3.5
|
|
Customer relationships
|
|
|
12,066
|
|
|
|
(1,554
|
)
|
|
|
10,512
|
|
|
|
8.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
15,227
|
|
|
$
|
(2,576
|
)
|
|
$
|
12,651
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-19
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2009
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Weighted Average Remaining
|
|
|
|
Gross
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life (years)
|
|
|
Developed technology
|
|
$
|
3,161
|
|
|
$
|
(390
|
)
|
|
$
|
2,771
|
|
|
|
4.4
|
|
Customer relationships
|
|
|
12,066
|
|
|
|
(347
|
)
|
|
|
11,719
|
|
|
|
9.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
15,227
|
|
|
$
|
(737
|
)
|
|
$
|
14,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense for the years ended December 31, 2010,
2009, and 2008, was $1,839, $635 and $102, respectively, and is
included in direct operating costs. Estimated amortization
expense, based upon the Companys intangible assets at
December 31, 2009, is as follows:
|
|
|
|
|
Year Ending December 31,
|
|
Amount
|
|
|
2011
|
|
$
|
1,839
|
|
2012
|
|
|
1,839
|
|
2013
|
|
|
1,765
|
|
2014
|
|
|
1,523
|
|
2015
|
|
|
1,207
|
|
Thereafter
|
|
|
4,478
|
|
|
|
|
|
|
Total
|
|
$
|
12,651
|
|
|
|
|
|
|
|
|
9.
|
OPERATING
LEASES AND OTHER COMMITMENTS
|
The Company maintains operating leases for facilities and
certain office equipment. The facility leases contain renewal
options and require payments of certain utilities, taxes, and
shared operating costs of each leased facility. The Company also
rents certain of its leased facilities to third-party tenants.
The rental agreements expire at various dates from 2011 to 2015.
The Company entered into a lease agreement with a new landlord
in connection with the relocation of its corporate offices in
June 2005. The Company assumed possession of the leased space in
January of 2005, with a rent commencement date of June 2005 and
expiration date of June 2015. The Company was not required to
pay rent from January 2005 through June 2005. The Company
recognizes rent escalations and lease incentives for this lease
on a straight-line basis over the lease period from January 2005
(date of possession) to June 2015.
Under the terms of such lease agreement, the landlord provided
approximately $9,400 in allowances to the Company for the
leasehold improvements for the office space and reimbursement of
moving costs. These lease incentives are being recorded as a
reduction of rent expense on a straight-line basis over the term
of the new lease and accounted for as a component of deferred
rent on the Companys Consolidated Balance Sheet. The
Company has recorded the leasehold improvements in property and
equipment in the accompanying balance sheets. Moving costs were
expensed as incurred.
Additionally, the landlord agreed to make all payments under the
Companys lease agreement relating to its previous office
space, amounting to approximately $2,100. The Company recognized
the lease costs when the Company ceased to use the previous
office space. The payments and incentives received from the new
landlord are being recognized over the new lease term and
accounted for as a component of deferred rent on the
Companys Consolidated Balance Sheet.
The lease agreement contains certain financial and operational
covenants. These covenants provide for restrictions on, among
other things, a change in control of the Company and certain
structural additions to the premises, without prior consent from
the landlord.
F-20
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Rent expense for the Companys Watertown, MA, location
totaled $2,871, $2,399, and $2,121 for the years ended
December 31, 2010, 2009, and 2008, respectively. In June
2005, the Company entered into a
sub-lease
agreement, which generated rental income of $40, $497, and $378
for the years ended December 31, 2010, 2009, and 2008,
respectively. Rental income is recorded as a reduction in rent
expense. The Company terminated this
sub-lease
effective February 2010.
The Company entered into a lease agreement with a new landlord
in connection with the relocation of its corporate offices in
India in May 2009. The Company assumed possession of the leased
space in May of 2009, with a rent commencement date of May 2009
and expiration date of April 2012. The Company was not required
to pay rent from May 2009 through August 2009. The Company
recognizes rent escalations for this lease on a straight-line
basis over the lease period from May 2009 (date of possession)
to April 2012. Rent expense totaled $250, $275, and $214 for the
years ended December 31, 2010, 2009, and 2008, respectively.
In March 2007, the Company entered into a non-cancelable
contract for data center services in the event of a service
interruption in the Companys primary data center. The term
of the agreement was 36 months, commencing in July 2007, at
a monthly rate of $27, for a total payment of $978 over the term
of the agreement. In December 2009, the Company entered into a
new non-cancelable contract, which superseded the March 2007
contract, for data center services in the event of a service
interruption in the Companys primary data center. The term
of the agreement is 26 months, commencing in December 2009,
at a monthly rate of $20 starting in February 2010, for a total
payments of $480 over the term of the agreement.
In May 2007, the Company entered into a ten-year, non-cancelable
lease agreement with a data center provider in Bedford,
Massachusetts. Under the agreement, the Company took possession
of a portion of the contracted space in June 2007. Minimum
payments under the lease total $6,133 over the life of the
agreement. The Company paid $652, $496 and $243 under this
agreement in 2010, 2009, and 2008, respectively.
Future minimum lease payments under non-cancelable operating
leases as of December 31, 2009, are as follows:
|
|
|
|
|
|
|
Future Rent
|
|
Year Ending December 31,
|
|
Payments
|
|
|
2011
|
|
$
|
5,699
|
|
2012
|
|
|
5,615
|
|
2013
|
|
|
5,259
|
|
2014
|
|
|
5,410
|
|
2015
|
|
|
3,067
|
|
Thereafter
|
|
|
1,075
|
|
|
|
|
|
|
Total minimum lease payments
|
|
$
|
26,125
|
|
|
|
|
|
|
|
|
10.
|
LONG-TERM
DEBT AND CAPITAL LEASE OBLIGATIONS
|
The summary of outstanding debt and capital lease obligations is
as follows:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Term loan
|
|
$
|
5,325
|
|
|
$
|
5,625
|
|
Capital lease obligation
|
|
|
3,891
|
|
|
|
6,763
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,216
|
|
|
|
12,388
|
|
Less current portion of long-term debt and capital lease
obligations
|
|
|
(2,909
|
)
|
|
|
(3,437
|
)
|
|
|
|
|
|
|
|
|
|
Long-term debt and capital lease obligations, net of current
portion
|
|
$
|
6,307
|
|
|
$
|
8,951
|
|
|
|
|
|
|
|
|
|
|
F-21
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2008 Term and Revolving Loans On
September 30, 2008, the Company entered into a Credit
Agreement (the Credit Agreement) with a financial
institution. The Credit Agreement consists of a revolving credit
facility in the amount of $15,000 and a term loan facility in
the amount of $6,000 (collectively, the Credit
Facility). The revolving credit facility may be extended
by up to an additional $15,000 on the satisfaction of certain
conditions and includes a $10,000 limit for the issuance of
standby letters of credit. The revolving credit facility matures
on September 30, 2011, and the term facility matures on
September 30, 2013, although either facility may be
voluntarily prepaid in whole or in part at any time without
premium or penalty. On September 30, 2008, the Company
borrowed $6,000 under the term loan facility for general working
capital purposes. The term loan has a
5-year term
which is payable quarterly starting March 31, 2009, for $75
each quarter. The Company has the option to extend the loan at
the end of the
5-year term.
As of December 31, 2010 and 2009, there were no amounts
outstanding under the revolving credit facility.
The revolving credit loans and term loan bear interest, at the
Companys option, at either (i) the London Interbank
Offered Rate (LIBOR), or (ii) the higher of
(a) the Federal Funds Rate plus 0.50% or (b) the
financial institutions prime rate (the higher of the two
being the Base Rate). For term loans, these rates
are adjusted down 100 basis points for Base Rate loans and
up 100 basis points for LIBOR loans. For revolving credit
loans, a margin is added to the chosen interest rate that is
based on the Companys consolidated leverage ratio, as
defined in the Credit Agreement, which margin can range from 100
to 275 basis points for LIBOR loans and from 0 to
50 basis points for Base Rate loans. A default rate shall
apply on all obligations in the event of a default under the
Credit Agreement at a rate per annum equal to 2% above the
applicable interest rate. The Company was also required to pay
commitment fees and upfront fees for this Credit Facility. The
interest rate as of December 31, 2010 and 2009, for the
term loan was 4.5%.
The obligations of the Company under the Credit Agreement are
collateralized by substantially all assets.
The Credit Agreement also contains certain financial and
nonfinancial covenants, including limitations on our
consolidated leverage ratio and capital expenditures, defaults
relating to non-payment, breach of covenants, inaccuracy of
representations and warranties, default under other indebtedness
(including a cross-default with our interest rate swap),
bankruptcy and insolvency, inability to pay debts, attachment of
assets, adverse judgments, ERISA violations, invalidity of loan
and collateral documents, and change of control. Upon an event
of default, the lenders may terminate the commitment to make
loans and the obligation to extend letters of credit, declare
the unpaid principal amount of all outstanding loans and
interest accrued under the Credit Agreement to be immediately
due and payable, require us to provide cash and deposit account
collateral for our letter of credit obligations, and exercise
their security interests and other rights under the Credit
Agreement.
Capital Lease Obligation In June 2007, the
Company entered into a master lease and security agreement (the
Equipment Line) with a financing company. The
Equipment Line allows for the Company to lease from the
financing company eligible equipment purchases, submitted within
90 days of the applicable equipments invoice date.
Each lease has a 36 month term which are payable in equal
monthly installments, commencing on the first day of the fourth
month after the date of the disbursements of such loan and
continuing on the first day of each month thereafter until paid
in full. The Company has accounted for these as capital leases.
As of December 31, 2010 and 2009, the Company had $3,891
and $6,763, respectively, of outstanding capital leases. The
weighted average interest rate implicit in the leases as of
December 31, 2010 and 2009, was 4.2% and 4.5%, respectively.
F-22
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Future principal payments on debt and outstanding capital leases
as of December 31, 2010, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital Lease
|
|
Year Ending December 31,
|
|
Debt
|
|
|
Obligations
|
|
|
2011
|
|
$
|
300
|
|
|
$
|
2,713
|
|
2012
|
|
|
300
|
|
|
|
1,301
|
|
2013
|
|
|
4,725
|
|
|
|
|
|
2014
|
|
|
|
|
|
|
|
|
Thereafter
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
5,325
|
|
|
|
4,014
|
|
Less: imputed interest
|
|
|
|
|
|
|
(123
|
)
|
|
|
|
|
|
|
|
|
|
Present value of future minimum lease payments
|
|
|
|
|
|
|
3,891
|
|
Less current portion
|
|
|
(300
|
)
|
|
|
(2,609
|
)
|
|
|
|
|
|
|
|
|
|
Long-term portion
|
|
$
|
5,025
|
|
|
$
|
1,282
|
|
|
|
|
|
|
|
|
|
|
The Companys borrowings are collateralized by
substantially all assets.
Interest paid was $873, $836, and $324 for the years ended
December 31, 2010, 2009, and 2008, respectively.
|
|
11.
|
INTEREST
RATE SWAP DERIVATIVE
|
The Company entered into a derivative instrument which has a
decreasing notional value over the term to offset the cash flow
exposure associated with its interest payments on certain
outstanding debt. In October 2008, we entered into an interest
rate swap to mitigate the cash flow exposure associated with our
interest payments on certain outstanding debt. Our interest rate
swap is not designated as a hedging instrument. The derivative
is accounted for at fair value with gains or losses reported in
earnings.
The swap had a notional amount of $5,850 to hedge changes in
cash flows attributable to changes in the LIBOR rate associated
with the September 30, 2008, issuance of the Term Loan due
September 30, 2028. We pay a fixed rate of 4.55% and
receive a variable rate based on one month LIBOR. The fair value
of derivatives as of December 31, 2010 and 2009, is
summarized in the following table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability Derivatives
|
|
|
|
|
|
|
Fair Value as of December 31,
|
|
|
|
Balance Sheet Location
|
|
|
2010
|
|
|
2009
|
|
|
Interest rate contracts
|
|
|
Interest rate derivative liability
|
|
|
$
|
490
|
|
|
$
|
291
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total derivatives
|
|
|
|
|
|
$
|
490
|
|
|
$
|
291
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The effect of derivative instruments on the consolidated
statements of operations is summarized in the following table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) Recognized in
|
|
|
Gain Recognized in
|
|
|
(Loss) Recognized in
|
|
|
|
|
|
Earnings for the
|
|
|
Earnings for the
|
|
|
Earnings for the
|
|
|
|
Location of (Loss) Gain
|
|
Year Ended December 31,
|
|
|
Year Ended December 31,
|
|
|
Year Ended December 31,
|
|
|
|
Recognized in Earnings
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Interest rate contracts
|
|
(Loss) gain on interest rate derivative contract
|
|
$
|
(199
|
)
|
|
$
|
590
|
|
|
$
|
(881
|
)
|
F-23
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Derivatives are carried at fair value, as determined using
standard valuation models and adjusted, when necessary, for
credit risk and is separately presented on the balance sheet.
The Company manages its interest rate exposures by maintaining a
fixed rate debt to minimize interest expense and interest rate
volatility. The following is a description/summary of the
derivative financial instrument the Company has entered into to
manage the interest rate exposure:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity
|
|
Fair Value
|
|
|
|
|
Notional
|
|
|
|
|
|
Fiscal Year
|
|
(Fiscal
|
|
as of December 31,
|
Description
|
|
Borrowing
|
|
Amount
|
|
Receive
|
|
Pay
|
|
Entered Into
|
|
Year)
|
|
2010
|
|
Interest rate swap
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
variable to fixed
|
|
Interest on
Term
Loan
|
|
$5,325
|
|
LIBOR
|
|
4.55%
Fixed
|
|
2008
|
|
2028
|
|
$(490)
|
The Companys board of directors has the authority, without
further action by stockholders, to issue up to 5,000 shares
of preferred stock in one or more series. The Companys
board of directors may designate the rights, preferences,
privileges, and restrictions of the preferred stock, including
dividend rights, conversion rights, voting rights, terms of
redemption, liquidation preference, and number of shares
constituting any series or the designation of any series. The
issuance of preferred stock could have the effect of restricting
dividends on the Companys common stock, diluting the
voting power of its common stock, impairing the liquidation
rights of its common stock, or delaying or preventing a change
in control. As of December 31, 2010 and 2009, no shares of
preferred stock were outstanding.
|
|
13.
|
COMMON
STOCK AND WARRANTS
|
Common Stock Common stockholders are entitled
to one vote per share and dividends when declared by the Board
of Directors, subject to any preferential rights of preferred
stockholders.
Warrants In connection with equipment
financing with a finance company and a bank in May 2001, the
Company issued warrants to purchase 65 shares of the
Companys Series D Preferred Stock at an exercise
price of $3.08 per share. The warrants are exercisable through
September 2012.
The Companys outstanding preferred stock was converted
into common stock in 2007 and, accordingly, all warrants to
purchase preferred stock were converted into warrants to
purchase common stock. During the year ended December 31,
2008, warrant holders exercised using the net issue exercise
provision resulting in 29 shares of common stock issued to
the warrant holder on the exercise of 32 warrants. No warrants
were exercised during the year ended December 31, 2010 and
2009.
Shares Reserved for Future Issuance The
Company has reserved shares of common stock for future issuance
of stock award plans of 4,912 and 4,615 for the years ended
December 31, 2010 and 2009, respectively.
|
|
14.
|
STOCK-BASED
COMPENSATION
|
Stock
Option Plans
The Companys stock award plans provide the opportunity for
employees, consultants, and directors to be granted options to
purchase, receive share awards, or make direct purchases of
shares of the Companys common stock, up to
20,000 shares of which 3,712 shares have been reserved
for future issuance as of December 31, 2010. Options
granted under the plan may be incentive stock options or
non-qualified stock options under the applicable provisions of
the Internal Revenue Code.
F-24
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
In 2007, the board of directors and the Companys
stockholders approved the 2007 Stock Option and Incentive Plan
(the 2007 Stock Option Plan). Options granted under
this plan may be incentive stock options or non-qualified stock
options under the applicable provisions of the Internal Revenue
Code. The 2007 Stock Option Plan includes an evergreen
provision that allows for an annual increase in the number
of shares of common stock available for issuance under the 2007
Stock Option Plan. The annual increase will be added on the
first day of each fiscal year starting January 1, 2008,
inclusive, and will be equal to the lesser of (i) 5.0% of
the number of then-outstanding shares of stock and of the
preceding December 31 and (ii) a number as determined by
the board of directors. On January 1, 2010 and 2009,
another 995 and 1,105 options, respectively, became available
for grant under this evergreen provision.
Incentive stock options are granted with exercise prices at or
above the fair value of the Companys common stock at the
grant date as determined by the Board of Directors. Incentive
stock options granted to employees who own more than 10% of the
voting power of all classes of stock are granted with exercise
prices at 110% of the fair value of the Companys common
stock at the date of the grant. Non-qualified stock options may
be granted with exercise prices up to the fair value of the
Companys common stock on the date of the grant, as
determined by the Board of Directors. All options granted vest
over a range of one to four years and have contractual terms of
between five and ten years. Options granted typically vest 25%
per year over a total of four years at each anniversary, with
the exception of options granted to members of the board of
directors, which vest on a quarterly basis over a total of four
years or vest on an annual basis over one year.
Pursuant to stock option awards granted under the 2007 Stock
Option Plan, unvested stock options awarded under these awards
shall become accelerated by a period of one year upon the
consummation of an acquisition of the Company. For purposes of
these agreements, an acquisition is defined as: (i) the
sale of the Company by merger in which its shareholders in their
capacity as such no longer own a majority of the outstanding
equity securities of the Company; (ii) any sale of all or
substantially all of the assets or capital stock of the Company;
or (iii) any other acquisition of the business of the
Company, as determined by its board of directors.
As of December 31, 2010 and 2009, there were approximately
1,298 and 1,151 shares, respectively, available for grant
under all of the Companys stock award plans.
The following table presents the stock option activity for the
year ended December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-
|
|
|
|
|
|
|
|
|
|
Weighted-
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
|
|
|
Exercise
|
|
|
Contractual Term
|
|
|
Intrinsic
|
|
|
|
Shares
|
|
|
Price
|
|
|
(in years)
|
|
|
Value
|
|
|
Outstanding January 1, 2010
|
|
|
3,432
|
|
|
$
|
21.62
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
762
|
|
|
|
37.12
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(604
|
)
|
|
|
12.47
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(269
|
)
|
|
|
32.69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding as of December 31, 2010
|
|
|
3,321
|
|
|
$
|
25.94
|
|
|
|
7.4
|
|
|
$
|
50,423
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable as of December 31, 2010
|
|
|
1,569
|
|
|
$
|
19.19
|
|
|
|
6.3
|
|
|
$
|
34,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest as of December 31, 2010
|
|
|
3,112
|
|
|
$
|
25.48
|
|
|
|
7.4
|
|
|
$
|
48,638
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average fair value of options granted for the year
ended December 31, 2010
|
|
|
|
|
|
$
|
19.06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company recorded compensation expense of $11,765, $8,314,
and $5,558, for the years ended December 31, 2010, 2009,
and 2008, respectively. There was an impact of $9,245, $2,505
and $526 on the
F-25
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
presentation in the consolidated statements of cash flows
relating to excess tax benefits on the federal and state tax
level that have been realized as a reduction in taxes payable
for the year ended December 31, 2010, 2009, and 2008,
respectively.
The Company uses the Black-Scholes option pricing model to value
share-based awards and determine the related compensation
expense. The assumptions used in calculating the fair value of
share-based awards represent managements best estimates.
The following table illustrates the weighted average assumptions
used to compute stock-based compensation expense for awards
granted:
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2010
|
|
2009
|
|
2008
|
|
Risk-free interest rate
|
|
1.5% - 3.0%
|
|
1.9% - 3.0%
|
|
1.9% - 3.5%
|
Expected dividend yield
|
|
0.0%
|
|
0.0%
|
|
0.0%
|
Expected option term (years)
|
|
6.25
|
|
6.25
|
|
6.25
|
Expected stock volatility
|
|
45% - 52%
|
|
48% - 53%
|
|
48% - 54%
|
The risk-free interest rate estimate was based on the
U.S. Treasury rates for U.S. Treasury zero-coupon
bonds with maturities similar to those of the expected term of
the award being valued. The expected dividend yield was based on
the Companys expectation of not paying dividends in the
foreseeable future.
The weighted average expected option term reflects the
application of the simplified method. The simplified method
defines the life as the average of the contractual term of the
options and the weighted average vesting period for all option
tranches. We have utilized this methodology for the year ended
December 31, 2010, due to the short length of time our
common stock has been publicly traded. The resulting fair value
is recorded as compensation cost on a straight-line basis over
the requisite service period, which generally equals the option
vesting period. Since the Company completed its initial public
offering in September 2007, it did not have sufficient history
as a publicly traded company to evaluate its volatility factor
and expected term. As such, the Company analyzed the
volatilities of a group of peer companies to support the
assumptions used in its calculations. The Company averaged the
volatilities of the peer companies with
in-the-money
options, sufficient trading history and similar vesting terms to
generate the assumptions. Starting January 1, 2011, the
Company will begin to use its own volatility and weighted
average expected option term.
As of December 31, 2010 and 2009, there was $26,400 and
$25,474, respectively, of unrecognized stock-based compensation
expense related to unvested stock option share-based
compensation arrangements granted under the Companys stock
award plans. This expense is expected to be recognized over a
weighted-average period of approximately 2.4 years.
Summary of Employee Stock Option Exercises
The weighted average fair value of stock options granted
during fiscal 2010, 2009, and 2008, was $19.06, $14.56, and
$16.52, respectively. Cash received from stock option exercises
during the years ended December 31, 2010, 2009, and 2008,
was $7,527, $1,895 and $4,918, respectively. Employees purchased
604 shares, 488 shares, and 991 shares,
respectively, for fiscal 2010, 2009, and 2008. The Company
generally issues previously unissued shares for the exercise of
stock options; however the Company may reissue previously
acquired treasury shares to satisfy these issuances in the
future. The intrinsic value of shares purchased during fiscal
2010, 2009, and 2008, was $15,215, $16,547, and $25,932,
respectively. The intrinsic value is calculated as the
difference between the market value on the date of purchase and
the purchase price of the shares.
Restricted
Stock Units
The 2007 Stock Option Plan also allows for granting of
restricted stock unit awards under the terms of the plan.
Majority of restricted units vest in four equal, annual
installments on the anniversaries of the vesting start date or
in four equal, quarterly installments on anniversaries of the
vesting date. The Company estimated
F-26
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the fair value of the restricted stock units using the market
price of its common stock on the date of the grant. The fair
value of restricted stock units is amortized on a straight-line
basis over the vesting period. The following table presents the
restricted stock unit activity for the year ended
December 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Grant Date
|
|
|
|
Shares
|
|
|
Fair Value
|
|
|
Outstanding January 1, 2010
|
|
|
|
|
|
$
|
|
|
Granted
|
|
|
308
|
|
|
|
35.10
|
|
Vested
|
|
|
(1
|
)
|
|
|
30.00
|
|
Forfeited
|
|
|
(15
|
)
|
|
|
36.78
|
|
|
|
|
|
|
|
|
|
|
Outstanding as of December 31, 2010
|
|
|
292
|
|
|
$
|
35.24
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2010, $8,506 of total unrecognized
compensation costs related to restricted stock units is expected
to be recognized over a weighted average period of
3.4 years. Stock-based compensation expense of $2,300 was
recorded for restricted stock units during the year ended
December 31, 2010. The fair value of restricted stock
awards vested was not material in fiscal year 2010. There were
no restricted stock units outstanding during the years ended
December 31, 2009 and 2008.
Employee
Stock Purchase Plan
In 2007, the Companys 2007 Employee Stock Purchase Plan
(2007 ESPP) was adopted by the board of directors
and approved by the stockholders. A total of 500 shares of
common stock has been reserved for future issuance to
participating employees under the 2007 ESPP. Employees may
authorize deductions from 1% to 10% of compensation for each
payroll period during the offering period. On February 8,
2008, the board of directors approved an amendment to the
Companys 2007 ESPP. Under the terms of the amendment to
the 2007 ESPP, the purchase price shall be equal to 85% of the
lower of the closing price of the Companys common stock on
(1) the first day of the purchase period or (2) the
last day of the purchase period. On May 1, 2008, the board
of directors approved another amendment to the 2007 ESPP, which
allows employees, officers, and directors of the Companys
subsidiary, athenahealth Technology Private Limited, to
participate in the 2007 ESPP. The expense for the years ended
December 31, 2010, 2009, and 2008, was $412, $388 and $172,
respectively.
Summary
of Stock-Based Compensation Expense
Total stock-based compensation expense for the years ended
December 31, 2010, 2009, and 2008, are as follows (no
amounts were capitalized):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Stock-based compensation charged to:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
$
|
2,298
|
|
|
$
|
1,589
|
|
|
$
|
872
|
|
Selling and marketing
|
|
|
3,509
|
|
|
|
2,126
|
|
|
|
1,383
|
|
Research and development
|
|
|
2,014
|
|
|
|
1,015
|
|
|
|
1,086
|
|
General and administrative
|
|
|
6,656
|
|
|
|
3,584
|
|
|
|
2,217
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
14,477
|
|
|
$
|
8,314
|
|
|
$
|
5,558
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-27
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The components of the Companys income tax provision
(benefit) for the years ended December 31, 2010, 2009, and
2008, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Current Provision:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
6,194
|
|
|
$
|
174
|
|
|
$
|
(16
|
)
|
State
|
|
|
3,141
|
|
|
|
2,706
|
|
|
|
647
|
|
Foreign
|
|
|
49
|
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,384
|
|
|
|
2,911
|
|
|
|
631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Provision:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
1,284
|
|
|
|
6,527
|
|
|
|
34
|
|
State
|
|
|
(272
|
)
|
|
|
(609
|
)
|
|
|
9
|
|
Valuation allowance reversal
|
|
|
|
|
|
|
|
|
|
|
(23,876
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,012
|
|
|
|
5,918
|
|
|
|
(23,833
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income tax provision (benefit)
|
|
$
|
10,396
|
|
|
$
|
8,829
|
|
|
$
|
(23,202
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During the year ended December 31, 2010, the Company
utilized tax federal and state net operating loss
(NOL) carryforwards to reduce the current tax
provision by $4,611 and $0, respectively. During the year ended
December 31, 2009, the Company utilized tax federal and
state net operating loss carryforwards to reduce the current tax
provision by $8,246 and $21, respectively. The Company
recognized an alternative minimum tax expense for the year ended
December 31, 2010, 2009, and 2008. During the year ended
December 31, 2008, the Company utilized tax net operating
loss carryforwards to reduce the current tax provision by $7,797.
F-28
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The components of the Companys deferred income taxes as of
December 31, 2010 and 2009, are as follows:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Federal net operating loss carryforward
|
|
$
|
2,181
|
|
|
$
|
4,851
|
|
State net operating loss carryforward
|
|
|
211
|
|
|
|
151
|
|
Research and development tax credits
|
|
|
1,296
|
|
|
|
881
|
|
Allowance for doubtful accounts
|
|
|
894
|
|
|
|
611
|
|
Deferred rent obligation
|
|
|
2,046
|
|
|
|
2,346
|
|
Stock compensation
|
|
|
5,908
|
|
|
|
3,197
|
|
Other accrued liabilities
|
|
|
1,184
|
|
|
|
920
|
|
Deferred revenue
|
|
|
10,380
|
|
|
|
10,395
|
|
Other
|
|
|
766
|
|
|
|
422
|
|
|
|
|
|
|
|
|
|
|
Total gross deferred tax assets
|
|
|
24,866
|
|
|
|
23,774
|
|
Valuation allowance
|
|
|
(211
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
24,655
|
|
|
|
23,774
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Intangibles
|
|
|
(4,849
|
)
|
|
|
(5,527
|
)
|
Capitalized software development
|
|
|
(1,445
|
)
|
|
|
(924
|
)
|
Property and equipment
|
|
|
(3,510
|
)
|
|
|
(1,412
|
)
|
Investments
|
|
|
(9
|
)
|
|
|
(17
|
)
|
Other
|
|
|
(27
|
)
|
|
|
(66
|
)
|
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities
|
|
|
(9,840
|
)
|
|
|
(7,946
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
14,815
|
|
|
$
|
15,828
|
|
|
|
|
|
|
|
|
|
|
The Company classifies its deferred tax assets and liabilities
as current or noncurrent based on the classification of the
related asset or liability for financial reporting giving rise
to the temporary difference. A deferred tax asset that is not
related to an asset or liability for financial reporting,
including deferred tax assets related to NOLs, is classified
according to the expected reversal date. The Company booked a
valuation allowance against certain state net operating losses
related to Anodyne. The Company evaluated the ability to utilize
the losses and determined they could not meet the more likely
than not standard of utilizing the losses.
As of December 31, 2010, the Company had federal and state
NOLs of approximately $37,929 (which includes $31,513 of NOLs
from stock-based compensation) and $5,363 (which includes $1,752
of NOLs from stock-based compensation), respectively, to offset
future federal and state taxable income. The state NOLs expire
at various times from 2011 through 2030, and the federal NOLs
expire at various times from 2017 through 2028. As of
December 31, 2009, the Company had federal and state NOLs
of approximately $55,895 (which includes $41,627 of NOLs from
stock-based compensation) and $16,549 (which includes $14,717 of
NOLs from stock-based compensation), respectively, to offset
future federal and state taxable income.
The Company has generated NOLs from stock-based compensation
deductions in excess of expenses recognized for financial
reporting purposes (excess tax benefits). Excess tax benefits
are realized when they reduce taxes payable, as determined using
a with and without method, and are credited to
additional paid-in capital rather than as a reduction of income
tax provision. During the years ended December 31, 2010,
2009, and 2008, the Company realized excess tax benefits from
federal and state tax deductions of $9,245, $2,505
F-29
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and $526, respectively, which was credited to additional paid-in
capital. As of December 31, 2010, the amount of
unrecognized federal and state excess tax benefits is $10,715
and $96, respectively, which will be credited to additional
paid-in capital when realized.
The Company records a deferred tax asset or liability based on
the difference between the financial statement and tax bases of
assets and liabilities, as measured by enacted tax rates assumed
to be in effect when these differences reverse. In evaluating
the Companys ability to recover its deferred tax assets,
the Company considers all available positive and negative
evidence including its past operating results, the existence of
cumulative income in the most recent fiscal years, changes in
the business in which the Company operates and its forecast of
future taxable income. In determining future taxable income, the
Company is responsible for assumptions utilized including the
amount of state, federal and international pre-tax operating
income, the reversal of temporary differences and the
implementation of feasible and prudent tax planning strategies.
These assumptions require significant judgment about the
forecasts of future taxable income and are consistent with the
plans and estimates that the Company is using to manage the
underlying businesses. Based on the consideration of the weight
of the positive and negative evidence, the Company concluded
that as of December 31, 2008, there was sufficient positive
evidence that its deferred tax assets will be fully utilized.
Accordingly, the remaining valuation allowance was reversed as
of December 31, 2008. As of December 31, 2010, the
Company continues to believe that it is more likely than not
that the deferred tax assets will be fully realized, except for
certain state net operating losses relating to Anodyne as
discussed above.
The Companys federal research and development tax credit
carryforward as of December 31, 2010 and 2009, was $1,296
and $881, respectively. This credit is available to offset
future federal and state taxes and expire at various times
through 2030.
A reconciliation of the federal statutory income tax rate to the
Companys effective income tax rate is as follows for the
years ended December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Income tax computed at federal statutory tax rate
|
|
|
34
|
%
|
|
|
34
|
%
|
|
|
34
|
%
|
State taxes net of federal benefit
|
|
|
6
|
%
|
|
|
8
|
%
|
|
|
9
|
%
|
Research and development credits
|
|
|
(1
|
)%
|
|
|
(1
|
)%
|
|
|
(2
|
)%
|
Permanent differences
|
|
|
5
|
%
|
|
|
8
|
%
|
|
|
8
|
%
|
Valuation allowance
|
|
|
1
|
%
|
|
|
0
|
%
|
|
|
(328
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
45
|
%
|
|
|
49
|
%
|
|
|
(279
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A reconciliation of the beginning and ending amount of
unrecognized tax benefits is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Beginning uncertain tax benefits
|
|
$
|
986
|
|
|
$
|
301
|
|
|
$
|
610
|
|
Prior year decreases
|
|
|
0
|
|
|
|
0
|
|
|
|
(365
|
)
|
Prior year increases
|
|
|
93
|
|
|
|
18
|
|
|
|
|
|
Current year increases
|
|
|
531
|
|
|
|
667
|
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,610
|
|
|
$
|
986
|
|
|
$
|
301
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in the balance of unrecognized tax benefits at
December 31, 2010, are $1,074 of tax benefits that, if
recognized, would affect the effective tax rate. Included in the
2009 year increases was $627 of unrecognized tax benefits
which the Company acquired through its acquisition of Anodyne.
The Company does not expect unrecognized tax benefits will
significantly change within 12 months of the reporting date.
F-30
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
For state tax purposes, the tax years 1997 through 2010 remain
open to examination by major taxing jurisdictions to which the
Company is subject, which years primarily resulted in
carryforward attributes that may still be adjusted upon
examination by the Internal Revenue Service or state tax
authorities if they have or will be used in a future period. The
Company recently concluded an Internal Revenue Service audit for
tax years 2006 through 2008. The closing of this audit resulted
in no change to the income tax benefit (provision) or previously
recorded net operating loss carryforwards.
|
|
16.
|
EMPLOYEE
BENEFIT PLAN
|
The Company sponsors a 401(k) retirement savings plan (the
401(k) Plan), under which eligible employees may
contribute, on a pre-tax basis, specified percentages of their
compensation, subject to maximum aggregate annual contributions
imposed by the Internal Revenue Code of 1986. All employee
contributions are allocated to the employees individual
account and are invested in various investment options as
directed by the employee. Employees cash contributions are
fully vested and non-forfeitable. The Company may make a
discretionary contribution in any year, subject to authorization
by the Companys Board of Directors. During the years ended
December 31, 2010, 2009, and 2008, the Companys
contributions to the Plan were $1,170, $901, and $673,
respectively.
|
|
17.
|
COMMITMENTS
AND CONTINGENCIES
|
On March 2, 2010, a complaint was filed by Prompt
Medical Systems, L.P. naming the Company and several other
defendants in a patent infringement case (Prompt Medical
Systems, L.P. v. AllscriptsMisys Healthcare Solutions, Inc.
et al., Civil Action No. 6:2010cv00071, United States
District Court for the Eastern District of Texas). The complaint
alleges that the Company has infringed on U.S. Patent
No. 5,483,443 with a listed issue date of January 9,
1996 entitled Method for Computing Current Procedural
Terminology Codes from Physician Generated Documentation.
The complaint seeks an injunction enjoining infringement,
damages, and pre- and post-judgment costs and interest. The
Company and other several defendants filed motions to dismiss
the complaint. On February 11, 2011, the Court issued an
Order
granting-in-part
and
denying-in-part
the motions to dismiss. The Court ordered the plaintiff to
replead certain claims within fourteen days of the Order.
On November 24, 2010, several defendants filed (i) a
motion for summary judgment of invalidity against the
patent-in-suit
on the basis that it claims only non-patentable subject matter;
and (ii) a motion to stay all proceedings pending the
resolution of the motion for summary judgment. The Company filed
a motion to join in the motion to stay the proceedings. The
motions are fully briefed and awaiting a decision by the Court.
The case is currently in the discovery phase. A claim
construction hearing is scheduled for November 11, 2011.
Trial is scheduled for June 11, 2012.
The Company is being indemnified in this lawsuit from and
against any liability and reasonable costs, including attorneys
fees, incurred by the Company in its defense, pursuant to a
license agreement with its vendor.
The Company believes that it has meritorious defenses to the
lawsuit and continues to contest it vigorously.
On March 19, 2010, a putative shareholder class action
complaint was filed in the United States District Court for the
District of Massachusetts against the Company and certain of its
current and former officers entitled Casula v.
athenahealth, Inc. et al, Civil Action
No. 1:10-cv-10477.
On June 3, 2010, the court appointed Waterford Township
General Employees Retirement System as the lead plaintiff. On
August 2, 2010, the lead plaintiff filed an amended
complaint. The amended complaint alleges that the defendants
violated the federal securities laws by disseminating false and
misleading statements through press releases, statements by
senior management, and SEC filings. The alleged false and
misleading statements concern,
F-31
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
among other things, the amortization period for deferred
implementation revenues. The amended complaint seeks unspecified
damages, costs, and expenses. The defendants filed a motion to
dismiss the amended complaint on October 1, 2010, and a
reply brief in further support of the motion to dismiss the
amended complaint on December 30, 2010. We believe that we
have meritorious defenses to the amended complaint, and we will
contest the claims vigorously.
In addition, from time to time we may be subject to other legal
proceedings, claims, and litigation arising in the ordinary
course of business. We do not, however, currently expect that
the ultimate costs to resolve any pending matter will have a
material adverse effect on our consolidated financial position,
results of operations, or cash flows. There are no accruals for
such claims recorded at December 31, 2010.
The Companys services are subject to sales and use taxes
in certain jurisdictions. The Companys contractual
agreements with its customers provide that payment of any sales
or use tax assessments are the responsibility of the customer.
Accordingly, the Company believes that sales and use tax
assessments, if applicable, will not have a material adverse
effect on the Companys financial position, results of
operations, or cash flows.
F-32
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
18.
|
QUARTERLY
FINANCIAL INFORMATION (UNAUDITED)
|
Selected quarterly financial information follows for the year
ended December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
|
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Year
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
52,565
|
|
|
$
|
56,399
|
|
|
$
|
61,087
|
|
|
$
|
67,094
|
|
|
$
|
237,145
|
|
Implementation and other
|
|
|
1,912
|
|
|
|
2,153
|
|
|
|
2,056
|
|
|
|
2,272
|
|
|
|
8,393
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
54,477
|
|
|
|
58,552
|
|
|
|
63,143
|
|
|
|
69,366
|
|
|
|
245,538
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
23,519
|
|
|
|
24,101
|
|
|
|
24,543
|
|
|
|
24,419
|
|
|
|
96,582
|
|
Selling and marketing
|
|
|
12,060
|
|
|
|
12,693
|
|
|
|
13,233
|
|
|
|
14,689
|
|
|
|
52,675
|
|
Research and development
|
|
|
4,074
|
|
|
|
4,824
|
|
|
|
4,645
|
|
|
|
4,905
|
|
|
|
18,448
|
|
General and administrative
|
|
|
11,677
|
|
|
|
11,403
|
|
|
|
10,390
|
|
|
|
9,649
|
|
|
|
43,119
|
|
Depreciation and amortization
|
|
|
2,420
|
|
|
|
2,657
|
|
|
|
2,869
|
|
|
|
3,171
|
|
|
|
11,117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
53,750
|
|
|
|
55,678
|
|
|
|
55,680
|
|
|
|
56,833
|
|
|
|
221,941
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
727
|
|
|
|
2,874
|
|
|
|
7,463
|
|
|
|
12,533
|
|
|
|
23,597
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
78
|
|
|
|
66
|
|
|
|
75
|
|
|
|
90
|
|
|
|
309
|
|
Interest expense
|
|
|
(217
|
)
|
|
|
(118
|
)
|
|
|
(102
|
)
|
|
|
(316
|
)
|
|
|
(753
|
)
|
(Loss) gain on interest rate derivative contract
|
|
|
(60
|
)
|
|
|
(304
|
)
|
|
|
(111
|
)
|
|
|
276
|
|
|
|
(199
|
)
|
Other income
|
|
|
30
|
|
|
|
33
|
|
|
|
33
|
|
|
|
50
|
|
|
|
146
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (expense) income
|
|
|
(169
|
)
|
|
|
(323
|
)
|
|
|
(105
|
)
|
|
|
100
|
|
|
|
(497
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax (provision) benefit
|
|
|
558
|
|
|
|
2,551
|
|
|
|
7,358
|
|
|
|
12,633
|
|
|
|
23,100
|
|
Income tax (provision) benefit
|
|
|
(281
|
)
|
|
|
(1,253
|
)
|
|
|
(3,532
|
)
|
|
|
(5,330
|
)
|
|
|
(10,396
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
277
|
|
|
|
1,298
|
|
|
|
3,826
|
|
|
|
7,303
|
|
|
|
12,704
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.01
|
|
|
$
|
0.04
|
|
|
$
|
0.11
|
|
|
$
|
0.21
|
|
|
$
|
0.37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.01
|
|
|
$
|
0.04
|
|
|
$
|
0.11
|
|
|
$
|
0.21
|
|
|
$
|
0.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
34,014
|
|
|
|
34,106
|
|
|
|
34,174
|
|
|
|
34,419
|
|
|
|
34,181
|
|
Diluted
|
|
|
35,201
|
|
|
|
35,019
|
|
|
|
35,156
|
|
|
|
35,278
|
|
|
|
35,204
|
|
F-33
athenahealth,
Inc.
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Selected quarterly financial information follows for the year
ended December 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
|
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Year
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
39,895
|
|
|
$
|
44,429
|
|
|
$
|
45,609
|
|
|
$
|
53,297
|
|
|
$
|
183,230
|
|
Implementation and other
|
|
|
1,133
|
|
|
|
1,219
|
|
|
|
1,796
|
|
|
|
1,149
|
|
|
|
5,297
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
41,028
|
|
|
|
45,648
|
|
|
|
47,405
|
|
|
|
54,446
|
|
|
|
188,527
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
18,561
|
|
|
|
19,397
|
|
|
|
19,942
|
|
|
|
21,117
|
|
|
|
79,017
|
|
Selling and marketing
|
|
|
6,999
|
|
|
|
8,888
|
|
|
|
8,963
|
|
|
|
9,222
|
|
|
|
34,072
|
|
Research and development
|
|
|
3,181
|
|
|
|
3,439
|
|
|
|
3,748
|
|
|
|
3,980
|
|
|
|
14,348
|
|
General and administrative
|
|
|
8,201
|
|
|
|
8,394
|
|
|
|
9,732
|
|
|
|
9,784
|
|
|
|
36,111
|
|
Depreciation and amortization
|
|
|
1,639
|
|
|
|
1,798
|
|
|
|
2,098
|
|
|
|
2,232
|
|
|
|
7,767
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
38,581
|
|
|
|
41,916
|
|
|
|
44,483
|
|
|
|
46,335
|
|
|
|
171,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
2,447
|
|
|
|
3,732
|
|
|
|
2,922
|
|
|
|
8,111
|
|
|
|
17,212
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
402
|
|
|
|
320
|
|
|
|
216
|
|
|
|
78
|
|
|
|
1,016
|
|
Interest expense
|
|
|
(174
|
)
|
|
|
(283
|
)
|
|
|
(270
|
)
|
|
|
(241
|
)
|
|
|
(968
|
)
|
(Loss) gain on interest rate derivative contract
|
|
|
192
|
|
|
|
308
|
|
|
|
(125
|
)
|
|
|
215
|
|
|
|
590
|
|
Other income
|
|
|
36
|
|
|
|
79
|
|
|
|
96
|
|
|
|
44
|
|
|
|
255
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
456
|
|
|
|
424
|
|
|
|
(83
|
)
|
|
|
96
|
|
|
|
893
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax (provision) benefit
|
|
|
2,903
|
|
|
|
4,156
|
|
|
|
2,839
|
|
|
|
8,207
|
|
|
|
18,105
|
|
Income tax (provision) benefit
|
|
|
(1,365
|
)
|
|
|
(1,912
|
)
|
|
|
(1,673
|
)
|
|
|
(3,879
|
)
|
|
|
(8,829
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
1,538
|
|
|
|
2,244
|
|
|
|
1,166
|
|
|
|
4,328
|
|
|
|
9,276
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.05
|
|
|
$
|
0.07
|
|
|
$
|
0.03
|
|
|
$
|
0.13
|
|
|
$
|
0.28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.04
|
|
|
$
|
0.06
|
|
|
$
|
0.03
|
|
|
$
|
0.12
|
|
|
$
|
0.27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
33,418
|
|
|
|
33,527
|
|
|
|
33,610
|
|
|
|
33,785
|
|
|
|
33,584
|
|
Diluted
|
|
|
34,814
|
|
|
|
34,822
|
|
|
|
34,900
|
|
|
|
35,133
|
|
|
|
34,917
|
|
F-34